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Synthetic biology offers a new horizon in designing complex systems. However,
unprecedented complexity hinders the development of biological systems to its full
potential. Mitigating complexity via adopting design principles from engineering
and computer science fields has resulted in some success. For example, modulari-
sation to foster reuse of design elements, and using computer assisted design tools
have helped contain complexity to an extent. Nevertheless, these design practices
are still limited, due to their heavy dependence on rational decision making by
human designers. The issue with rational design approaches here arises from the
challenging nature of dealing with highly complex biological systems of which we
currently do not have complete understanding. Systematic processes that can al-
gorithmically find design solutions would be better able to cope with uncertainties
posed by high levels of design complexity. A new framework for enabling de-
sign automation in synthetic biology was investigated. The framework works by
projecting design problems into search problems, and by searching for design solu-
tions based on the dual-evolutionary approach to combine the respective power of
design domains in vivo and in silico. Proof-of-concept ideas, software, and hard-
ware were developed to exemplify key technologies necessary in realising the dual
evolutionary approach. Some of the areas investigated as part of this research in-
cluded single-cell-level microfluidics, programmatic data collection, processing and
analysis, molecular devices supporting solution search in vivo, and mathematical
modelling. These somewhat eclectic collection of research themes were shown to
work together to provide necessary means with which to design and characterise
biological systems in a systematic fashion.
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A string of light pierced into a space filled with what seemed like
eternal darkness. I chased the light, chased the light, and chased the
light. Still out of reach, but never out of sight was the light of
wisdom. Better not be an illusion, nor hallucination, as I have begun
to run out of breath. The Plato's cave, where I have been locked up
against my will for life, pulls me back into the safe harbour, into the
eternal bliss of ignorance. I have been adrift in the void for so long; I
wish to tell my olde days so long. I erected my petrified soul and
hurled it against the air in a paddling motion. Out of desperation
goes my wishful thought of making butter out of thin air; so one day,
I may be able to stand on the butter of wisdom and strut out of this
cave. For thee who shalt not doubt, making air taste like cream
would be as miraculous an act as making wine out of water. For
philosophers like I who question and reason, phenomena exist not in
miracle but in causality. So I keep on paddling my soul as yet, by
tuning into a coxswain's shout, toasting once to the art of doubting,
and twice to doubting my own doubts.
But there are some things I am determined never to doubt: that I
owe a debt of gratitude to my parents, my brother and my wife, and
that I love them.
I would like to dedicate this thesis to my parents Soonja and
Juhnguen who shaped me to dream my dream, to my brother
Moonshic who introduced to me the art of computing for chasing my
dream with, and to my wife Yeji who made the tortuous marathon
run of beating the butter of wisdom a bearable journey.
Shakespeare did a great job distilling my prose into poetry:
'Doubt thou the stars are fire;
Doubt that the sun doth move;
Doubt truth to be a liar;
But never doubt I love.'
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One of the most useful characteristics of humanity, differentiating us from other
high-order animals, is our capability to design complex systems. We have the
mental ability to abstract ideas, which has helped us create and expand sciences
and meta-sciences [59, 90]. Our abstracting and design capability is at the core of
how we could have built the civilisation as we know it today. Technological and
scientific advancements achieved so far have begun to open ways for us to read
and write the code of life - deoxyribonucleic acid (DNA) sequences. There is an
old saying that sums up quite nicely what is going to unravel with this newfound
capability of ours. The proverb, with a little twist, goes like this: where there
is a way, there is a will (to design). Brian Cox inadvertently proved the general
trueness of this proverbial eventuality, in his quantum theoretic perspective on
questioning the universal phenomenon: why anything that can happen, does
[43]. The field of synthetic biology has been born, and there are wills galore to
walk the way to take humanity to whole new levels of design feats. Designing
complex synthetic biological systems is, undoubtedly, the next frontier in science,
technology, engineering, and mathematics.
The primary thesis being set out here for discussion is about design in syn-
thetic biology. The topic's key concept, with respect to its semantics, needs to
be clarified, before the discussion can proceed any further though. It is the de-
ceivingly simple, yet difficult, question of what it means by design. There are
a plethora of partial definitions on the meaning of design. Nevertheless, there
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1. INTRODUCTION
has not been any universally agreeable formal definition of design existing to date
[141]. In an article about the etymology of design [174], Terzidis reflects on the
meaning of design the word's Greek root, σχεδόν (pronounced schedon), meaning
nearly, almost, about, or approximately. Terzidis explains, From its Greek defi-
nition, design is about incompleteness, indefiniteness, or imperfection, yet it also
is about likelihood, expectation, or anticipation. In its largest sense, design sig-
nifies not only the vague, intangible, or ambiguous, but also the strive to capture
the elusive. This etymological definition associates design to some activity that
is intrinsically vague, trying to capture the vague. While such a definition may
inspire some philosophical thoughts, it is a rhetoric far from providing a tangible
definition as to what design really is in a practical sense.
According to Freeman and Hart [65], Design encompasses all the activities
involved in conceptualizing, framing, implementing, commissioning, and ultimately
modifying complex systems. This modern definition of software systems design
exhibits uncanny relevance to design in synthetic biology, and is connoting the idea
of engineering in its definition. Yet another interesting perspective on the meaning
of design relevant to synthetic biology comes from the field of engineering design. In
a book on engineering design [57], Dym explains design as part of a central activity
in engineering focused on the final goal of creating artefacts, and argues that (the
meaning of) design incorporates both representation of the artifact being designed
as well as the process by which design is completed. This definition suggests
that engineering design is more than just providing a conceptual blueprint for
the construction of artefacts or the artefacts per se. Dym's argument, by saying
design incorporates . . . the process by which design is completed, is defining the
scope of design to be inclusive of implementation level details, or documentation
unequivocally delineating how desired artifacts can be constructed.
That synthetic biology is a field of biological science harnessed with engineer-
ing principles is an argument we often hear [5, 82, 99, 115]. This argument en-
tails synthetic biology's unique need for modifying existing systems, contrasting
other bio-science fields primarily focused on characterising existing systems. Mod-
ification as a purpose is what differentiates engineering from science. Such an
engineering-centric view of systems design in synthetic biology is also in line with
the prevalent use of specifications in discussing synthetic biological designs. The
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initiatives in Synthetic Biology Open Language (SBOL) [69], for instance, epit-
omise the importance of specifications in the field. The role of specifications in
design can be related to the following excerpt on differentiating engineering from
science. Kroes argues [103], Whereas in science our ideas and beliefs are adjusted
to how things are in the world, the engineering attitude is precisely the opposite,
namely to adapt the world to our ideas, desires and needs. The medium by which
our ideas, desires and needs can be captured is what a specification is to design.
Within the context of this thesis, I would like to adopt the systems engineering
perspective on the meaning of design, where design encompasses all the activities
and artefacts needed in the realisation of functional properties. In this view,
design contains not only the `what' of the implementation but also the `how,' via
unequivocally documenting and constructing the mechanisms with which designed
artifects, whether they be ideas, aesthetics, data, energy, materials, or genetic
sequences, can possess intended functional properties. Such a definition of design
is also relevant to the repeatability of design, a quality necessary in achieving
automation.
To design is to solve design problems. Conventionally, the process of solving
design problems follows its Greek root in being nebulous, requiring highly cognitive
brain tasks by humans, and involving such obscure activities as brainstorming. I
believe the lack of clarity in this process, at least in part, stems from having to deal
with highly complicated data, leading to analysis paralysis. Choices made by the
human brain are heavily influenced by how options are presented [50]. According to
Herbert Simon's theory [75, p.1], the human mind has bounded rationality in that
people reason and choose rationally, but only within the constraints imposed by
their limited search and computational capacities. For problems with incomplete
or complex information, rational decision making by the human brain relies on
simplified heuristics or rule-of-thumb principles that rather deviate from the laws
of probability [75, p.1].
Is complexity the major culprit in causing obscurity in design activities? If
so, can we make design problems more trivial to solve by making the process of
dealing with highly complex data more straightforward? Would there be ways
to employ a set of simple, well-defined processes, to make easily manageable any
given task and corresponding data a human designer or a computerised logic deals
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with? Would it ever be possible to replace the good old-fashioned, enigma-laden,
and human-intelligence-driven design approach with a mindless systematic design
approach more amenable to automation? Ultimately, is achieving full automation
in designing synthetic biological systems a possibility?
In an attempt to shed light on these questions, my research aims to build sup-
porting technologies to enable design automation in synthetic biology. To this end,
the work presented here explores some of the key areas in the design process that
would greatly benefit from automation. This work explores genetic and microflu-
idic means to provide an interface to facilitate data exchange between the in vivo
and in silico domains. Among other important aspects of design automation, the
data exchange interface would allow for the programmatic execution of tasks such
as gathering and analysing measurement data, and would serve as the cornerstone
in building a full design automation stack.
1.1 How design is done
Traditionally, approaches to designing complex systems can be classified into being
either top-down or bottom-up [44], depending on the flow of design processes. The
use of such classification is widespread across various design domains ranging from
integrated circuits [98], to software systems [137, 175], and to trade agreements [2].
This dichotomous classification provides conceptual frameworks for understanding
how knowledge is organised in performing design. The former refines a design
through decomposition: breaking down broader concepts into narrower details.
This flow can offer relatively easy a transition from the initial specification into
a design. There are clear downsides to this approach in that designed systems
may end up with no parts to fulfill the need, and that testing cannot start until
the systems are decomposed into testable parts. The latter starts from identifying
available parts, and builds a system through composition, hence testing can start
early on in the design process. However, the final system may not necessarily
reflect what was initially intended in the specification. Neither approach cannot
be declared to be outright superior to the other. Often, designing complex systems
would need to incorporate both approaches. While these classifications can give
some indication as to the directionality of a design flow, they do not provide clear
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methodological steps to be followed in terms of accomplishing a design.
Designing complex systems, synthetic biological systems included, requires
strenuous analyses involving various domains of knowledge. Without having a sys-
tem of methodologies to define and govern such analyses, it would not be possible
to wield the complexity in design. Software engineering principles, such as those
advocated by the Agile Manifesto [14], provide insightful ideas about managing the
processes involved in the design of complex systems. Agile software development
uses iterative and incremental design approaches by working with manageably
small analyses and implementation tasks. Extreme programming (XP) [15] is a
type of agile software development methodologies that particularly stresses the
importance of testing as part of design and implementation cycles. According
to the proponents of XP, how software systems design is done depends on the
cost of change. One of the common assumptions about the cost of change taken
into consideration in design projects is that the cost would rise exponentially as
projects progress. XP proponents claim that trying to account for the future cost
of change in design would impose burdensome constraints in making design de-
cisions. Unnecessary design decisions are made early-on in the design process in
order to avoid any late changes. Such a strategy would be especially detrimental
to design problems with which only partial information is available upfront, as
are the cases in most synthetic biology design problems. If there is a strategy
that can make the cost of change a non-issue, critical decisions can be made as
late in the design process as possible. XP finds the answer to the issue of cost
of change in systematic testing. Having a solid testing scheme would mean that
frequent changes can be applied to a design with relative ease. How costly it is to
introduce late design changes would dictate the applicability of iterative and in-
cremental design approaches to building complex systems. The more iterations of
changes a design is subject to, the more feedbacks the design can receive towards
satisfying the specification. XP takes this argument further by adding that no
systems design can even start without first defining how to test the systems, and
that no design is complete without testing. Testing in XP is what makes possible
the decomposition of a complex systems design problem into as many manageably
small design elements and/or iterations as possible without losing the integrity of
the whole system. The notion that testing is an integral part of design is key to
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taking a systematic approach to design in synthetic biology. Testing is where in-
tended functionalities are verified, where design criteria can be defined, and where
measurements and analyses can be translated into design elements. Furthermore,
systematic testing keeps the cost of change contained at a reasonably low and
predictable level in order to allow for late changes inevitable in synthetic biology
design problems.
1.2 Design by abstraction
In dealing with complex design tasks, it is not an option but a necessity to use
computer aided or automated design processes. Synthetic biology is certainly not
an exception to having the need for computerised design processes. Complex
designs have a lot to benefit from model-driven engineering (MDE) approaches.
MDE is an approach pioneered in computer science with the aim of facilitating
computer-aided systems engineering through abstraction offered by the use of mod-
els [64]. The model checking community has long been advocating the value of
using abstraction in validating complex system designs. Abstraction in design al-
lows its systems or subsystems to be tested in isolation, which in turn facilitates
the achievement of higher degrees of design complexity [37]. MDE has enabled,
via abstraction, large-scale design projects in software [64] and automotives [23],
among others. MDE has also been adopted in synthetic biology with some success
in designing RNA devices [27] and engineering metabolic pathways [97]. MDE
enables the inspection of complex systems being designed via the versatile lens of
in silico models. Models allow the simulation of physical realities at the granu-
larity as fine as required. Models, for instance, can be used to represent physical
reality at the molecular, or even lower levels, if need be. Models also provide a
highly organised and functionally active means for capturing experimental data
that tend to be structurally flat and functionally inactive in their original forms.
Without doubt, using MDE in synthetic biology will offer to be of great help in
mitigating the challenges associated to design complexity. However, the current
lack of availability of well characterised biological parts from which to produce
models is a hindrance to the use of MDE in practice. Adopting a MDE approach
that would require minimal a priori knowledge is, therefore, crucial to the success
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of modelling in synthetic biology.
1.3 Design in synthetic biology
The field of synthetic biology arose from the development of technological advances
in molecular biology, electrical engineering and computer science. Many of the
principles of electrical engineering and computer science have been adopted in
synthetic biology, so much so that use of the term 'biological engineering' in the
design of novel biological systems is prevalent in the field. The synthetic biology
engineering life cycle includes many of the stages familiar to software engineering:
specification, design, modelling, implementation, testing and maintenance. Some
of the technological developments concerning this field, including Next Generation
Sequencing and DNA synthesis, have begun to outpace Moore's law as witnessed
in the computer industry. It is not unimaginable to foresee the design complexity
of synthetic biological systems to eventually surpass that of electrical engineering
and the reasoning capacity of the human brain.
Natural evolution employs iterative selection and randomness as universal means
to solve complex genome-scale biological design problems. Nature's system of find-
ing design solutions has inspired me to pursue the investigation into an evolution-
ary approach to achieving genome-scale design in synthetic biology. The challeng-
ing nature of genome-scale design is intensified by the computational complexity
and the large parameter space inherent to modeling approaches [139], heavily de-
pendent on kinetic [147, 176, 177], stochastic [143, 152], and cybernetic elements
[161, 167]. Furthermore, parameters in models could largely be unknown, and
are often costly or impossible to be characterised [148]. The dual-evolutionary
approach (DEA) as suggested by Hallinan and her colleagues [80] is an attempt
to provide a genome-scale design framework that can overcome the current lack
of availability of well characterised parts and computational power to handle com-
plex systems design. The approach employs solutions from two iterative search
domains, namely the in silico and the in vivo counterparts. The marriage of the




1.4 Motivation for design automation in synthetic
biology
Engineering microbial organisms under the paradigm of synthetic biology has a
huge potential for igniting a new era of industrial revolution. Designed organisms
will have impacts on our daily lives in the future soon to arrive. In the short
run, the idea of harnessing cell factories will be indispensable to the economical
production of pharmaceutical substances and renewable energy resources [127].
In the long run, designed organisms will eventually open ways to provide general
biocomputing platforms that can be programmed to solve problems deemed too
difficult or costly for conventional silicon-based computing architectures.
Designing biological organisms de novo would require highly challenging engi-
neering feats. One of the major hurdles in the design of biological systems is that
molecular interactions at the genome-scale level are extremely complicated [182].
The lack of availability of well-characterised biological parts and tools in synthetic
biology further restricts the design flexibility at such complex levels. Most design
in synthetic biology today is done on an ad hoc and manual basis by domain ex-
perts [115]. This practice not only hampers genome-scale design but also involves
trial and error far too costly for achieving the economy of scale. For designing
large-scale biological systems, synthetic biologists can no longer rely on manual,
impromptu processes. Current design practice in synthetic biology, heavily reliant
on the intuition of domain experts, can only fulfill the field's market potential
to a limited extent. Impending in synthetic biology, therefore, is a demand for
systematic design approaches, that are more amenable to automation.
1.5 Hypothesis, aims, and objectives
Given many uncertainties associated with engineering complex biological systems,
the synthetic biology engineering cycle would need to be highly iterative. Rational
design decisions would be inefficient for any such iterative tasks, and would hinder
large-scale design. More promising is the use of an inherently iterative, heuristic
approach such as DEA, which would potentially be much easier to be automated
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and be more capable in handling design complexity. Having speculative arguments
thus far given about DEA, this research was based on the following hypotheses:
that design complexity would correspond to the time taken to find design solutions
or vice versa; that the DEA framework would be an effective means to shorten time
to design, subsequently mitigating design complexity; and that the framework
would be amenable to automation.
With respect to these hypotheses, the overarching aim of this project was to
establish a groundwork for DEA with which to further the investigation and the
development of methodologies for accomplishing design automation in synthetic
biology. One of the objectives, stemming from this aim, was to investigate the
feasibility of employing DEA as an effective framework to facilitate the design
of complex systems in synthetic biology. Another objective was to investigate
the duality of in silico and in vivo design domains, and to suggest how the two
can be integrated, minding the cross-domain gap. The final objective as part of
this research work was to investigate and suggest how process automation can be
achieved for streamlining the highly iterative design processes of DEA.
1.6 Contributions
Some of the original works done as part of this research contributed to the following
publications. The application of automated, iterative, dual evolutionary strategies,
which formed the basis of many ideas put together in this research work under the
umbrella term of DEA, was initially published as a positional piece [80] in which
I participated as a co-author. My work on modelling genome-scale enzymatic
pathways and analysing the flux balance of riboflavin biosynthesis in B. subtilis was
applied in the prediction of key metabolisms out of the pentose phosphate pathway
for riboflavin production [156]. Some parts of my work on microfluidics, including
the application of novel methods on fabrication, single-cell-level measurement and




Due to the interdisciplinary nature of the field of synthetic biology, multiple scien-
tific disciplines contributed to the writing conventions adopted as part of structur-
ing this thesis. Chapter 2 briefs on the subject field and the prior arts of synthetic
biology, and Chapter 3 gives an overview of the DEA framework. Immediately fol-
lowing this is Chapter 4 showing the wetlab methods used as part of this research
work. Placing the methods chapter before the body chapters (Chapter 5, 6, and 7)
was for abiding by the bioscience writing convention. This way of organising infor-
mation was deliberately chosen as a gentle reminder of the importance of wetlab
works in synthetic biology. The methods text taking precedence in the positional
order would also be more practical in serving its purpose as an immediate reference
point for any hands-on works in the wetlab.
The body part comprises three chapters. The first of which (Chapter 5) covers
the in vivo design domain, followed by the work on the in silico design domain
(Chapter 6). These two juxtaposed body chapters convey the details underpinning
the duality of the DEA framework. The last body chapter to follow (Chapter 7)
covers the research work on accomplishing process automation in synthetic biol-
ogy via using microfluidics. Chapter 8 provides concluding remarks, in reflection
of the project aims and objectives, with a comprehensive discussion about poten-






Synthetic biology is an interdisciplinary research field that applies engineering prin-
ciples to the design and construction of novel biological systems [5, 82, 99, 115].
Having the word engineering as part of describing this emerging biology field
signifies that it is not just about observation but more about modification that
matters about the field. To pursue the modification of biological systems in or-
der to make systems that can perform useful tasks is the defining characteristic
of synthetic biology. In fact, such an endeavour to alter biological systems is not
new to biology. Throughout history, we have long been using selective breeding
techniques to improve the yield, flavours, or aesthetics of various biological organ-
isms such as crops [117], cattle [145], and flowers [192]. More recently, the field
of genetic engineering has already opened ways to genetically modify biological
systems. What would then make synthetic biology distinguished from these pio-
neering attempts of other fields in modifying the phenotypes and the genotypes
of biological systems? The answer to this question can be found by drawing a
parallel line in history and looking at the Industrial Revolution.
Steam engines are attributed to be one of the key elements that precipitated
the Industrial Revolution [125]. However, the idea of using steam power to make
a rotary movement had already been contemplated by ancient Greeks in the 1st
11
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century AD (see Figure 2.11). Yet, harnessing steam power to its full potential
was not materialised till the 18th century. What differentiated industrialists and
engineers of the 18th century from ancient Greeks was the prevalent use of stan-
dardisation. Standardised parts during the Industrial Revolution made it easy to
document designs and to build artifacts from documentations in turn [53]. This
consequently allowed many engineers to easily share their ideas and build ideas on
top of one another. Standardised parts lowered technological barriers and fostered
modularisation and reuse of functional units. Engineers in the 18th century could
see further by standing on the shoulders of giants, by not having to build things
from scratch.
Figure 2.1: An illustration of the ancient Greek steam engine, aeolipile [101]
The idea of fully embracing standardisation is at the heart of what distin-
guishes synthetic biology from the old school of genetic engineering. This nascent
1The aeolipile illustration is an excerpt from Knights American Mechanical Dictionary([101]),
and its copyright is in the public domain.
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bio-engineering field is still premature and has yet to unravel its full potential.
Nevertheless, there have already been exciting achievements that exemplify the
revolutionary nature of synthetic biology. Perhaps, synthetic biology is the first
field to have the true potential of becoming the engineering counterpart of biology,
much like chemical engineering has been for the field of chemistry. That is to say
synthetic biology will bring about a new era of revolution to humanity.
2.2 Building blocks in synthetic biology: parts and
devices
There has been a recurring research theme in synthetic biology skewed to imple-
menting proof-of-concept biological equivalents of logic gates or the building blocks
of electronic engineering [124, 165, 170]. The popularity in building biological logic
gates [4] exemplifies the current trend of parts-based and bottom-up design ap-
proaches prevalent in synthetic biology. Such design approaches, if taken in an
attempt to replicate, verbatim, the functional complexity of electronic devices in
biological systems, would be fundamentally flawed. Unlike electronic systems, bi-
ological systems cannot be hardwired to construct networks of dense logic gates
functioning together. The use of chemical signals as a means to wiring gates, as
shown by Tamsir and his colleagues [170], can only be scaled to a limited design
complexity owing to the lack of available orthogonal signals that do not interfere
each other. Regot and others [142] have suggested a way to reduce wiring con-
straints in biological gate designs, using the concept of distributed computing
via multiple cells working in collaboration. Their approach allowed a successful
implementation of a 1-bit adder. Nevertheless, their approach would still suffer
from the scalability issue in building complex systems with practical real-world
applications.
2.3 Bio-design automation in synthetic biology
Bio-design automation (BDA) is critical to achieving the level of design complexity
necessary in solving real-world problems. There have been initiatives in synthetic
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biology communities with a consensus goal towards automating the process of bi-
ological systems design. However, the majority of these initiatives have so far
been centered in computer-aided design (CAD), as versus to BDA in its true sense
[115]. CAD evolves around software tools that can assist human designers with
their design tasks often in terms only of managing information in a bottom-up fash-
ion. BDA practices in synthetic biology have mainly been focused on what would
be considered low-hanging fruits, only capable of providing rudimentary forms of
automation as would CAD tools. Some of the software tools in this endeav-
our include TinkerCell [33] and GenoCAD [48]. TinkerCell provides a graphical
user interface where a human designer can drag and drop genetic parts such as
promoters, RBS, CDS, and terminators to put together a design construct. Tin-
kerCell allows the study of the dynamics of molecular interactions by allowing the
definition of cellular boundaries and types of molecular reactions using kinetic pa-
rameters. GenoCAD took a little more formalised approach to integrating genetic
parts by working with rules with which matching parts from databases such as
the Registry of Standard Biological Parts can be found. Tools such as GEC [135]
and Eugene [19] lean towards the programmatic exploration of genetic designs by
working with the concept of programming languages and abstraction to specify ge-
netic circuit designs. These tools can be used to convert abstract low-level designs
into genetic circuits with specific parts. However, they are still limited to offering
parts-based and bottom-up approaches to accomplishing genetic design.
Parts-based, bottom-up approaches would offer design perspectives relatively
more straight-forward, not only in terms of developing software tools but also
in using such tools to document rationalised ideas by designers. However, the
subject in this design process is still the human experts. This means that rational
decision making is required on every critical details of a design on a manual basis.
Regardless of whether all the mental somersaults in rational decision making were
performed in perfection or not, the resulting design is still subject to errors in the
expert knowledge and limits in the reasoning capacity of humans. The current
bias toward bottom-up design approaches in synthetic biology software tool bases
is perhaps attributed in part by that fruit harvest competition and heavy reliance
on ad hoc, rational design processes. Lux and his collaborators have addressed the
concerns regarding the ad hoc nature of current design practice in synthetic biology
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[115], and urged for the formalization of genetic design rules that determine the
complex relationships between genotype and phenotype.
2.4 Metabolic engineering as an application of syn-
thetic biology
Metabolic engineering is an attempt to design and manipulate cellular metabolism
in order to facilitate the biosynthesis of molecules of interest, usually of high com-
mercial value [187]. Metabolism is an integral cellular process involving complex
sequences of chemical reactions that transport, convert and harness carbon and ni-
trogen fluxes for the maintenance of biological systems [36]. Metabolism provides
cells with pathways to convert nutrients into energy and base chemical species nec-
essary for making everything cells need. The kinds of chemical species or metabo-
lites required by cells, consequently made available by their metabolism, differ
depending on the environmental niches to which the cells of any given organism
evolved to adapt [92].
While there are highly conserved metabolic constituents such as nucleic acids,
amino acids and various hydrocarbon chains that make up some of the essential
cellular components including DNA, RNA, proteins and lipids, there are whole
other spectrums of esoteric secondary metabolites unique only to a handful of
organisms in their wildtype conditions [93].
Metabolic engineering and recombinant DNA technologies have enabled us to
make cellular factories that can produce nearly any organic molecules [47]. In
that capacity, metabolic engineering seems to have a lot of common aspects with
synthetic biology. Metabolic engineering could be considered a subset of areas
in which synthetic biology can be applied. Nielsen and Keasling expressed in
their opinion piece [127] that there currently is some degree of disconnect as well
as overlap between three different disciplines of metabolic engineering, systems
biology, and synthetic biology. They opined that different endeavours from these
three fields will eventually have to merge together in order to facilitate progress in
the engineering of biological systems.
15
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2.5 Current affairs in synthetic biology
The field of synthetic biology is still at its infancy. While the big picture of this
nascent field is portrayed as being aimed at the genome-scale design of synthetic
organisms, the reality now is far from achieving designs of such a grandiose scale.
Many synthetic biology projects to date have investigated the bottom-up compo-
sition of genetic circuitries out of a handful of genetic elements such as promoters,
ribosome binding sites, coding sequences, and terminators. Even computer aided
design tools developed for applications in synthetic biology lean towards the same
bottom up approach, and are focused on providing visual means for building and
simulating models that are often represented by a serial juxtaposition of a limited
number of genetic elements. This approach has been moderately successful insofar
as domain experts with in-depth knowledge of the biological system of interest can
manually design the system. However, the interim success of CAD-based manual
design approaches is going to be short-lived for the following reason. The man-
ual, expert-driven practice of designing synthetic biological systems is not only
expensive but also limited in the level of achievable design complexity.
Large-scale engineering of entire genomes has been attempted, including the
de novo syntheses of poliovirus cDNA [31], bacteriophage genome [159], bacterial
genome [74], and a chromosome of Saccharomyces cerevisiae [6]. However, these
works have focused on the reconstruction of existing genomes. While the work of
Gibson and colleagues [74] did involve modifications to the existing genome, they
were confined to non-functional modifications, such as inserting watermark se-
quences into non-essential genes. There have been some synthetic biology projects
taking genome-scale modification more seriously, rather than just tackling verba-
tim synthesis of wildtype genome. One faction of synthetic biologists has been
tinkering with the idea of eliminating nonessential genes for genome reduction in
Escherichia coli [138], and in Bacillus subtilis [172], while other faction has dealt
with genome refactoring in bacteriophage T7 [32], and in Klebsiella oxytoca [173].
Genome refactoring attempts are especially noticeable in that functional genes
are completely revamped, via forward engineering, to make synthetic strains that
are phenotypically better, and genotypically more organised. To date, however,
true genome-scale engineering for introducing appreciable, novel, and nontrivial
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functionality in a biological system has not been achieved yet. The difficulty in
reaching such a high level of engineering feat is due, in part to the heavy reliance
on domain experts' manual labour, and in part to the lack of a viable design





A dual-evolutionary strategy for
synthetic biology
There is an inherent limit to the use of domain expertise or rational decisions in de-
sign, since some design problems can harbour solution space much larger than our
mind can hold. A systematic framework that can harness evolutionary strategies
to design genome-scale synthetic biological systems was proposed to improve upon
the limit of rational approaches [80]. The framework, called dual-evolutionary ap-
proach (DEA), comprises two complementary evolutionary processes, respectively
running in in silico and in vivo domains. The idea of using DEA in exploring
the design space of biological systems initially stood on the speculation that dif-
ferences between in vivo and in silico evolutionary domains can be leveraged to
bring about a complementary effect towards increasing each domain's design ca-
pability. The initial advocates of the idea warned against a potential gap between
the two domains due to the dichotomy of the inter-domain differences, and called
for research that can close the gap.
Design is a search problem. To be more specific, it is a search problem that has
an indefinitely large solution space to be explored. Evolutionary processes in vivo
have built-in mechanisms for finding solutions to design problems encoded in DNA
as directed by environmental conditions. Solutions found by the in vivo search
operation are robust, so much so that they are guaranteed to work as advertised.
On the flip side, they tend to be rather too specific, and may not easily offer the
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generality required. Given enough time and the right prescription of environmental
conditions, solutions satisfying any criteria, as long as they conform to the law
of physics, will emerge. Difficulties arise when we try to harness evolutionary
processes in engineering biological systems. Firstly, there is a timescale dilemma.
The normal evolutionary timescale is not something for which synthetic biologists
trying to engineer genetic systems would have patience to wait. Also troublesome
is that there is no framework with which to manipulate environmental conditions
for directing evolution to find its ways to desired solutions.
DEA can come as a rescue in terms not only of reducing the evolutionary
timescale, but also of serving as a framework for genome-scale biological systems
design. Any data generated as a result of directed evolution in vivo can be stored
digitally, to serve as reference ingredients to be filtered, mixed, and recombined
in variable combinations as directed by evolutionary processes in silico. The dual
evolutionary domains can run in iterative cycles towards reaching a design goal,
as depicted in Figure 3.1.
The solution space for a genome-scale design is hugely vast. The norm in
the current practice of engineering biological systems is still heavily dependent
on the use of scarce domain experts and manual labour. This manual approach
unnecessarily imposes on the designer a large portion of the burden of exploring
solution space, hence does not scale well to genome-scale designs hidden in com-
plex, high-dimensional solution space. The adoption of evolutionary algorithm
(EA) or EA-like principles in the exploration of solution space in DEA bodes well
with the framework's requirements for supporting the following aspects: general
applicability, flexibility, and scalability in handling a wide range of different types
of problems. These aspects would offer to be an effective arsenal against problems
lacking a priori knowledge, as is often the case in synthetic biology. DEA can
lessen designer's burden by providing a viable framework with which much of the
solution exploring endeavour can be delegated, in a standard manner, to the dual,
mutually complementary search domains. Due to its heavy reliance on the EA-
like principles, DEA would also be affected by the same drawbacks of EA. These
include the issue of premature settlement on local optima, or the lack of means to
determine if solutions at hand are local or global.
The DEA framework can overcome the issue of local optima, via supporting
20
Figure 3.1: Overview of the DEA framework for synthetic biology
Functional specification is used 1 to define a desired model behaviour for in silico evolu-
tion, 2 to come up with an initial starting point of a design, or 3 to define environmental
incentives for in vivo evolution. A design can be converted, as necessary, to 4 in silico
models, or 5 in vivo genetic implementations. 6 A model is simulated. 7 The character-
istics of genetic implementations, including any changes in the genome sequences and in
key phenotypes, are measured. 8 Model simulation predicts the potential behaviour of
a design. 9 Measured characteristics may reveal the in vivo behaviour (phenotype) of a
genetic implementation. 10 Model behaviour is compared to the desired behaviour. 11
In vivo behaviour is affected by environmental incentives defined by fitness landscapes
and vice versa. 12 In vivo behaviour is compared to in silico behaviour. 13 Differences
between the desired and model behaviours feed back into the Evolutionary Algorithm
(EA). 14 The dynamics between environmental incentives and phenotypes is the driving
force (f) for directing evolutionary changes. 15 The comparison between in silico and in
vivo behaviours can be used as a basis for parameter optimisation, and reasoning about
changes to the design, the model, or the measurement criteria. 16 The EA can affect
the model view of the design, and 16a its subsequent simulation. 17 Any evolutionary
changes are directly recorded in the genome, serving as a medium for genetic implemen-
tations in vivo. 17a Genetic changes may result in behavioural changes. 18 Parameter
optimisation, via studying the differences of the two domains can help refine the model.
Reasoning based on the comparison of the two domains can 19 lead to design changes
or 20 affect measurement criteria. 21 Information on meaningful mutations in genetic
implementations due to evolutionary changes can be used in the reasoning process to
refine the design, or 22 to refine the model. Note: The ∆ symbol denotes difference or
comparison in 10 and 12, and change or modification in 4, 5, 16, 17, 18 and 19. The
thick arrows (20, 21, and 12) constitute cross-domain information exchange, indicating
the areas of concern for building a cross-domain data interface.
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effective means to assess the fitness of solutions in each domain (See Note 1, 3, 10,
and 11 in Figure 3.1). Successful fitness assessment would subsequently grant the
possibility of determining the validity of design solutions, and make the uncertainty
of whether a solution is local or global a nonissue.
There are key elements necessary in achieving genome-scale designs through
the dual evolutionary approach, as depicted and noted throughout Figure 3.1.
First, we need modeling schemes that would require as little parameterisation
(Note 15 and 18) as possible, as each parameter costs a substantial amount of
computation. Also needed are means by which solutions are encoded (Note 4 and
5), generated (Note 16 and 17), explored (Note 8 and 9), assessed (Note 10 and
11), and measured (Note 6 and 7) in either or both side(s) of the two domains.
And finally, we need means to integrate the findings from the two domains (Note
15 and 21) in order to perform reasonably efficient exploration of the solution space
via refining the model (Note 22); The integration of which requires a cross-domain
data interface as noted in thick arrows in Figure 3.1.
As hinted by the thick arrows being the only links constituting the cross-domain
data interface, the Measurement element, depicted in Figure 3.1, is of paramount
importance to the realisation of the in vivo domain, in terms of closing the in
silico-in vivo gap. Regarding theMeasurement element, affecting the measurement
criteria (Note 20) includes making changes not only in the measurement apparatus
level, but also in the growth condition level directly affecting mutant cells. The
latter case may induce some conditional behaviours in mutant cells, intended as
part of the controlling process of DEA in the evolutionary processes. It seems
as though, on the depiction in Figure 3.1, the comparison of in silico and in vivo
behaviours (Note 12) takes place directly between theMeasurement and theModel
behaviour elements. However, the comparison in actuality takes place inside the
Reasoning element. So the cross-domain data interface, in essence, only comprises






Table 4.1: Bacterial strains used in this study:
Strain Genotype Source*
E. coli DH5alpha F- λ- Φ80lacZ∆M15 ∆(lacZYA-argF )U169 recA1 endA1 CBCB
hsdR17 ∆phoA8 supE44 thi-1 gyrA96 relA1
E. coli MC1061 str. K-12 F- λ- ∆(ara-leu)7697 [araD139 ]B/r ∆(codB-lacI )3 galK16 CBCB
galE15 e14- mcrA0 mcrA0 relA1 rpsL150 (StrR) spoT1 mcrB1 hsdR2
B. subtilis 168 trpC2 BGSC, CBCB
B. subtilis BSB1 str. 168 trp prototroph CBCB
B. subtilis EVOt2 str. BSB1 amyE ::pEVOt2 This study
* BGSC: Bacillus Genetic Stock Center at Ohio State University. CBCB: Centre for
Bacterial Cell Biology at Newcastle University. Among the CBCB acquired strains,
E. coli DH5alpha [171] was a gift from Wendy Smith, E. coli MC1061 [30] from Ling
Juan Wu, B. subtilis 168 [194] from Heath Murray, Aurelie Guyet and Wendy Smith,
and B. subtilis BSB1 [126] from Wendy Smith.
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Table 4.2: Plasmids used in this study:
Plasmid Description Usage Source*
pUC57 bla, ColE1/pMB1/pBR322/pUC ori, lacZα transformation Genscript
pMUTIN4 bla, erm, Pspac, spoVG_RBS-lacZ, lacI, ColE1 ori integration vector CBCB
pSG1729 spc, bla, ColE1 ori, amyE'-'amyE, Pxyl gfpmut1 integration vector CBCB
pET28 Kan, T7 promoter, His-Tags T7-Tag, expression CBCB
lacI, pBR322 ori, f1 ori
pUC57_evo pUC57::evo_insert transformation This study
pMUTIN4_evo pMUTIN::evo_insert integration vector This study
pEVOt2 pSG1729::EVOt2 integration vector This study
* CBCB: Centre for Bacterial Cell Biology at Newcastle University. Among the CBCB
acquired plasmids, pMUTIN4 [180] and pSG1729 [112] were a gift from Ling Juan
Wu, and pET28 from Jad Sassine.
Table 4.3: Reagents used in this study:
Reagents Source
dNTP Promega
PCR DNA oligos IDT
Q5 DNA polymerase NEB
Restriction digest enzymes NEB
Gibson assembly cloning kit NEB
QIAquick PCR purification kit QIAGEN
QIAprep Spin Miniprep kit QIAGEN
DNA gel extraction kit QIAGEN
DNeasy Blood & Tissue kit QIAGEN
Ethidium Bromide Sigma-Aldrich
Bacto-trypton BD Biosciences
Bacto Yeast extract BD Biosciences
Bacto Agar BD Biosciences
Starch Fisher
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4.2 The construction of pMUTIN4_evo plasmid
vector
The FMN sensor construct together with other constructs for inducible hypermu-
tation, collectively dubbed the name the evo_insert as discussed in chapter 5, were
synthesised by Genscript (NJ, USA). The evo_insert sequence (See Appendix B.1
for sequence details) was designed to be flanked by two restriction sites, BamHI
and HindIII, and was inserted into the corresponding sites in the multiple cloning
site (MCS) of pUC57 (Genscript, USA). This pUC57 plasmid carrying the insert
sequence was named pUC57_evo (Figure 4.1).
4.2.1 Subcloning the evo_insert construct from pUC57_evo
into pMUTIN4
Using pUC57_evo as the donor plasmid, the insert sequence was subcloned into
pMUTIN4 [180]. This recipient plasmid with the insert in between its BamHI and
HindIII was named pMUTIN4_evo (Figure 4.2).
4.2.1.1 Restriction digests to prepare evo_insert and pMUTIN4 back-
bone fragments
A double restriction digest was performed as described in Table 4.4. A 100 mL
agarose gel (0.7 %) was made using the standard protocol (Section 4.5.3) with the
exception of not adding EtBr in the gel. A comb with the largest available well
size was taped to make two wells, large enough to accomodate 96µL of solutions
in each well. 80µL of each of the reactants ID'ed i and ii from Table 4.4 was
mixed with 16µL of 6X loading dye. An electrophoresis tray was prepared with
1X TAE buffer without EtBr, and the gel was placed in. Each of the 96µL of
reactant solutions mixed with dye were loaded onto the gel. 80 V of electricity was
applied for 1.5 h. The gel was transferred into MilliQ water with 0.5 µg mL−1 EtBr
and was stained for 15 min, followed by resting 15 min in fresh MilliQ water for
destaining. The gel was then UV inspected, on low dose, long wavelength light, to
quickly excise the pUC57_evo's evo_insert band at around 3585bp region, and the
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Figure 4.1: The pUC57_evo plasmid map.
pMUTIN4 backbone band at around 8600bp region out of the gel, using a sterile
scalpel. The pUC57_evo and pMUTIN4 gel slices were weighed to be 160 mg and
100 mg respectively. The two gel slices were subject to the DNA gel extraction
protocol as detailed in Section 4.5.1. Nanodrop runs on the gel extracted DNA
resulted in:
4.2.1.2 Double Restriction Enzyme Digestion
E. coli DH5α cultures respectively transformed with pUC57_evo and pMUTIN4
were grown overnight on a shaking incubator at 37.0 ◦C. The overnight cultures
26





























































































Figure 4.2: The pMUTIN4_evo plasmid map.
were Miniprep'ed using the standard protocol described in Section 4.5.8 The double
digest was performed as summarised in Table 4.4.
A diagnostic gel electrophoresis was performed to verify the result of the re-
striction digest reactions. 0.7 % agarose gel was made by following the standard
protocol (Section 4.5.3). The gel was placed into an electrophoresis buffer tray,
loaded with reaction samples (with 6X loading dye), and applied with 100 V for
1 h. The gel was UV imaged on a gel dock afterwards. Figure 4.3 shows that







Table 4.4: Double restriction enzyme digest reaction, as a prestep to subcloning
evo_insert into pMUTIN4
Doner plasmid (main) Vector backbone (main) Doner plasmid (diagnostic) Vector backbone (diagnostic)
(pUC57_evo) (pMUTIN4) (pUC57_evo) (pMUTIN4)
Rxn ID i ii iii iv
Total rxn volume 100µL 100µL 20µL 20µL
pUC57_evo (288.9ng/µL) 38µL (11µg) N/A 1.7µL (0.5µg) N/A
pMUTIN4 (276.7ng/µL) N/A 39.8µL (11µg) N/A 1.8µL (0.5µg)
10X rxn buffer 10µL 10µL 2µL 2µL
dH2O 50.0µL 48.2µL 15.8µL 15.7µL
BamHI (NEB) 1µL 1µL 0.5µL 0.5µL
HindIII (NEB) 1µL 1µL N/A N/A
Incubation 37°C for 4 hours 37°C for 4 hours 37°C for 4 hours 37°C for 4 hours
Inactivation 80°C for 20 mins 80°C for 20 mins N/A N/A
number of bands with right sizes.
4.2.1.3 Ligation assembly of evo_insert and pMUTIN4 vector back-
bone
A ligation reaction to assemble the evo_insert and pMUTIN4 backbone fragments
was performed as summarised in Table 4.5. Competent E. coli DH5alpha was
Table 4.5: The reaction setup of the ligation of evo_insert and pMUTIN4 frag-
ments:
evo_insert+pMUTIN4 backbone
Total rxn volume 20µL
300ng insert 8.2µL (36.5ng/µL)
100ng vector 3.8µL (26.6ng/µL)
10X rxn buffer 2µL
T4 ligase 2µL
dH2O 4µL
Incubation 25°C for 2 hours
transformed (See the protocol in Section 4.5.7), by adding 15µL of the above lig-
ate in lieu of adding circular plasmid DNA. The transformant E. coli culture was
spread on ampicillin (100µg mL−1) LB agar plates pre-treated with a 200µL solu-
tion made of 20µL 1 M IPTG, 140µL MilliQ water, 40µL 4 % Xgal (40µg mL−1).
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Figure 4.3: A diagnostic gel electrophoresis image for the restriction digest from Table
4.4.
test1. Two overnight cultures in LB with 100µg mL−1 ampicillin were set up from
the two colonies. Only one of the two cultures turned turbid. This culture was
minipreped as per Section 4.5.8, and the resulting plasmid DNA was subject to
diagnostic restriction enzyme digest and gel electrophoresis as follow.
Table 4.6: Diagnostic restriction enzyme digest reactions, to determine the validity
of the putative pMUTIN4_evo
Rxn1 Rxn2 Rxn3
Total rxn volume 20µL 20µL 20µL
DNA (372.5ng/µL) 1.4µL (0.5µg) 1.4µL (0.5µg) 1.4µL (0.5µg)
10X rxn buffer 2µL 2µL 2µL
dH2O 15.7µL 16.0µL 16.3µL
BamHI (NEB) 0.3µL 0.3µL 0.3µL
HindIII (NEB) 0.3µL 0.3µL N/A
SalI (NEB) 0.3µL N/A N/A
The diagnostic gel electrophoresis was run using 0.7 % gel, and the resulting
bands indicated the size of pUC57_evo, not that of pMUTIN4_evo (See Figure
1A successful insertion of the evo_insert fragment into the multiple cloning sites of the
pMUTIN4 backbone would result in the disruption of lacZ and result in white colonies.
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Figure 4.4: A diagnostic gel electrophoresis image for the above restriction digest reac-
tions: the bands are indicative of pUC57_evo, not pMUTIN4_evo.
4.4).
Transformation using the ligation product out of the gel-purified fragments
(Section 4.2.1.1 and 4.2.1.3) revealed poor efficiency resulting in only a single
transformant worthy of diagnostic inspection. In the following ligation method,
column purification (QIAquick spin columns) instead of gel purification was used
for preparing the restriction digested DNA fragments.
A triple restriction digest was performed as described in Table 4.9. The digest
solution was subject to column purification as described in Section 4.5.9. Nanodrop





The assembly of pMUTIN4_evo using ligation was performed in a second trial.
DNA fragments resulting from restriction digests followed by column purification
were used in the ligation assembly of pMUTIN4_evo. The second ligation reaction
was run as summarised in Table 4.7. Competent E. coli DH5alpha was transformed
(See the protocol in Section 4.5.7), by adding 15µL of the above ligate in lieu of
adding circular plasmid DNA. The transformant E. coli culture was spread on
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Table 4.7: The reaction setup of the second ligation of evo_insert and pMUTIN4
fragments:
evo_insert+pMUTIN4 backbone
Total rxn volume 20µL
300ng insert 3.5µL (85.3ng/µL)
100ng vector 3.2µL (31.7ng/µL)
10X rxn buffer 2µL
T4 ligase 2µL
dH2O 9.3µL
Incubation 25°C for 2 hours
ampicillin (100µg mL−1) LB agar plates pre-treated with a 200µL solution made
of 20µL 1 M IPTG, 140µL MilliQ water, 40µL 4 % Xgal (40µg mL−1). After
overnight growth, there was an abundance of colonies surviving and passing the
blue/white colony test. Overnight cultures in LB with 100µg mL−1 ampicillin were
set up from nine colonies. The overnight cultures were minipreped as per Section
4.5.8, and their resulting plasmid DNAs were subject to diagnostic restriction
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Figure 4.5: The diagnostic restriction digest gel electrophoresis of putative
pMUTIN4_evo clones: all the screened colonies showed negative results.
According to the diagnostic gel electrophoresis (Figure 4.5), all of the nine
colonies were shown to be habouring pUC57_evo instead of the much anticipated
plasmid of pMUTIN4_evo. The ligation protocol without gel purification could
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Table 4.8: Diagnostic restriction enzyme digest reactions, to determine the validity
of the putative pMUTIN4_evo, assembled from column purified fragments:
colony ID 1 2 3
rxn ID i ii iii i ii iii i ii iii
0.4µg DNA 1.6µL (253.7ng/µL) 2.4µL (115.1ng/µL) 1.4µL (289.1ng/µL)
Total rxn volume 20µL 20µL 20µL 20µL 20µL 20µL 20µL 20µL 20µL
10X rxn buffer 2µL 2µL 2µL 2µL 2µL 2µL 2µL 2µL 2µL
dH2O 15.5µL 15.8µL 16.1µL 14.7µL 15.0µL 15.3µL 15.7µL 16.0µL 16.3µL
BamHI (NEB) 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL
HindIII (NEB) 0.3µL 0.3µL N/A 0.3µL 0.3µL N/A 0.3µL 0.3µL N/A
SalI (NEB) 0.3µL N/A N/A 0.3µL N/A N/A 0.3µL N/A N/A
Incubation 37°C for 4 hours
colony ID 4 5 6
rxn ID i ii iii i ii iii i ii iii
0.4µg DNA 4.2µL (93.5ng/µL) 1.3µL (296.5ng/µL) 1.5µL (273.0ng/µL)
Total rxn volume 20µL 20µL 20µL 20µL 20µL 20µL 20µL 20µL 20µL
10X rxn buffer 2µL 2µL 2µL 2µL 2µL 2µL 2µL 2µL 2µL
dH2O 12.9µL 13.2µL 13.5µL 15.8µL 16.1µL 16.4µL 15.6µL 15.9µL 16.2µL
BamHI (NEB) 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL
HindIII (NEB) 0.3µL 0.3µL N/A 0.3µL 0.3µL N/A 0.3µL 0.3µL N/A
SalI (NEB) 0.3µL N/A N/A 0.3µL N/A N/A 0.3µL N/A N/A
Incubation 37°C for 4 hours
colony ID 7 8 9
rxn ID i ii iii i ii iii i ii iii
0.4µg DNA 4.6µL (86.6ng/µL) 1.5µL (271.6ng/µL) 2.8µL (142.7ng/µL)
Total rxn volume 20µL 20µL 20µL 20µL 20µL 20µL 20µL 20µL 20µL
10X rxn buffer 2µL 2µL 2µL 2µL 2µL 2µL 2µL 2µL 2µL
dH2O 12.5µL 12.8µL 13.1µL 15.6µL 15.9µL 16.2µL 14.3µL 14.6µL 14.9µL
BamHI (NEB) 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL 0.3µL
HindIII (NEB) 0.3µL 0.3µL N/A 0.3µL 0.3µL N/A 0.3µL 0.3µL N/A
SalI (NEB) 0.3µL N/A N/A 0.3µL N/A N/A 0.3µL N/A N/A
Incubation 37°C for 4 hours
have retained quite a large quantity of the unwanted pUC57 backbone as part of
the final ligation. As a counter-measure to having such impurity in the reaction,
pUC57_evo was digested with an extra enzyme XbaI (See Table 4.9) to remove
one of the two sticky ends in the backbone required for ligating it to evo_insert
fragments. However, there might have been enough intact unwanted backbone
fragments remaining to dominate the reactions.
One of the difficulties in subcloning pUC57_evo into pMUTIN4_evo was that
they both rely on a beta-lactamese-based antibiotics marker for screening E. coli
transformants. An intermediate plasmid offering a different class of antibiotics
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marker could make the selection for valid clones easier. Among others, pET28
befitted such a need as the plasmid has a kanamycin resistance cassette, and has
BamHI as well as HindIII as part of its multiple cloning site.
4.2.1.4 Triple Restriction Enzyme Digestion
Table 4.9: triple restriction enzyme digest reaction, as a prestep to subcloning
evo_insert into pMUTIN4
Doner plasmid (main) Vector backbone (main)
(pUC57_evo) (pMUTIN4)
Rxn ID i ii
Total rxn volume 50µL 50µL
pUC57_evo (277.1ng/µL) 18µL (5µg) N/A
pMUTIN4 (253.3ng/µL) N/A 19.7µL (5µg)
10X rxn buffer 5µL 5µL
dH2O 25.5µL 24.3µL
BamHI (NEB) 0.5µL 0.5µL
HindIII (NEB) 0.5µL 0.5µL
XbaI (NEB) 0.5µL N/A
Incubation 37°C for 4 hours 37°C for 4 hours
Inactivation 80°C for 20 mins 80°C for 20 mins
E. coli DH5α transformed with pUC57_evo and pMUTIN4 were grown overnight
on a shaking incubator at 37.0 ◦C The overnight cultures were Miniprep'ed using
the standard protocol described in Section 4.5.8 The triple digest was performed
as summarised in Table 4.9. pUC57_evo was triple digested, in order to obtain a
larger separation between evo_insert fragments and pUC57 backbone fragments.
XbaI would break the pUC57 backbone into smaller pieces.
4.2.2 Subcloning the evo_insert construct from pUC57_evo
into pET28
In the following procedure, the evo_insert from pUC57_evo was subcloned into
pET28 to construct the intermediate plasmid named pET28_evo. The evo_insert
fragments were sourced from the gel-purified double-restriction digest of pUC57_evo
(rxn i) as described in Table 4.4. The pET28 backbone was prepared by double
digesting it with BamHI and HindIII, followed by column purification. A ligation
reaction was prepared based on a 1:3 molar ratio of the backbone (5.3 kb) and the
insert (3.5 kb) as in Table 4.10. Competent E. coli DH5alpha was transformed (See
the protocol in Section 4.5.7), by adding 5 µL of the above ligate in lieu of adding
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Table 4.10: The reaction setup of the ligation of evo_insert and pET28 backbone
fragments:
evo_insert+pET28 backbone
Total rxn volume 10µL
198ng insert 5.4µL (36.5ng/µL)
100ng vector 3.2µL (49.3ng/µL)
10X rxn buffer 1µL
T4 ligase 1µL
dH2O 0.6µL
Incubation 25°C for 3 hours
circular plasmid DNA. The transformant E. coli culture was spread on kanamycin
(50µg mL−1) LB agar plates. After overnight growth, there was an abundance of
colonies surviving. Overnight cultures in LB with 50µg mL−1 kanamycin were set
up from nine randomly chosen colonies. The overnight cultures were minipreped
as per Section 4.5.8, and their resulting plasmid DNAs were subject to diagnostic
restriction enzyme digests and gel electrophoresis as follow (See Table 4.11 and
Figure 4.6).
Table 4.11: Diagnostic restriction enzyme digest reactions, to determine the valid-
ity of putative pET28_evo clones:
rxn ID 1 2 3 4 5 6 7 8 9
Plasmid conc.(ng/µL) 79.5 114.4 85.8 79.5 126.6 200.6 101.4 98.5 114.5
0.2µg plasmid DNA (µL) 2.5 1.8 2.3 2.5 1.6 1.0 2.0 2.0 1.8
Total rxn volume (µL) 20 20 20 20 20 20 20 20 20
10X rxn buffer (µL) 2 2 2 2 2 2 2 2 2
dH2O (µL) 14.5 15.2 14.7 14.5 15.4 16.0 15.0 15.0 15.2
BamHI (µL) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
HindIII (µL) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Incubation 37°C for 4 hours
The lanes labelled 2 and 9 in Figure 4.6 showed two bands approximately at
about 5.3 kb and 3.5 kb. These two bands were highly likely to be respectively
representative of pET28 and evo_insert, and indicated that the corresponding
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Figure 4.6: The diagnostic restriction digest gel electrophoresis of putative pET28_evo
clones: lanes 2 and 9 showed positive results.
4.2.3 Subcloning the evo_insert construct from pET28_evo
into pMUTIN4
In the following procedure, the evo_insert from pET28_evo was subsequently
subcloned into pMUTIN4 to construct pMUTIN4_evo. Double restriction digests
were performed to source the ligation fragments as shown in Table 4.12.
Table 4.12: Restriction enzyme digest reactions, to obtain the evo_insert and
pMUTIN4 backbone fragments:
Doner plasmid Vector backbone
(pET28_evo) (pMUTIN4)
Rxn ID 1 2
Plasmid conc. 114.5ng/µL 253.3ng/µL
Total rxn volume 60µL 20µL
DNA amount 52µL (6µg) 11.8µL (3µg)
10X rxn buffer 6µL 2µL
dH2O 0.0µL 5.2µL
BamHI (NEB) 1µL 0.5µL
HindIII (NEB) 1µL 0.5µL
Incubation 37°C for 4 hours 37°C for 4 hours
The restriction enzyme digest product of pET28_evo was gel purified as per Sec-









A ligation reaction was prepared and was incubated at 25 ◦C for 3 hours, based on
a 1:3 molar ratio of the backbone (8.6 kb) and the insert (3.5 kb) as follows:
evo_insert+pMUTIN4 backbone
Total rxn volume 12µL
122ng insert 5.9µL (20.8ng/µL)
100ng vector 3.7µL (26.7ng/µL)
10X rxn buffer 1.2µL
T4 ligase 1.2µL
dH2O 0.0µL
Competent E. coli DH5alpha was transformed (See the protocol in Section 4.5.7),




Total rxn volume 20µL
DNA amount 1.7µL (0.2µg)



















Figure 4.7: A diagnostic restriction di-
gest gel electrophoresis of the putative
pMUTIN4_evo clone: the bands indicate a
successful pMUTIN4_evo clone.
transformant E. coli culture was spread on ampicillin (100µg mL−1) LB agar plates
pre-treated with a 200µL solution made of 20µL 1 M IPTG, 140µL MilliQ water,
40µL 4 % Xgal (40µg mL−1). After overnight growth, there was a single colony
surviving and passing the blue/white colony test. An overnight culture in LB with
100µg mL−1 ampicillin was set up from that colony. The overnight culture was
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minipreped as per Section 4.5.8, and the resulting plasmid DNA was subject to a
diagnostic restriction enzyme digest followed by a diagnostic gel electrophoresis as
shown in Figure 4.7.
Figure 4.7 at lane 1 showed two bands approximately at about 8.6 kb and
3.5 kb. These two bands were highly likely to be respectively representative of
pMUTIN4 and evo_insert, and indicated that the corresponding clone may habour
pMUTIN4_evo.
4.2.4 Transformation of pMUTIN4_evo into B. subtilis BSB1
The overnight culture of E. coli DH5alpha with pMUTIN4_evo was minipreped.
Competent B. subtilis BSB1 cells were transformed by following the B. subtilis
transformation protocol (see 4.5.6). The transformation culture was spread onto
LB agar plates with 5 µg mL−1 erythromycin and 1 mM IPTG. The plates were
incubated at 37 ◦C overnight. One transformant plate had three colonies, another
transformant plate two colonies, and the negative control plate had zero colonies.
Five colonies were picked for colony PCR to verify their insert sizes. These colonies
were labelled i, ii, iii, iv, and v, together with a wildtype negative control (vi)
and a PCR negative control (vii). The primers were designed to amplify a 4.7 kbp
long band across the evo_insert between the 5-prime end and the 3-prime end of
target locus in the chromosome of B. subtilis. See Table B.4 for the information
on PCR primers used.
Table 4.13: pMUTIN4_evo B. subtilis transformation: colony PCR
Colony PCR table
evo_insert_fwd1 primer 1.25 µL
evo_insert_rev1 primer 1.25 µL
5X PCR buffer 5 µL
dNTP 0.5 µL
Q5 0.25 µL
MilliQ H2O 13.75 µL
template DNA 3.0 µL







Final extension 72°C (2min)
A diagnostic gel electrophoresis was performed to verify the result of the colony
PCRs. A 0.7 % agarose gel was made by following the standard protocol (Section
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4.5.3). The gel was placed into an electrophoresis buffer tray, loaded with reaction
samples (with 6X loading dye, Promega), and applied with 100 V for 1 h. The gel
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Figure 4.8: A diagnostic gel electrophoresis image for the colony PCRs of putative B.
subtilis pMUTIN4_evo clones.
sample on lane v had a band appear little below the 1500 bp ladder, quite distant
from the expected size of successfully amplified DNA fragments (i.e. 4.7 kbp).
Following the unsuccessful result, numerable attempts to transform B. subtilis
using pMUTIN4_evo had failed. Some of the likely explanations to this failure in
transforming B. subtilis with pMUTIN4_evo are as follows. Firstly, the size of the
plasmid is over 12 kb, and this could be too large for the transformation method
using the natural competency of B. subtilis. Transformation using electroporation
(results not shown) was tried with no avail either. Another potential culprit might
be to do with the 500 bp long sequence homologous to the chromosomal insertion
locus in that the homology might be too short with respect to the 12 kb vector to
be inserted as a whole using a single cross-over. The third possibility is that the
insertion of pMUTIN4_evo to the target locus might be fatal to the cell. After
all, I had to move on without finding any definitive answers to these suggested
possibilities due to time constraints in the project.
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4.3 Constructing pSG1729_EVOt2 using Gibson
assembly
Using pUC57_evo as the donor plasmid, two parts of the evo_insert sequence from
the donor plasmid were PCR amplified and subcloned into the pSG1729 backbone
via Gibson assembly. The two-part PCR amplifications of the evo_insert sequence
were aimed at excluding the sfGFP element in the evo_insert sequence. This
recipient plasmid with the two inserts assembled into the backbone's locus under
the regulatory control of the PxylR promoter was named pSG1729_EVOt2 or
pEVOt2 in short (Figure 4.9).
Table 4.14: Gibson primers used for the assembly of pSG1729_EVOt2
Primer ID Oligo sequence
pSG1729 FWD ACGAAAAGGAGGAATTCAAAATGAGTAAAGGAGAAGAACTTTTC
pSG1729 REV CCAACAACCACTCGCCGACGAGATGCATTTTATGTCATATTGTAAG
assembled_seq FWD 1 ATATGACATAAAATGCATCTCGTCGGCGAGTGGTTGTTGG
assembled_seq REV 1 CCATTACAGGCCGGCTTTTTGAATGCTTATTAAACAGCGTCTGCT
assembled_seq FWD 2 ACGCTGTTTAATAAGCATTCAAAAAGCCGGCCTGTAATGG
assembled_seq REV 2 AGTTCTTCTCCTTTACTCATTTTGAATTCCTCCTTTTCGTC




m (°C) Binding(bp) Overhang(bp) ∆Ghairpin(kcal)
pSG1729 FWD 71.0 58.9 0.49 24 20 -0.9
pSG1729 REV 75.3 58.4 0.49 26 20 -5.3
assembled_seq FWD 1 74.9 68.7 4.30 20 20 -4.4
assembled_seq REV 1 76.9 64.4 4.30 25 20 -2.8
assembled_seq FWD 2 74.6 63.7 4.92 20 20 -1.7
assembled_seq REV 2 70.8 58.8 4.92 21 20 0
The pSG1729 and pUC57_evo plasmids were diluted to the concentrations of
1 ng µL−1 PCRs were run as specified in Table 4.15 and Table 4.14.
PCR samples were column purified using QIAGEN PCR Purification Kit. Nan-
odrop readings were obtained for PCR results (see Table 4.16) DpnI digestion was
performed on PCR samples (see Table 4.17) A 3-fragment Gibson assembly was
done (see 4.5.2) as per Table 4.18 Colony PCR was performed to identify trans-
formants with successful plasmid assembly. Five colonies were picked (samples
labelled i through v, in addition to a negative sample (vi)) using sterile pipette
tips and each picked colony was suspended in 20µL of cold MilliQ H2O. 1 µL
from each suspended sample was used as template DNA in PCR set up as in the
following Table 4.19. See Table B.4 for the information on PCR primers used.
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Figure 4.9: The pSG1729_EVOt2 plasmid map.
A diagnostic gel electrophoresis was performed to verify the result of the colony
PCRs. A 0.7 % agarose gel was made by following the standard protocol (Section
4.5.3). The gel was placed into an electrophoresis buffer tray, loaded with reaction
samples (with 6X loading dye), and applied with 100 V for 1 h. The gel was UV
imaged on a gel dock afterwards. Figure 4.10 shows that samples i and ii had
bands appear in between the 1500 bp and 2000 bp ladders very close to the 2000
bp ladder. The expected size of successfully amplified DNA fragment, as a result
of the colony PCR, is 1918 bp, and these two bands seem to be in correct sizes.
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Table 4.15: pSG1729_EVOt2 assembly PCR details:
PCR #1: backbone
pSG1729 FWD primer 1.25 µL
pSG1729 REV primer 1.25 µL
5X PCR buffer 5 µL
dNTP 0.5 µL
Q5 0.25 µL
MilliQ H2O 16.25 µL
pSG1729 plasmid (1ng/µL) 0.5 µL







PCR #2: insert 1
assembled_seq FWD 1 primer 1.25 µL
assembled_seq REV 1 primer 1.25 µL
5X PCR buffer 5 µL
dNTP 0.5 µL
Q5 0.25 µL
MilliQ H2O 16.25 µL
pUC57_evo plasmid (1ng/µL) 0.5 µL







PCR #3: insert 2
assembled_seq FWD 2 primer 1.25 µL
assembled_seq REV 2 primer 1.25 µL
5X PCR buffer 5 µL
dNTP 0.5 µL
Q5 0.25 µL
MilliQ H2O 16.25 µL
pUC57_evo plasmid (1ng/µL) 0.5 µL







Table 4.16: pSG1729_EVOt2 assembly: PCR Nanodrop results
Nanodrop readings
PCR #1 PCR #2 PCR #3
ng/µL 40.6 66.1 41.2
260/280 1.88 1.88 1.83
260/230 1.52 2.26 1.81
Table 4.17: pSG1729_EVOt2 assembly: DpnI digestion
Restriction Enzyme reaction table
PCR #1 PCR #2 PCR #3
DNA sample 8 µL (325ng) 6.9 µL (455ng) 6.3 µL (257.7ng)
RE buffer (10X) 1 µL 1 µL 1 µL
MilliQ H2O 0 µL 1.1 µL 1.7 µL
DpnI (NEB) 1 µL 1 µL 1 µL
Total rxn volume 10 µL 10 µL 10 µL
Gibson: sample molar value 1X molar (100ng) 3X molar (45.5ng) 3X molar (12.6ng)
Gibson: sample volume 3.1 µL 1 µL 0.5 µL
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Table 4.18: pSG1729_EVOt2 assembly: Gibson reaction
Gibson reaction table
PCR sample #1 3.1 µL (100ng: 1X molar)
PCR sample #2 1.0 µL (45.5ng: 3X molar)
PCR sample #3 0.5 µL (12.6ng: 3X molar)
MilliQ H2O 5.4 µL
Gibson master mix (2X) 10 µL
Total rxn volume 20 µL
Table 4.19: pSG1729_EVOt2 assembly: colony PCR
Colony PCR table
pEVOt2_colpcr FWD primer 1.25 µL
pEVOt2_colpcr REV primer 1.25 µL
5X PCR buffer 5 µL
dNTP 0.5 µL
Q5 0.25 µL
MilliQ H2O 15.75 µL
template DNA 1.0 µL
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Figure 4.10: A diagnostic gel electrophoresis image for the colony PCRs from Table
4.19.
42
4.3.1 Resuspension of lyophilised DNA (Revised from the
Genscript protocol)
The vial containing lyophilised DNA was centrifuged at 6000x g for 1 minute.
20µL of deionised water (MilliQ) was added to the vial. The solution was heated
at 50 ◦C for 15 minutes.
4.3.2 Amplification of plasmid DNA using E. coli transfor-
mation
Plasmid vectors (e.g. pMUTIN4 or pUC57_evo) were used in transforming chem-
ically competent E. coli culture (DH5alph or MC1061) via the heat-shock pro-
tocol (see 4.5.7). Ampicillin (100µg µL−1) LB agar plates were used for select-
ing E. coli transformants of pMUTIN4 and pUC57_evo. Approximately about
200 ng of circular plasmid DNA was used in each transformation reaction. 3 µL
of pMUTIN4 in 83 ng µL−1 was added per 100µL of competent cells. 1 µL of
pUC57_evo in 200 ng µL−1 was added per 100µL of competent cells. E. coli trans-
formants were cultured overnight and their plasmids were extracted. 10 mL of LB
with 100µg mL−1 of ampicillin was innoculated with a single colony from the E.
coli transformant plates (see 4.5.7). Three colonies from the plate of pMUTIN4
transformants and three colonies from the plate of pUC57_evo transformants
were picked, and used for respectively innoculating 10 mL ampicillin LB in 50 mL
polypropylene conical centrifuge tubes. The innoculated culture tubes were incu-
bated for 16 hrs at 37 ◦C on a shaker. Plasmid DNA from each overnight culture
was extracted using Miniprep (see 4.5.8).
4.3.3 Transformation of pSG1729 into B. subtilis BSB1
B. subtilis BSB1 was transformed using the same protocol as shown in Section 4.4
with the exception of using pSG1729 instead of pSG1729_EVOt2.
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4.4 Transformation of pSG1729_EVOt2 into B.
subtilis BSB1
The overnight culture of E. coli MC1061 with pSG1729_EVOt2 was minipreped.
Competent B. subtilis BSB1 cells were transformed by following the B. subtilis
transformation protocol (see 4.5.6). The transformation culture was spread onto
LB Spec agar plates. The plates were incubated at 37 ◦C overnight. Colonies were
picked and replica plated on a starch plate for checking the loss of amylase activity
on correct transformants. Colonies that have lost amylase activity were picked for
colony PCR to verify their insert sizes. These colonies were labelled i, ii, iii, iv,
v and vi, together with a negative control (vii). The primers were designed to
amplify a 1464 bp long band carrying a portion of the gene for spectinomycin
resistance (from pSG1729_EVOt2) and a portion of the 3-prime end of the amyE
gene (from the chromosome of B. subtilis). See Table B.4 for the information on
PCR primers used.
Table 4.20: pSG1729_EVOt2 B. subtilis transformation: colony PCR
Colony PCR table
colpcr_pSG_spec_spec_cds_fwd primer 1.25 µL
colpcr_amyE_3p_end_rev primer 1.25 µL
5X PCR buffer 5 µL
dNTP 0.5 µL
Q5 0.25 µL
MilliQ H2O 15.75 µL
template DNA 1.0 µL







Final extension 72°C (2min)
A diagnostic gel electrophoresis was performed to verify the result of the colony
PCRs. A 0.7 % agarose gel was made by following the standard protocol (Section
4.5.3). The gel was placed into an electrophoresis buffer tray, loaded with reaction
samples (with 6X loading dye), and applied with 100 V for 1 h. The gel was UV
imaged on a gel dock afterwards. Figure 4.11 shows that samples iii, iv and vi
had bands appear little below the 1500 bp ladder, very close to the expected size
of successfully amplified DNA fragment (i.e. 1464 bp). The mutant colony used
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Figure 4.11: A diagnostic gel electrophoresis image for the colony PCRs from Table
4.20.
4.4.1 Sequence verification of the B. subtilis EVOt2 mutant
The chromosomal DNA of B. subtilis EVOt2 was prepared using DNeasy Blood &
Tissue kit (QIAGEN), and was sequenced using Illumina MiSEQ at the sequencing
facility in CBCB. The raw sequence reads were stored in FASTQ format, and were
assembled using the sequence assembly pipeline shown in Section 5.3.2.1. The
EVOt2 sequence was blasted against the nucleotide sequences of contigs generated
from the de novo assembly in the pipeline, to find a contig that carried a chromo-
somally inserted copy of the EVOt2 sequence. The chromosomal copy of EVOt2
was compared against the original EVOt2 sequence for any anomalies. As shown
in Figure 4.12, the chromosomal EVOt2 sequence and its amyE insertion locus in
the B. subtilis BSB1 genome were examined to be 100 % accurate.
4.4.2 Flow cytometry of the B. subtilis EVOt2 mutant
B. subtilis EVOt2 clone was cultured overnight in LB with 50µg mL−1 spectino-
mycin. Four different growth media as shown in Table 4.21 were innoculated from
the overnight culture and were incubated at 37 ◦C on a shaker. At 150 min into the
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Figure 4.12: An annotated sequence showing the region in and around the chromoso-
mally inserted copy of EVOt2.
incubation, 10µL of culture from each growth media was harvested and diluted
in 1 mL of chilled PBS. The PBS diluted samples were immediately placed in ice.
Flow cytometry was performed on each of the four samples. Flow cytometry was
repeatedly performed on samples harvested at 60 min intervals till 390 min using
the same PBS dilution ratio. The resulting raw cytometry data readings were
processed by the Python script1 to automatically generate Figure 5.8.
Table 4.21: B. subtilis EVOt2 growth conditions and expected outcomes.
Media ID Composition Expected fluorecence level
m0 LB with 1% xylose lowest
m1 LB with riboflavin and 1% xylose higher than m0 and lower than m3
m2 LB higher than m0 and lower than m3
m3 LB with riboflavin high
1Appendix A.3 shows an instruction to invoke a Docker container to use the Python script.
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4.5 Standard lab protocols
4.5.1 DNA gel extraction using QIAGEN kits (modified from
the original instructions)
An empty microcentrifuge tube was used to tare a scale. A gel slice was placed
into the microcentrifuge tube and weighed. Given the rough estimate of 100 µg =
100 µL, 3X gel volume equivalent of QG buffer was added to the tube. With-
out any vortexing, the tube was incubated at 50 ◦C for 5 min to dissolve the gel.
1X gel volume equivalent amount of isopropanol was added to the tube and gen-
tly mix by flicking with a finger. The disolved solution was added to QIAGEN
spin column(s) to be centrifuged at 13 000 RPM for 1 min. The flow-through was
discarded. Each spin column was topped up with fresh 500µL QG buffer, and
centrifuged to discard the flow-through. 750µL Buffer PE was added to each spin
column, to be incubated at room temperature for 4 min. All columns were cen-
trifuged and the flow-throughs discarded. The columns were centrifuged for one
more run of 13 000 RPM to rid of residual buffer. Each column was placed in a
sterile 1.5 µL microcentrifuge tube. 25µL EB, warmed to 50 ◦C, was added to the
center of each column's membrane. The columns were incubated at room tem-
perature for 5 min, centrifuged at 13 000 RPM for 1 min. 25µL of fresh EB was
added again before the tubes get incubated for 5 min in room temperature, and
centrifuged at 13 000 RPM for 1 min. The 50µL of elute in each collection tube was
run through the same column again, to be incubated and centrifuged under the
same conditions as before. The final step was repeated one more time to increase
the yield.
4.5.2 Gibson Assembly
Assembly reactions were set up as explained in Table 4.221. Reaction samples were
incubated at 50 ◦C for 1 hour using a thermocycler with the lid temperature set at
99 ◦C. Chemically competent E. coli cells were transformed using the heat shock
protocol (see 4.5.7).
1Based on NEB Gibson assembly protocol
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Table 4.22: Gibson Assembly reaction setup chart.
23 fragment assembly 46 fragment assembly
Total amount of fragments X µL (0.02  0.5 pmols) X µL (0.2  1 pmols)
Gibson Assembly master mix (2X) 10 µL 10 µL
MilliQ H2O 10 - X µL 10 - X µL
Total Volume 20 µL 20 µL
4.5.3 Making 0.7 % agarose gel for electrophoresis
For a 40 mL volume, 0.28 g of agarose was measured out, and poured into a 150 mL
flask. 40 mL of 1X TAE was added into the flask and microwaved up to about
1.5 min till the solution started to boil. The flask was gently swirled until the
molten agarose solution was clear. The flask was rested on a bench, till it cooled
to a level, warm to touch. 1.0 µL of stock EtBr solution (10 mg mL−1) was added
to the molten agarose and was gently swirled to mix. A well comb of chosen size
was placed onto an appropriately sealed casting tray. The agarose solution was
poured into the tray. A sterile pipette tip or a toothpick was used to remove any
impurities and bubbles. The gel was left in room temperature for about 30 min
till it firmly solidified.
4.5.4 Freezing B. subtilis competent cells
The starvation culture was centrifuged down and was concentrated by 10X. The
supernatant was used for resuspending the spun-down cells. Glycerol was added in
the culture to the 15 % (v/v) concentration (e.g. 300µL of 50 % glycerol in 700µL
culture). 100µL aliquots of the glycerol culture werepipetted to Eppendorf tubes.
The tubes were snap-frozen in liquid nitrogen, and stored in −80 ◦C.
4.5.5 B. subtilis transformation using frozen competent cells
Frozen competent cells would result in a lower transformation efficiency compared
to freshly prepared competent cells. Competent B. subtilis cells in 100µL aliquot
was thawed at room temperature. 500 ng to 2 µg of plasmid DNA was added to the
cells. The tube was incubated at 37 ◦C for 1 hr. 200µL of the incubated culture
was plated on a selection plate, and incubated overnight at 37 ◦C.
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4.5.6 B. subtilis transformation using natural competency
This protocol worked for 168 and BSB1 with high efficiency. A single colony was
scraped from a plate of B. subtilis wildtype strain, and was used to inoculate
5 mL of MM competence media (see B.5.2) in a 15 mL Falcon tube. The culture
was incubated at 37 ◦C, 180 RPM overnight. 0.3 mL of the overnight culture was
transferred into fresh 5 mL MM competence media in a 50 mL Falcon tube, and
incubated for 3 hrs at 37 ◦C, 180 RPM. 5 mL of pre-warmed (37 ◦C) Starvation
media (see B.5.3) was added, and incubated for 2 more hours at 37 ◦C, 180 RPM1.
0.4 mL of the culture was transferred to a 1.5 mL micro-centrifuge tube, and 1 µg
DNA was added. Nanodrop was used to measure the DNA concentration of the
plasmid Miniprep. Negative controls, such as a separate 0.4 mL culture without
adding plasmid DNA were included. The tubes were incubated at 37 ◦C, 180 RPM
for 1 hr. For each incubation culture, 200µL was plated to a selection plate,
and was incubated overnight. Plates with an appropriate antibiotics were used as
an initial screening. Replica plating on starch plates was performed to test for
transformants with the successful integration into the amyE locus.
4.5.7 E. coli transformation using heat shock
A heat block was preheated to 42 ◦C. LB agar plates containing appropriate an-
tibiotics (selection plates) were rested in room temperature, so the plates were not
too cold before plating transformed cells. 1.5 mL microcentrifuge tubes containing
100µL aliquots of chemically competent E. coli cells (e.g. DH5alpha or MC1061)
that had been kept frozen at −80 ◦C were taken out immediately before use. The
competent cell tubes were placed on ice and were incubated for 10 minutes to
slowly thaw. Approximately about 200 ng of circular plasmid DNA was added
into each tube. The tubes were incubated on ice for further 20 minutes. The
tubes were heated at 42 ◦C for 50 seconds using the preheated heat block. The
tubes were placed back onto ice, and were incubated for 2 minutes, in order to
reduce the heat shock damage. 1 mL of LB was added to each tube. Then the
1Competent cells were frozen after the starvation incubation. See the protocol for freezing B.




tubes were incubated in 37 ◦C on a shaker for 45 minutes. 100µL of the resulting
culture from each tube was pipetted onto a selection plate, and spreaded using
sterile beads. 400µL of the remaining culture from each tube was pipetted onto
another selection plate and spreaded using sterile glass beads. This second high-
cell-count plating was used as a contingency measure in case of low transformation
efficiency. The plates were incubated at 37 ◦C overnight.
4.5.8 QIAprep Spin (Qiagen) Miniprep
The overnight cultures were pelleted by centrifugation at 6800x g for 3 minutes
at room temperature. After discarding the supernatant, the pelleted cell mass in
each tube was resuspended in 500µL resuspension buffer (Buffer P1), and vortexed.
The composition of the resuspension buffer was 50 mM Tris-HCl at pH 8.0, 10 mM
EDTA, and RNAse A in 100µg mL−1 concentration. Due to the presence of RNAse
in the buffer, the buffer had been kept in 4 ◦C, and was chilled on ice prior to use.
Each 500µL cell resuspension was transfered to two 1.5 mL microcentrifuge tubes
in aliquots of 250µL. To each microcentrifuge tube, 250µL lysis buffer (Buffer P2),
with a composition of 200 mM NaOH and 1 % SDS, was added. All tubes were
inverted back and forth until the solutions were mixed well and turned clear. The
tubes were incubated at room temperature for 3 minutes. Immediately following
the previous step, 350µL neutralisation buffer (Buffer N3), with a composition of
4.2 M GuHCl and 0.9 M KAc at pH 4.8, was added to each tube, and thoroughly
mixed by inverting 5 times. The solution formed white precipitates out of SDS,
lipid and protein, and exhibited gooey consistency mostly due to the presence of
chromosomal DNA. The tubes were spun down for 10 minutes at 13000 rpm on
a benchtop centrifuge. The supernatant was transfered to respectively labelled
QIAprep spin columns. The spin columns were centrifuged for 60 seconds, and
the flow-through was discarded. 500µL wash/binding buffer (Buffer PB), with
a composition of 5.0 M GuHCl and 30 % isopropanol, was added to each spin
column. The columns were centrifuged for 60 seconds at 13000 rpm to discard
the flow-through. 750µL wash buffer (Buffer PE), with a composition of 10 mM
Tris (pH 7.5), and 80 % EtOH, was added to each spin column. The columns were
centrifuged for 60 seconds at 13000 rpm to discard the flow-through. The columns
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were centrifuged for 1 additional minute to remove residual wash buffer. Each
column was moved to a sterile 1.5 mL microcentrifuge tube, then was added 50µL
elution buffer (Buffer EB), with a composition of 10 mM Tris-HCl, pH 8.5. After
incubating the columns in room temperature for 5 minutes, they were centrifuged
for 1 minute at 13000 rpm to elute plasmid DNA. Then aliquots of the plasmid
DNAs were stored in 4 ◦C for a short-term storage, and in −20 ◦C for a long-term
storage.
4.5.9 Purification of restriction digested DNA fragments us-
ing QIAquick spin columns
250µL Buffer PB was added to each of 50µL restriction digested solution A spin
column was mounted per solution mix into a collection tube, and the mix was
pipetted into the spin column. Spin columns were centrifuge at 13000 RPM for
1 minute, and the flow through was discarded. 750µL Buffer PE was added to
each tube. Tubes were incubated at room temperature for 2 minutes, and were
centrifuged at 13000 RPM for 1 minute. The flow through was discarded after-
wards. One more centrifugation was performed at 13000 RPM for 1 minute to rid
fo residual wash buffer. Each spin column was moved to a sterile 1.5 mL centrifuge
tube. 30µL elution buffer was added to the centre of each spin column's filtering
membrane. Spin columns were incubated at room temperature for 5 minutes, and





The in vivo evolutionary design
process
5.1 Introduction
Rationality is one of the underlying assumptions used in game theory to explain
how people make decisions [18]. Endowed with the propensity to reason, human
mind is inclined to make rational decisions. Our mind likes to secure the sense
of being in control so much so that all decisions taken need to make rational
sense, if at all possible. The pitfall in such a perfectionist's approach to decision
making is that it has heavy reliance on a priori knowledge. To make rational sense
of something requires having the knowledge to determine so [155]. For problem
domains that are novel and complex, the extent to which rational decisions can
hold as valid is severely limited. In the biomedicine field, for instance, drug design
based on trial and error is more likely to succeed than rational design approaches
[181]. The issue with rational design approaches here arises from the challenging
nature of dealing with highly complex biological systems of which we currently
do not have complete understanding. As such, rational decision making is only
capable of playing limited roles in engineering complex biological systems.
That a search process taking random walks in the solution space can accomplish
design is a notion wholly adopted by natural evolution. Nature employs DNA as
a medium to encode the solution space, and harnesses random mutagenesis as a
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vehicle to explore the space in search for sample solutions. Environmental niches
would provide selection pressure to reinforce small subsets of solutions that happen
to meet the needs of interest. The net result of which processes is so powerful
that there exist a plethora of genetic designs encoding proteins with incredibly
complex and diverse functions in nature. Charles Darwin, during his journey
around the world onboard HMS Beagle, marvelled at the diversity of species, and
their remarkably adapted functional features suitable for specific environmental
needs [49].
In the design of synthetic biological systems, the use of random solutions of-
fers a viable alternative to rational approaches [80]. The hurdle in going random,
however, is finding ways to cope with the problem of search space explosion. The
volume of a given search space would exponentially expand and quickly become
unwieldy as more and more genes are combinatorially considered as part of a de-
sign. Richard Bellman, a mathematician, summed up this search space expansion
problem so elegantly by coining the term, the curse of dimensionality, to explain
the difficulty of dealing with high-dimensional solution spaces [16].
To a degree, the curse has negatively affected numerical sciences in that use
of the term is often associated with the justification for going against the idea
of dealing with high dimensional spaces. In synthetic biology, with respect to
harnessing random solutions in design, the curse would need to be a subject not
to be avoided but to be embraced. In order to make significant progresses in
the field, dealing with high-dimensional spaces is inevitable. To this end, there
are interesting research questions to be asked. Would it be possible to contain
the curse of dimensionality as a result of harnessing random design strategies in
synthetic biology? If so, how can this containment be articulated? What would
then be the limit to the complexity of genetic systems design, practically achievable
by employing random design?
5.1.1 Establishing the scope of design in synthetic biology
Often, the term design is perceived only by the final outcome or artefact of
design [59, 60]. With respect to the current discussion of design, the focus is not
on the design artefact per se but on the art of engineering design or the processes
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that lead into producing design artefacts. Crucial in the art of design engineering
is design documentation with which to capture information sufficient enough to
specify how the functional properties of final design artefacts can be achieved, as
explained in Chapter 1.
Design artefacts of biological systems in the context of synthetic biology are
functional properties of the systems being designed that can carry out meaning-
ful cellular processes. Therefore, biological systems design should ideally convey
unequivocal documentations on how to achieve desired cellular functions of the sys-
tems being designed. In agreement with the central dogma, generally regarded as
true [45], is the idea that cellular functions of biological systems are emergent prop-
erties of relevant genetic elements. This proposition makes genetic sequences well
positioned to be the documenting medium for design implementation in synthetic
biology. However, design in synthetic biology is not simply about documenting
genetic sequences. It is more importantly about how to evaluate the fitness level
of genetic sequences in fulfilling desired cellular functionalities. Design in synthetic
biology should, therefore, be inclusive of the means with which a particular genetic
sequence can be tested for the possession of intended functional properties.
5.1.2 Solution generation via random mutagenesis
Random mutagenesis of cellular DNA sequences can be induced from various
sources including chemicals [84, 166, 188], transposons [109, 157, 185], and stress
factors such as aging [20], starvation [26], UV irradiation [67], or oxidation [20].
Mutations can also occur spontaneously due to errors in the DNA replication ma-
chinery and the mismatch repair mechanism [56, 169, 179]. Aspects concerning
safety and automation were considered in this study as part of adopting a mu-
tagenesis strategy for use in the iterative design cycle of the dual-evolutionary
approach. Chemically induced mutagenesis strategies were excluded due to safety
concerns, and strategies involving transposons and stress factors were excluded
due to difficulties in automating their induction procedures. Adopting the sponta-
neous mutagenesis strategy befitted the criteria as the strategy offered to be both
safe and amenable to automation.
Evaluating the spontaneous mutation of microbes provided some useful insight
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into the feasibility of using this mutagenesis strategy in directed evolution. Spon-
taneous mutation in E. coli for instance, is known to occur at a rate of about
1 × 10−3 per genome and generation [179]. The probability of a single point mu-
tation was assumed to be roughly equal to the mutation rate. This is a valid
assumption given the small value for the rate. This means that a single point
mutation is expected to occur every 1000 cells being replicated. Provided that the
bacterial genome has 4.22 × 106 base pairs, the mutation rate per base pair per
replication is 4.22−1 × 10−9. This number is largely based on the error rate of the
DNA replication machinery when cells are dividing. In order to find a cell that
ends up with a specific point mutation, it is expected that 4.22 × 109 cells need
screening1.
An E. coli culture at OD600 of 1.0 would roughly amount to a cell density of
about 8 × 108 cells/mL [153]. The ∆mutSL mutation in Listeria monocytogenes
was shown to result in 100- to 1000-fold increase in the spontaneous mutation
rate [119]. Assuming the same OD600 readings to cell density conversion, and a
1000-fold increase in mutagenesis via ∆mutSL in B. subtilis, 4.22 × 106 cells, or
roughly about 5.28 uL of B. subtilis cell culture at OD600 of 1.0 would contain a
cell with a specific point mutation. Extrapolating this thought experiment, 22.3 L
culture at OD600 of 1.0 would amount to approximately about 1.78× 1013 cells, a
cell population large enough to expect a cell with a specific double SNPs.
In nature, the hypermutation state resulting from the lack of mut genes re-
sponsible for DNA mismatch repair was shown to have significant consequences in
facilitating bacterial adaptation, such as enhancing virulence and surviving in hos-
tile environments [13, 132, 189]. The possibility of successful bacterial adaptation
cases demonstrated in nature corroborates the idea that viable solutions to com-
plex problems can be generated from random solution pools driven by spontaneous
mutagenesis.
1Let a specific point mutation be an event that occurs with probability p = 4.22−1 × 10−9,
then the mathematically expected number of cells (E) to be screened before seeing the first
occurrence of a cell with the specific point mutation is E = 1/p
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5.1.3 Feasibility of finding solutions in randomness
There are numerable factors, considerable, affecting the feasibility of using directed
evolution and random mutagenesis in genetic systems design. These include de-
sign complexity, microbial sample size, selection throughput and mutation rate.
Design complexity would be positively correlated to the volume of the search-
able solution space - the more complex a design is, the further the solution space
exponentially expands. As the solution space begins to explodingly expand, a
proportionately large population of cells is necessary to support enough random
solutions to harbour a fit solution. Having a large population of cells subject to
random mutagenesis, hence a large pool of solution candidates, would be bene-
ficial to counteracting the curse of dimensionality associated to complex designs.
However, there is a downside to having a large cell count. The larger the cell count
is, the more critical the selection throughput becomes, as the process of screening
and sorting cells based on measurements has costly overhead [35].
Fluorescence-activated cell sorting (FACS) devices, touted to offer an ultra-high
throughput screening in today's standard, can perform at a rate of approximately
about 107 particles per hour [193]. While it seems as though a large number, such
a throughput is still far from being sufficient, at least for the purpose of employing
directed evolution in complex designs. For example, it would require screening
through a minimum of 4.22 × 106 cells in order to ensure that a specific point
mutation can be found in B. subtilis, assuming a mutation rate of 4.22−1 × 10−6
per base pair per replication (See Section 5.1.2). This means it would need about
half an hour1 of continuous operation of a FACS device, before a desired single
point mutation can be isolated, provided that the FACS device is error-free. In
reality, FACS-based screening and sorting would take longer.
The search time worsens exponentially as we enter the territory of multiple
point mutations. In screening for a specific double point mutations, the minimum
search space is as large as 1.78 × 1013 cells. This would amount to about 1.78
million hours of continuous operation of a single FACS device to ensure a desired
mutant to be found. Using multiple FACS machines for parallel search operations
would only be able to diminish the numbers in a linear fashion. While limited,
14.22× 106 cells divided by 107/60 particles per minute = 25.32 minutes
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increased mutation rates can take some load off of the screening and sorting process
by reducing the total number of cells per point mutation. Increased mutation rates
would amount to higher solution densities per unit cell population, hence would
reduce the total number of cells to be screened per desired solution. Nonetheless,
the improvement offered by increased mutation rates would be limited, certainly
not meaningful enough to warrant the adoption of mechanical sorting in directed
evolution.
The process of random mutagenesis is indifferent to which way changes are
made in the genome. It is only that the selection process is intrinsically biased by
the constant pressure of the need to sustain life, and ends up favouring one muta-
tion to another. Directed evolution can harness random mutagenesis and extrinsic
evolutionary pressure to drive random changes towards meeting certain fitness cri-
teria [9, 193], unessential to sustaining life. The biosynthesis of secondary metabo-
lites accounting for many commercially significant high-value chemicals [11, 92]
are good examples relevant to the application of such extrinsic fitness criteria.
Whether intrinsic or extrinsic, evolutionary pressure is a type of a selection pro-
cess. In case of the intrinsic pressure, the selection process is the survival of the
fittest, the end result of which is the enrichment of traits deemed advantageous or
necessary for sustaining life in the given environmental conditions. The selection
process concerning extrinsic pressure, on the other hand, can enrich groups with
traits, normally considered unessential for the purpose of sustaining life.
How can we enrich groups with unessential traits then? Cherry picking cells
after screening for desirable traits is one obvious way, albeit such a selection process
is limited by the throughput of the screening and sorting procedures as well as the
feasibility of trait quantification. Alternatively, extrinsic selection processes can
take place by being coupled to the intrinsic selection process, so that the traits of
interest, that are otherwise unessential, become conditions for survival. Making
survival dependent on certain unessential traits can be challenging on its own
right. Nevertheless, the coupling approach offers an attractive means for effectively
exploring a large design space via random mutagenesis, since the approach does not
suffer as much from the bottleneck imposed by screening and sorting throughput
as the cherry picking approach.
What does it mean by being throughput limited in terms of the selection pro-
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cesses in directed evolution? Given a finite search time, it amounts to having a
limited coverage in the solution space, therefore having a reduced likelihood of
running into a solution. Adding more equipment, let alone the problem of doing
so not being economically viable an option, would not help much in an attempt to
increase the throughput, as the throughput gain in doing so only goes up linearly.
Simply put, such a linear gain cannot deal with solution space explosion.
What if each cell had the capability to screen itself in or out? Suffice it to say,
the selection process would then no longer be the limiting factor. The bottleneck
would then be at the mutagenesis rate, or the rate of churning out solution can-
didates. The work described in Section 5.2 was an attempt to provide a viable
solution to the problem of developing an in vivo genetic device that can couple
the biosynthesis of a non-essential metabolite to a survival condition. The genetic
device was designed to confer the capability of self-screening or selecting for given
fitness criteria on individual cells.
5.1.4 Application of the in vivo evolutionary approach to a
metabolic engineering case in bacteria
A specific application case was needed, in order to explain implementation-level
details of the concept of harnessing the in vivo evolutionary approach to design.
A metabolic engineering case, more specifically the biosynthesis of riboflavin, was
considered in this study as an example.
Riboflavin is essential to the production of biologically critical coenzymes such
as FMN and FAD. Since higher organisms, such as mammals, have lost their ability
to naturally synthesize the metabolite in vivo, higher organisms rely on dietary
intakes for the supply of this essential nutrient, commonly known as vitamin B2.
Only microorganisms and plants can produce riboflavin. The industrial riboflavin
production is estimated to have exceeded 3000 metric tons per year, and about
80% of which is produced by employing microorganisms [114].
Taking the evolutionary design approach to the biosynthesis of riboflavin would
offer to be an exemplary synthetic biology application having potentials for imme-
diate industrial implications. Also, there already exist known genetic mutations
that would result in riboflavin overproduction [40, 164] in a number of different or-
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ganisms including B. subtilis. Those known mutations can act as reference points
for comparing potential solutions generated by the evolutionary approach.
5.1.5 Minimising testing overheads via automation
As previously pointed out, testing is one of the most important elements in design.
Its importance is especially pronounced in taking the evolutionary approach to
design where solutions are found in randomness. The evolutionary approach is an
iterative design scheme in which random solutions get repeatedly tested for their
fitness.
The in vivo device shown in Section 5.2 was in fact designed to embed a molec-
ular testing mechanism into individual cells. It is a form of automated testing
achieved at the cellular level. There are other levels of testing that necessitate
benchwork and data analysis in order to better understand putative genetic so-
lutions at hand. Tests of such kind have costly overheads. The work shown in
Section 5.3 addressed the subject of automating the analysis of data acquired
from routinely performed laboratory procedures such as cytometry and genome
sequencing.
5.2 Designing a genetic system to support in vivo
evolutionary design
If the phenotypic change introduced by a point mutation of interest confers resis-
tance to some substance that is otherwise fatal to the organism, its screening is
as easy as using intrinsic selection or conventional molecular biology techniques
in which survivors are picked from plates with selective growth conditions. In ex-
trinsic selection cases, such as finding the trait of riboflavin biosynthesis, the same
plate screening technique is not a viable option, as the production of riboflavin is
normally considered unessential to survival.
In order to address this issue, an in vivo genetic system was designed to couple
intrinsic selection pressure to extrinsic selection. The trait of riboflavin biosyn-
thesis can be coupled to the survival condition of B. subtilis via using a molecular
sensor capable of detecting the presence of riboflavin in the organism. Bacillus
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subtilis possesses a negative feedback mechanism by which riboflavin production
in vivo in the wildtype organism is regulated, as the microorganism only needs a
trace amount of riboflavin in normal conditions.
FMN is a phosphorylated form of riboflavin that is involved in the negative
feedback regulation of riboflavin biosynthesis in some microoragnisms including B.
subtilis. B. subtilis uses a form of riboswitch that can have conformational changes
depending on the presence of FMN in the cytosol [110, 186]. In the presence of
FMN, the riboswitch forms a rho-independent termination loop at the 5-prime-
end untranslated region of the rib operon, resulting in the premature termination
of the operon's transcriptional events. In the absence of FMN, the termination
loop structure is disrupted to a level not stable enough to halt transcriptional
events. The endogenous FMN riboswitch of B. subtilis, used in the following
coupler design, was adopted from a part of the 5-prime-end untranslated region of
the rib operon1 of Bacillus subtilis 168.
5.2.1 Building a FMN sensor construct
The FMN riboswitch sequence was obtained from the 285bp leader sequence up-
stream of the start codon of ribD2 in B. subtilis 168. The strain's reference genome
sequence from which the leader sequence was obtained is accessible via Genbank
accession ID AL009126.3 [105]. The 285bp leader sequence should carry the native
promoter and RBS of ribD. The sequence's FMN dependent riboswitch property
provides a mechanism for the inhibition of the expression of any downstream genes
concatenated to the sequence in tandem.
Two different ways to apply selection pressure was considered using this sensor
construct. One was to use selective activation of a kill switch, and the other was
to use selective activation of an antibiotic resistance. The former would need to
actively promote a death mechanism for the unfit, while the latter would need
a survival mechanism for the fit. Given the inhibitory regulation of the FMN ri-
boswitch, it would seem that concatenating a death mechanism downstream of the
sensor construct can be an effective measure to select for the population producing
1The rib operon expresses enzymes for metabolising nutrients into riboflavin and FMN.
2The ribD gene is synonymous to ribG in B. subtilis.
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(or with the cytosolic presence of) FMN. It is true in a logical sense that inhibiting
death of the fit is equivalent to promoting the fit. However, this approach would
drive the fate of the unfit to plunge into death by default. This means that initially
unfit mother cells (lacking the target phenotype) would be deprived of any chances
to evolve. Therefore, it is imperative that the default status of mother cells not
be death but survival. This design requirement was achieved by concatenating a
NOT gate followed by an antibiotic resistance. By opting for the survival mech-
anism via antibiotic resistance, the time point in which selection takes place can
be controlled at will. Mother cells can then take as much time as needed before
being subject to antibiotic screening that selectively kills off the unfit.
Figure 5.1: The sensor construct coupled to a survival mechanism via a NOT gate
5.2.2 A NOT gate coupled to the FMN sensor for positive
regulation
A NOT gate was introduced to reverse the logic of the inhibitory regulation of the
FMN riboswitch, so that the presence of FMN can be tied to survival (See Figure
5.1). The 285bp FMN riboswitch sequence was joined together with the coding
sequence of tetR from transposon Tn10 (BBa_C0040), sourced from the Registry
of Standard Biological Parts. The -35 and -10 regions of the xylA promoter of
B. subtilis 168 [71] were used together with O1 TetR operator sequence [72] in
building a B. subtilis promoter negatively regulated by TetR.
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Table 5.1: The truth table of FMN vs antibiotic resistance for survival.
FMN available TetR expressed resistance
True False True
False True False
Figure 5.2: An inducible mutSL operon to programmatically regulate mutagenesis
rates
5.2.3 A construct to regulate the mutagenesis rate
The mutagenesis rate of an organism is one of the most critical factors governing
the speed of evolution. For organisms in the wild, mutagenesis is a dual-edged
blade in that it is beneficial for survival during the times of trouble, while it can
also destruct the integrity of genes. Evolution has worked out optimal mutagenesis
rates that best suit the varying natural needs of different organisms. The usual
rule-of-thumb strategy taken by nature is to inhibit mutagenesis when cells are
happy, and to encourage mutagenesis when cells are under stress. In B. subtilis,
for example, there are molecular mechanisms in place to regulate mutagenesis rates
depending on cellular conditions via the mutS mutL operon [76, 158].
In light of directed evolution, mutagenesis is one of the critical bottlenecks in
the process of generating and finding design solutions (See the discussion in Section
5.1.3). The wildtype spontaneous mutation rate would be too slow and inefficient
in exploring large solution spaces of complex designs. For this reason, a genetic
device that can induce a hyper-mutant state was devised (See Figure 5.2). The
wildtype promoter of the mutS mutL operon in B. subtilis was replaced with an
inducible promoter that can be regulated by IPTG. Rudimentary though it may
be, the genetic device is a good example of how simple genetic modifications as
such can make in vivo cellular systems capable of interfacing in silico systems, via
a microfluidics device programmatically modulating the IPTG concentration. The
ramification of having such an interface is quite significant in terms of achieving
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design automation; this interface can enable programmatic modulation of the speed
of evolution in the host chassis.








Figure 5.3: The evo_insert construct for insertion into pMUTIN4
See Appendix B.2 for the plasmid map of pMUTIN4.
The evo_insert construct was designed to have two functional modules mutu-
ally independent from each other (Figure 5.3). The first module is for regulating
the expression of mutSL operon, thus functions to switch random solution gener-
ation on or off. The second module is for detecting the presence of FMN and for
coupling the detection event to the expression of an antibiotics resistance marker
(e.g. cat1). The second module would function to evaluate the fitness of randomly
generated solutions, and to select the fitter ones.
5.2.5 Testing the coupler system: the EVOt2 construct
The EVOt2 construct was designed for testing the FMN sensor together with the
NOT gate (Figure 5.4). The regulatory region of the FMN sensor in this construct
had an additional xylose inducible promoter so that the strength of the downstream
FMN-regulated promoter can be modulated by varying xylose concentration. The
construct was designed to detect the presence of FMN and couple the detection
1The cat gene is for the expression of chloramphenicol acetyltransferase which confers resis-
tance to the antibiotics, chloramphenicol.
64
event to the expression of a fluorescence marker to assist in the characterisation






FMN sensor + NOT gate test
Figure 5.4: The EVOt2 construct for insertion into pSG1729
5.2.6 Cloning strategy
In molecular biology, the term cloning refers to a series of processes involved
in introducing an exogenous genetic construct into a host organism. Various fac-
tors were needed to be taken into consideration in deciding on the appropriate
cloning strategy. These included the host strain of choice, the target insertion lo-
cus (chromosome vs plasmid), the availability of vectors compatible for the chosen
locus, etc. The evo_insert construct, being cloned into the host strain B. sub-
tilis BSB1, was accounted for many strain-specific design factors such as the use
of promoters and Shine-Dalgarno sequences (ribosome binding sites) compatible
with B. subtilis. Initially, the evo_insert construct's two functional modules were
designed to be inserted into a single chromosomal locus, at the 5-prime-end of
mutS. The construct was synthesised by Genscript, assembled into the plasmid
vector pUC57, and was collectively named pUC57_evo. pUC57 is a plasmid vec-
tor with a replication origin of E. coli, and is not intended for used in B. subtilis.
The evo_insert construct, or the payload without the plasmid vector, was sub-
cloned into the B. subtilis plasmid vector pMUTIN4 [180] (Appendix B.2), and
was named pMUTIN4_evo (Section 4.2.1). pMUTIN4 was chosen as the backbone
because the vector allows insertion at an arbitrary chromosomal locus depending
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on the sequence homology built into the payload sequence. The evo_insert pay-
load was designed with a sequence homologous to the 500bp sequence immediately
following the promoter region of mutS. Please refer to Section 4.2.3 for details on
how pMUTIN4_evo was constructed.
The EVOt2 construct was assembled using Gibson techniques (See Section
4.3). Its assembly fragments were amplified out of the evo_insert (Appendix
B.1) in pUC57_evo (Figure 4.1), using the PCR primers listed in Table 4.14. As
part of the assembly, the EVOt2 construct was inserted into the plasmid back-
bone, pSG1729 (Appendix B.3), and the Gibson product was accordingly named
pSG1729_EVOt2 (Figure 4.9).
The EVOt2 construct was chromosomally integrated into the amyE locus of
B. subtilis BSB1 using pSG1729_EVOt2, and the mutant was named B. subtilis
BSB1 EVOt2 (Section 4.4). For use as an experimental control, the barebone
pSG1729 was used to transform B. subtilis BSB1 for the chromosomal insertion
of the vector's xylose inducible GFP expression circuitry at the amyE locus. The
control mutant was named B. subtilis BSB1 SG0.
5.3 Automation of the analysis of measurement
data
The evo_insert and EVOt2 constructs described so far are molecular devices de-
signed to facilitate information exchange between the in vivo and in silico domains.
By enabling single-cell-level phenotypic measurement coupled to selection, these
molecular devices can increase the information entropy (or information density)
per mutant population, consequently opening ways to increase the transfer rate
of useful information to the in silico domain. They are examples of how directed
evolution can be employed for finding solutions in light of the DEA framework.
Solution search can take place in a massively parallel fashion given the power of
the selection coupling (See Section 5.1.3). However, such molecular devices, albeit
capable of achieving high throughput screening, are still subject to noise, resulting
in multitudes of putative solutions that require further scrutiny.
Systematic characterisation required to scrutinise mutants at this stage is costly
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and time-consuming. At the core of the DEA framework is the idea of harnessing
iterative design cycles, where it becomes necessary to repeat laborious character-
isation procedures over and over again. In this framework, the versatility offered
by the following two characterisation means was promising: flow cytometry and
genome sequencing. They can generate copious amounts of data in raw format.
These data also need to be subject to postprocessing as well as downstream anal-
yses in order to extract any useful information. Dealing with experimental data
can be one of the most time consuming elements out of the characterisation effort.
The burden of characterising clones can be lessened to a large extent by employing
automation in this process.
Software pipelines were developed for postprocessing and analysing data ob-
tained in their raw formats from cytometry and genome sequencing. These data
pipelines were built as proof-of-concept examples of developing software compo-
nents that can readily participate in the design cycle of DEA, automated to involve
as little human intervention as possible. The pipelines were built as management
layers to invoke various open-source libraries [12, 21, 38, 108, 113, 118, 190], each
of which is good at handling specific data processing needs. There are useful
GUI-based software tools [8, 66] to assist the postprocessing and analysis of such
experimental data, primarily intended for occasional use by people on an ad hoc
basis. The pipelines developed in this study were meant not to be used directly
by people but to be used programmatically as part of an automated loop running
in parallel backend servers.
Firstly, a software script that can programmatically process raw flow cytometry
data was built and tested on B. subtilis clones labelled BSB1 EVOt2 and BSB1
SG0, respectively transformed as per Section 4.4 and Section 4.3.3. Secondly,
software pipelines to automate the assembly and the analysis of whole-genome
sequence data were developed and tested on the B. subtilis 168 and BSB1 wildtype
strains as well as on the BSB1 EVOt2 clone.
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5.3.1 Processing flow cytometry data for systematic analy-
sis
Flow cytometry offers an efficient way to gather fluorescence-marker-based experi-
mental data. Data of this kind are useful in testing whether relevant genetic parts
function as intended. Due to large volumes of data typical cytometry experiments
would produce, one of the most cumbersome steps in using cytometry is process-
ing raw data into a form ready to be interpreted. Besides, postprocessing raw
cytometry data is often influenced by inaccurate gating polygons hand-drawn at
the whim of people. A Python script, that can programmatically postprocess raw
experimental cytometry data, was developed. It is a rudimentary script consisting
of procedures for simple data array manipulations and plotting operations. Yet,
this test case was introduced to serve as an example contrasting the efficiency of
using process automation versus manual labour in performing downstream post-
experiment data analyses.
B. subtilis EVOt2 clone was cultured and subject to flow cytometry as ex-
plained in Section 4.4.2. The resulting raw cytometry data readings were processed
by the Python script1 to automatically generate Figure 5.8 in a matter of seconds.
This process, if performed manually in a conventional wet-lab setup, would take
hours, if not days.
5.3.2 Post-evolution whole-genome sequence analysis
Whole-genome sequence analysis provides a way of faithfully capturing and in-
specting genetic solutions offered by selected clones. As part of such analysis,
clones with potential solutions can be evaluated against relevant fitness criteria
before their solutions can be accepted. The evo_insert circuitry, for instance, has
a FMN sensor with which fitness measurements can be taken in vivo at the single
cell level. The circuitry was designed for coupling measurement results with the
application of antibiotics selection pressure. The significance of inspecting how
clones survived selection in this instance is to differentiate valid selections from
invalid selections. There are mainly two kinds of invalid selections: false negatives
1Appendix A.3 shows an instruction to invoke a Docker container to use the Python script.
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and false positives. False negatives are missed opportunities that would deem valid
solutions as invalid. False positives are the ones that would deem invalid solutions
as valid.
One possible cause to these problems is measurement error in the screening
process. Should measurement error be the culprit, these problems can be miti-
gated either by improving the quality of measurement systems (e.g. a better FMN
sensor) or by altering the fitness threshold (e.g. antibiotics concentration). While
improving measurement quality can reduce both kinds of problems, altering the
fitness threshold may only reduce one of the two depending on which way the
threshold is altered. Lowering the fitness threshold allows more sample solutions
to be screened in, and would result in the reduction of false negatives at the ex-
pense of increased false positives. On the other hand, raising the fitness threshold
restricts sample solutions from being screened in, and would result in the reduction
of false positives at the expense of increased false negatives.
Another possibility causing these selection problems is that the clones being
selected have anomalies in the evo_insert circuitry leading to conferring immu-
nity to selection pressure without having the primary trait of concern (i.e. FMN
biosynthesis). False positives as a result of the latter cause would need to be ac-
companied by a secondary screening scheme involving sequence analysis. As far
as synthetic biology and its application of DEA in metabolic engineering are con-
cerned, a secondary fitness evaluation via using whole-genome sequence analysis
is promising, owing to the ever-dropping Next Generation Sequencing (NGS) cost.
The caveat is that the secondary evaluation process would then need to be braced
for the challenges posed by the inundation of genome-scale sequence data.
The challenges posed by having to deal with overwhelming amounts of DNA
sequence data can be alleviated by using automation. The discussion to follow is
about automating post-evolution whole-genome sequence data maneuvers, such as
sequence data assembly and analysis. It is also worth noting that the discussion
of the following automated pipelines will be a preamble to discussing, in Section
6.4.3, how evolutionary solutions in vivo can be integrated to in silico solutions to
bridge the gap between the two domains.
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Figure 5.5: Overview of the hybrid sequence assembly pipeline
The pipeline consists of four main parts: sequence assembly de novo, locating the assem-
bled sequence of EVO_insert, sequence assembly against reference (assembly #2), and
combining assembly #2 and the assembled EVO_insert sequence.
5.3.2.1 NGS assembly pipeline
Automated NGS assembly pipelines can greatly reduce the burden of downstream
genomic analysis processes. The lessened burden would subsequently result in
an increase in the analysis throughput, key to success in the DEA framework.
NGS devices generate short sequence reads collated together into raw unassembled
sequence data formats, such as FASTQ. There are a series of steps involved in
converting the raw data into some form ready to be consumed by other high-
level bioinformatic analyses. Software pipelines were built, in order to automate
the assembly of NGS sequence data. Here, sequence assemblies can primarily be
done against a reference sequence of B. subtilis 168. However, de novo sequence
assemblies are also needed to incorporate the evo_insert construct as part of the
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final variant analysis. Figure 5.5 shows a sequence diagram of the hybrid assembly
pipeline to build a reference sequence using a sequence assembly done against a
gold-standard Bacillus subtilis 168 sequence (i.e. AL009126.3) together with an
evo_insert sequence assembled de novo. The hybrid assembly pipeline, developed
in Python 2.7, was packaged with all its dependent libraries to be provisioned
as a Docker image, ready to be deployed and tried out1. The Docker image has
an example demonstrating the hybrid assembly pipeline to build an annotated
sequence assembly file out of NGS data obtained from a Bacillus subtilis BSB1
EVOt2 clone (Section 5.2.5).
The same hybrid assembly pipeline can also be used to build a base annotated
sequence for a DEA mother cell with the evo_insert construct (Section 5.2.4).
Such a base annotated sequence would function as a reference sequence in the
variant analysis pipeline, shown in Figure 5.6, for investigating the SNPs in random
mutants stemming off of the mother cell.
5.3.2.2 Variant analysis pipeline
For the sake of using DEA in finding genetic solutions to problems such as ri-
boflavin biosynthesis in B. subtilis, it is imperative that experimental findings
resulting from evolution in vivo be bridged onto the EA in silico. Variant analysis
is appropriate for bridging such a gap, as the data made available by the anal-
ysis convey information on genetic variations among solution candidates readily
compatible to the type of data required in exploring the solution space of the EA
in silico. A further benefit to the use of variant analysis is providing a solution
to decrease false positives. Information regarding SNP variants, specifically in
the chromosomally integrated evo_insert construct, can be leveraged in having
solution candidates checked against false positives. Candidates with significant
mutations in the solution search module (Figure 5.3), as part of the evo_insert
construct, are prone to become false positives, therefore can be precluded from
further analysis. Significant mutations include non-silent SNPs2 in the coding re-
1Please see the instructions in Appendix A.2 to gain access to the Docker image and to
execute the pipeline as part of a Docker container.
2Non-silent mutations are significant mutations with possible alterations in the phenotypes of
the protein in which they occur. They occur in coding regions and involve changes to the amino
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gions of the solution search module, and mutations in the module's regulatory
elements such as promoters, operators, FMN riboswitch, and ribosome binding
sites. SNPs occurring in loci other than evo_insert can be used to help with the
in silico analysis as described in Section 6.4.2.
A software pipeline was developed (Figure 5.6) to enable variant analysis on
mutants in order to associate their SNPs to desirable mutant phenotypes such
as increase in the riboflavin biosynthesis. In order to test the variant analysis
pipeline, Bacillus subtilis 168 and BSB1 strain collections independently main-
tained by different research groups at the Centre for Bacterial Cell Biology in
Newcastle University were acquired, and sequenced via the in-house NGS service
using Illumina MiSeq. The resulting raw sequence data for each strain sample
were uniquely labelled, assembled against the reference (AL009126.3), and pro-
cessed through the variant analysis pipeline to respectively generate EMBL files
with SNP annotations (See Table 5.2).
The test clone described in Section 5.2.5, a B. subtilis BSB1 with the EVOt2
construct chromosomally integrated at its amyE locus, was sequenced using a
NGS device (Illumina MiSEQ). A docker image (see Appendix A.2) was built
to demonstrate the application of the workflow shown in Figure 5.6 for checking
if the transformation of the clone was done successfully. A reference sequence
was constructed by inserting the EVOt2 sequence at the amyE locus of the 168
reference sequence (AL009126.3), and was named AL009126_EVOt21.
acid sequence, or in non-coding regions and involve changes to critical regulatory sequences.
1The AL009126_EVOt2 sequence in Genbank format was made available via accessing the
Docker image sungshic/dea_hybrid_assembler:1.1 from Docker Hub. The Genbank file was
named AL009126_EVOt2.gb and was placed in /root/workspace/evot2, accessible as part of
the Docker container upon instantiation. See Appendix A.2 for details on the Docker image.
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Figure 5.6: Overview of whole-genome sequence analysis pipeline
The pipeline consists of four main parts: sequence assembly, sequence pre-processing,
variant analysis, and sequence annotation.
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5.4 Results from running the pipelines for sequence
assembly, variant analysis, and plotting cytom-
etry data
Table 5.2: Variant analysis of genome sequencing samples against reference
genomes
Table 5.2 summarises a SNP analysis result made available by the NGS analysis
pipeline discussed in Section 5.3.2.2 and Figure 5.6. The example raw sequence
data used here were chosen for the purpose of demonstrating the capability of the
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software pipeline. Samples labelled 1, 13, 16 and 21 were B. subtilis 168 strains.
It was shown that their sequences did not deviate much from the B. subtilis 168
reference AL009126, with the exception of Sample 13 and Sample 21. Sample 13
was a 168 strain from Pasteur Institute, and Sample 21 was a 168 strain acquired
from Bacillus Genome Stock Center.
Figure 5.7: The trpDCF region of Sample 14 carrying the majority of its SNPs
Indicated in purple bars below the green CDS arrows were the SNPs skewed in the
trpDCF region, contributing to 75 of a total of 84 SNPs reported in Sample 14 (Table
5.2). The SNP profile and the corresponding EMBL annotated sequence generated by
the pipeline developed in this study was visualised using Unipro UGENE [131].
It was evident from the pipeline's variant analysis result that the 168 strains of
Samples 13 and 21 had many non-silent SNP variants with respect to the reference.
Samples labelled 14, 21 and BSB1_wendy were B. subtilis BSB1 strains, derived
from B. subtilis 168 by replacing its trp operon to fix 168's tryptophan auxotrophy.
The two trp operons were clearly different, as the total SNP counts of BSB1 strains
exhibited striking differences between the counts including and excluding the trp
operon. As a control measure, the BSB1 strain (BSB1_wendy) was compared
against the old B. subtilis 168 reference sequence (SLR16.1) from Pasteur Institute.
Immediately noticeable in this comparison was how different the old 168 reference
(SLR16.1) was from the new 168 reference (AL009126). It was also interesting
to see that the uvrX SNPs recurrent on other samples against AL009126 were
no longer there against SLR16.1. After all, the pipeline was able to successfully
automate the processes of assembling raw short sequence reads and analysing
SNP variants. The correctness of the variant analysis pipeline was evident in its
ability to detect the tryptophan auxotrophic allele of 168 (i.e. trpC2 [3]). Sample
14 shown in Table 5.2, for instance, was a BSB1 strain which is a prototrophic
derivative of 168. As visualised in Figure 5.7, Sample 14's SNP profile with respect
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to 168 had a great majority of them skewed within the trp operon, more specifically
within trpDCF. The trpDCF region carried 75 SNPs out of a total of 84 SNPs
reported in Sample 14.
(a) (b)
Figure 5.8: Time-lapse flow cytometry results
There are four different growth media: m0, m1, m2, m3. m0: LB 1 % (w/v) xylose.
m1: LB 1 % (w/v) xylose + riboflavin. m2: LB. m3: LB + riboflavin. Fluorescence
is calculated by dividing the fluorescence values measured by the flow cytometer by
individual particles' forward scatter values. This division offsets the high fluorescence
values due to bacteria forming chains. (a) BSB1 EVOt2 in four different media conditions.
(b) BSB1 SG0 in the four different media conditions.
The results in Figure 5.8, showing time-series boxplots of the fluorescence of
individual cells, were programmatically produced from raw cytometry data (See
Section 5.3.1). Figure 5.8a was based on the BSB1 EVOt2 clone, and Figure 5.8b
on the BSB1 SG0 clone1.
The expected behaviour of the EVOt2 clone in the m0 media was to have
the lowest fluorescence level. The lack of riboflavin in the growth media would
mean the lack of FMN in the milieu. This would make the riboswitch in the
EVOt2 circuitry not to halt the expression of downstream genes (tetR in this
case). This ensues TetR to be available in the milieu, inhibiting the expression of
1BSB1 SG0 was cloned by transforming B. subtilis BSB1 with pSG1729 (See Appendix B.3)
to confer the clone with xylose inducible fluorescence (GFP).
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the fluorescent protein downstream of the promoter guarded by a tet operon. In
addition, having xylose in the media would increase the expression of tetR, further
intensifying its inhibitory role of the fluorescence level. The flow cytometry result
(labelled m0 shown in blue) in Figure 5.8a confirmed this expected behaviour by
exhibiting the lowest fluorescence out of the four conditions.
The m1 media given the presence of riboflavin in addition to the media com-
position of m0 was expected to have fluorescence higher than that of m0. A high
concentration of riboflavin would contribute to the rise of FMN concentration in
the milieu which consequently would inhibit the expression of tetR. A decrease
in TetR concentration would lower the inhibition of the fluorescence expression,
hence resulting in increased fluorescence.
The m2 media had neither riboflavin nor xylose. The lack of riboflavin, as
explained above, would contribute towards decreasing fluorescence, while the lack
of xylose would contribute towards increasing fluorescence. It was speculated that
the fluorescence due to m2 would be higher than that of m0, yet lower than that
of m3. This was confirmed to be the case in the experimental results summarised
in Figure 5.8a.
The m3 media had riboflavin (hence FMN) as the sole contributing factor
of fluorescence. The presence of which would increase fluorescence. Given the
lack of any inhibition factors, this media composition would result in the highest
fluorescence level out of the four conditions. This was also confirmed to be the
case in Figure 5.8a.
While the expected behaviours versus growth conditions were shown to be
maintained throughout the observed growth time span, all four conditions exhib-
ited gradual increase in fluorescence over time. The likely explanation to this result
is that the host system's native rib operon would, over time, produce riboflavin
in vivo contributing to the regulation of the EVOt2 circuitry. However, the veri-
fication of this claim requires a negative control such as a separate EVOt2 clone
with a deletion of the riboflavin synthase gene (ribB in Figure 6.3) involved in
producing riboflavin in vivo. Due to time constraints in the project, making the
clone for negative control was not pursued.
In fact, the EVOt2 construct had a glitch in the design. The emission spectrum
of riboflavin overlaps that of GFP, the choice of fluorescent protein in the EVOt2
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design. This clash attributed to the basal fluorescence levels in the measurements.
The side-effect of this design glitch was shown in Figure 5.8b generated from the
cytometry data of the BSB1 SG0 clone grown under the four growth conditions.
The BSB1 SG0 clone's fluorescence expression circuitry transformed from pSG1729
should normally be inducible only via xylose. Xylose was able to induce the
fluorescence expression of BSB1 SG0 to increase over time as shown in the m0 and
m1 conditions in Figure 5.8b. However, it was also evident that the m1 and m3
conditions, given the presence of riboflavin, elevated the basal fluorescence level
compared to the non-riboflavin conditions (i.e. m0 and m2). With the benefit of
hindsight, this design mistake helped highlight the importance of having a means
to make design amendments easier: that is to have an automated testing to appease
the pain of repeating experiments as exemplified in this chapter.
5.5 Discussion
Evolution is a powerful problem-solving framework. Harnessed with random mu-
tagenesis and selection, evolution is universally applicable and elegantly simple
a genetic solver that can give rise to an amazing array of genetic solutions with
diverse functionalities. In natural evolution, as Charles Darwin had speculated in
his seminal work [49], the selection process is intrinsically welded into the survival
of organisms amid the peculiarities of given environmental niches. Provided with
the survival as its ultimate goal, how that goal is achieved by organisms is not
a matter of concern. In directed evolution, with respect to DEA, the survival of
organisms, extrinsically coupled to the selection process in vivo, is not the ultimate
goal but an intermediary step to isolate clones bearing potential genetic solutions.
Here, how organisms managed to survive the selection pressure does matter, ne-
cessitating the clones or solutions selected as part of the in vivo selection process
to be subject to further scrutiny. The research work presented here addressed
the question of how the solution search can be facilitated in the immense pool of
random in vivo solutions. Screening for mutants at the molecular level via genetic
devices in vivo, and streamlining the characterisation of mutants bearing putative
solutions via automation were this study's attempts to provide an answer to this
non-trivial question. As yet, this only constituted half an answer. How in silico
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modeling and virtual evolution can improve on the validity of solutions found in
vivo was as difficult a question to be answered. Working on answering this resulted
in a significant section on its own, expansive enough to warrant Chapter 6.
One of the primary challenges in the dual-evolutionary design framework was
how in vivo and in silico design domains can be integrated. DNA was one of the
most obvious common denominators between the evolutionary solution spaces of
the two design domains. The DNA sequence analysis hitherto shown in this study
was an effective means with which transitions to and from the two solution domains
can be achieved. The variant analysis of in vivo solutions, for instance, provided
information at an abstraction level suitable for fitting into in silico solutions in a
manner that is computationally simple yet analytically meaningful.
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Chapter 6
In silico model based design to
bridge the gap in the
dual-evolutionary domains
6.1 Introduction
To date, proponents of design automation have contributed in the research and de-
velopment of building various means to achieve automated assistance in designing
processes. As a result of such endeavour, the use of computerised design assistance
tools has become a routine practice across varying fields of engineering [144]. These
tools, collectively termed Computer Aided Design (CAD) software, have made it
possible for humanity to achieve new levels of heights in wielding design complex-
ity [96]. Field experts claim that No product is designed today without the use of
computer-aided design (CAD) technology [22]. They are the means with which
the modern civilisation as we know it today has been technologically innovated.
CAD tools have helped raise the bar in the level of complexity manageable by
designers to a certain extent. Nevertheless, CAD tools are limited to providing
islands of automation [46], and are never intended for replacing human designers.
The use of automated assistance in CAD is still bottlenecked by the reasoning
capacity of designers. Given high degrees of complexity and uncertainty involved
in engineering biological designs, the validity of CAD tools [19, 33, 48, 135] will
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eventually reach a saturation point.
Biological systems, whose cryptic mechanisms have come about as a result of
natural evolution, are complex because of the bewildering diversity of interactions
and regulatory networks [182]. Our current lack of a total understanding of this
intricacy poses unprecedented challenges in engineering the design of biological
systems.
One of the primary hurdles in designing complex biological systems is the
current lack of methodological paradigms that can handle the scale of design com-
plexity in a significantly meaningful manner. In fact, nature has already been
mindlessly carrying out design tasks. Nature, without relying on any intelligent
agents to mastermind design tasks, has always been able to precipitate design solu-
tions reaching complexity well above the reasoning capacity of human minds. The
making of Homo sapiens by nature [29], for instance, is an epitome in reaching the
height of design complexity far beyond that achievable by our own capability to
design at the moment. Nature's vehicle for such a design feat and autonomy is evo-
lution [29, 55]. Evolution employs randomness and selection [107] as the universal
tools to explore and search for solutions to design problems. Natural evolution
is a living proof that complex biological designs can be achieved autonomously
without human interventions.
In Chapter 5, the idea of adopting the methodological paradigm offered by evo-
lution was explored in the in vivo design domain. At the core of this evolutionary
approach was seeing design as a search problem that can be systematically ma-
neuvered via randomness and selection. It was hypothesised that a combination of
molecular devices and programmatically executed analytic pipelines can facilitate
the search for design solutions in random in vivo pools, consequently opening up
ways to enable design automation in synthetic biology.
In light of seeing design as a search problem, the size of solution spaces to be
explored is proportionate to design complexity. Complex designs hosting larger
solution spaces would hence require more time before solutions can be found.
With respect to the dual evolutionary design approach, it was suggested [80] that
delegating some of the in vivo domain's search burdens to the in silico domain
would result in a significant reduction in time to solution. This claim was verified
in the work described in Section 6.4.3, following the presentation of details on how
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cellular systems were modelled to serve as an interface between the two domains
in an attempt to reduce their gap.
In engineering, design complexity can be mitigated to an extent by introducing
modularity in design [134, 154] or by using mathematical modelling [63]. Modu-
larity helps break larger problems into smaller manageable ones and facilitate the
reuse of designs. The complexity of systems design can be reduced by modules
decoupling unnecessary interdependencies of underlying subsystems. Mathemati-
cal modelling, on the other hand, helps quantitatively describe and assess complex
designs in a systematic fashion. Using modularity and modelling has already been
a practice well established in software engineering for conquering complexity [86].
The idea of using these mitigators in engineering biological designs has also been
attempted with some success [39, 62].
In modelling the example of riboflavin biosynthesis, two approaches, dynamic
versus static modelling, were respectively investigated in Section 6.3.2 and 6.3.3.
Each approach revealed different pros and cons, but the static model was more
promising to be used as a fitness function for in silico evolution, and offered to
provide a more compatible interface between the dual-evolutionary domains.
In addition to this finding, the extent to which the use of in silico evolution
can expand the searchable limit in the solution space was investigated in Section
6.4. This work confirmed the initial hypothesis by Hallinan and her colleagues [80]
in proposing the dual-evolutionary framework as an effective measure to mitigate
design complexity in synthetic biology. As part of this work, a novel method that
can model the population-level dynamics of mutagenesis was necessary and was
developed (See Section 6.3.4).
6.2 The significance of modelling
What is the significance of in silico modelling in terms of seeing design as a search
problem? Models in silico are virtual reconstructions of certain real-world func-
tions [7]. Out of such functional reconstructions, computers can calculate the
predicted output as a consequence of a given input.
Mathematical modelling allows relatively cost-effective grounds for estimating
whether certain design choices can meet given design goals. It is a well estab-
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Figure 6.1: Some examples of the archetypal function of the form y = f(x)
lished methodology in affecting design choices in the software field of requirements
engineering [129], for example. The practice of using mathematical abstraction
in this work was particularly concerned with the establishment of a systematic
naming convention. Achieving a mathematical abstraction permits the conceptual
labelling of a physical reality such that different aspects of the physical reality can
be systematically referred to by in silico processes.
Before things can be named anew, however, they would have to be defined first
[111]. How things can be defined is an open-ended question, highly dependent on
the context within which the definitions are to be used. Mathematical abstraction
offers an universal system of vocabularies, or a language, to allow things to be
defined in an unequivocal and consistent manner. It is a linguistic framework for
engineering [79]. Following is an archetypal mathematical equation that represents
the output y as a function f of the input x. Some arbitrary functions were plotted
in Figure 6.1 to exemplify this archetype.
y = f(x) (6.1)
Drawing a parallel with this functional archetype, biological systems can be
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defined with respect to the same three constituents, namely the input x, the output
y, and the function f defining the relationship between the input and the output.
For example, y can be the phenotypic outcome of a biological system or a function f
that responds to environmental conditions x. In the context of metabolic reactions,
for instance, x could be a set of metabolites subject to an enzymatic reaction f to
result in a different set of metabolites y.
6.2.1 Modelling as a tool for design documentation and ex-
ploration
Integral to the design process is the means with which real-world properties can
be documented. The old-fashioned way of documenting designs, as exemplified
by Leonardo da Vinci's schematic drawings [96], has been in written and drawn
forms using carbon copies. These manual practices continued well into the first
half of the 20th century [96], while they evolved to offer more accurate renderings
of engineering drawings compared to those of the Renaissance. CAD tools, since
the influential development of Sketchpad [168] in the sixties, have helped digitise
design documentations [25]. Often, CAD tools just provide authoring means to
help document design properties in digital formats, only allowing as much details
as carbon copies would contain. Digitising information, even at such a rudimentary
level, has immediate benefits, including the ease of archiving, sharing, editing, and
finding information.
More substantial a benefit from digitisation would be that designs can be rep-
resented using much more dynamic context via in silico models. Modelling allows
the documentation of a rich array of dynamic design properties unattainable by
the carbon-copy driven documentation of designs. However, the in silico modelling
of complex systems is inherently limited by finite computer resources. This means
that the minute details of real-world properties cannot be represented in full by
models. It is imperative that only the properties pertinent to the modelling goal
of interest need consideration using the parsimonious principle of Occam's razor
[160]. Mathematical abstraction is a great ally in abiding by such principles [106],
playing an important role in the documentation of complex designs.
It is argued that facilitating the re-use of up-to-date design knowledge, infor-
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mation and data can help increase the efficiency of producing novel designs [46]. In
the dual-evolutionary approach, as demonstrated in this work, functional in silico
models by expanding from Equation 6.1 were developed to serve as a means to
document and to share the complex fabric of biological systems and their designs.
This effort is in agreement with the efficiency argument, in that it not only bolsters
the important role of documentation in design but also of mathematical models in
documenting the insight into the functions of design.
Dealing with in silico models is cost-effective in that models can be evaluated
repeatedly against various conditions. As such, models offer ways to explore
the solution spaces of design problems without needing to implement solutions in
reality. Therefore, models are great means with which to search for fitting solutions
in design spaces. Being able to programmatically search for solutions is especially
useful in terms of mitigating design complexity.
Furthermore, in silico models can enable introspection into the realm that
are normally out of reach in reality. Such capability of models is a perfect fit
for exploring the solution spaces of designs involving aspects that are physically
infeasible to be measured in reality. It is a promising notion to use modelling as
an exploration tool in the quest to finding design solutions.
6.3 Modelling cellular systems
Cellular systems have underlying molecular mechanisms that enable the systems
to function. The law of physics governing those molecular mechanisms can be
encapsulated using in silico modelling. Modelling allows the reconstruction of
functional behaviours of the systems in light of mathematical abstraction. Models
can be used to further the understanding of how cellular systems work, and to
predict their behaviours. In silico models can be broadly categorised into two
classes - dynamic and static models. Dynamic models address temporal changes in
systems, while static models evolve around time-invariant steady-state conditions
of systems in equilibrium. In the following, riboflavin biosynthesis was used as an
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Figure 6.2: The rib operon and its transcriptional regulation in B. subtilis
6.3.1 Riboflavin biosynthesis and metabolic pathways in bac-
teria
In Bacillus subtilis, the riboflavin biosynthesis and its metabolic pathway are
largely affected by a set of five genes (ribGBAHT, Figure 6.2) comprising the
rib operon [121, 184]. It has been postulated that the metabolism and transport
of riboflavin are regulated via transcriptional attenuation in Gram-positive bacte-
ria, as opposed to the translational level regulation of riboflavin in most Gram-
negative bacteria [184]. The five rib genes encode catalytic enzymes for converting
one molecule of guanosine-5-triphosphate (GTP) and one molecule of ribulose-5-
phosphate (R5P) into one molecule of 6,7-dimethyl-8-ribityl-lumazine (DMRL),
and for subsequently converting two molecules of DMRL into one molecule each of
riboflavin and 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione [10, 114] (See
Figure 6.3). The two precursor metabolites, GTP and R5P, are sourced through
two distinct pathways, GTP via the purine metabolic pathway and R5P via the
pentose phosphate pathway. These precursors go through a series of enzymatic
reactions catalysed by the protein products of the rib operon, leading to DMRL,
the immediate precursor of riboflavin in these pathways. The DMRL to riboflavin
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Figure 6.3: Riboflavin biosynthesis pathway in B. subtilis
GTP: guanosine-5-triphosphate DARPP: 2,5-diamino-6-ribosylamino-4(3H)-
pyrimidinone-5'-phosphate DArPP: 2,5-diamino-6-ribitylamino-4(3H)-pyrimidinone-
5'-phosphate ArPU: 5-amino-6-(5'-phosphoribitylamino)uracil ArU: 5-amino-6-
ribityl-aminouracil DMRL: 6,7-dimethyl-8-ribityl-lumazine R5P: ribulose-5-phosphate
DHBP: 3,4-dihydroxy-2-butanone-4-phosphate
reaction is catalysed by riboflavin synthase (RibB in B. subtilis). The B. sub-
tilis genes ribA (DHBP synthase), ribG and ribB have different names in E. coli,
respectively called ribB, ribD and ribE [184].
Most bacteria produce less than 10 mg/L of riboflavin, while some clostridia
can yield up to 100 mg/L, some yeast such as Candida flareri up to 600 mg/L,
and molds such as Eremothecium ashbyii and Ashbya gossypii can yield well over
1000 mg/L depending on the fermenting conditions [52].
It has been reported that some flavinogenic species overproduce riboflavin when
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FMNRiboflavin RibC FADRibC
FMN: flavin mononucleotide 
FAD: flavin adenine dinucleotideFigure 6.4: The bifunctional enzyme RibC in B. subtilis
Riboflavin to FMN and FAD are catalysed by RibC. FMN: flavin mononucleotide FAD:
flavin adenine dinucleotide
purine derivatives are in abundance [10]. B. subtilis with mutations in the ribC
gene (putatively encoding flavokinase and FAD synthetase) was shown to overpro-
duce riboflavin [40, 116, 136]. The combination of mutations in ribC as well as in
the leader sequence (i.e. regulatory region) of the rib operon could boost riboflavin
production in B. subtilis beyond 10 g/L [136]; that is three orders of magnitude
higher a level of production compared to those of most naturally occurring bacte-
ria.
The effector molecule directly involved in the regulation of riboflavin biosyn-
thesis had not been elucidated until recently. Experimental results have suggested
that riboflavin biosynthesis is regulated not via employing riboflavin as an effec-
tor molecule but via FMN [10]. It seems FMN has inhibitory effects on the rib
operon by binding to the conserved regulatory element in the 5' UTR called rfn
[128]. Moreover, FMN's being an effector molecule is congruent to the ribC mu-
tants exhibiting riboflavin overproduction - The ribC mutations would probably
have some sort of inhibitory effect on flavokinase (an enzyme for riboflavin to
FMN conversion) or activating effect on FAD synthetase (an enzyme for FMN to
FAD conversion), resulting in a lower overall intracellular FMN concentration (See
Figure 6.4).
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6.3.2 Constructing a dynamic model for riboflavin metabolism
Dynamic models can offer exciting possibilities for understanding metabolic path-
ways by allowing detailed inspection of the temporal dynamics of metabolites
and enzymatic reactions. The seminal work of Guldberg and Waage in the law of
mass action [78] initiated the developments of chemical kinetics, such as Michaelis-
Menten kinetics [120] in the area of enzyme catalysis. Michaelis-Menten kinetics
is probably one of the most popular enzyme kinetics models, still in prevalent use
after its inception more than a century ago [41].
The premise of the Michaelis-Menten kinetics model, as best described in the
work by Briggs and Haldane [73], is based on an enzyme (E) and a substrate (S)
associating at a rate of kf to form a complex (ES), or ES dissociating at a rate
of kr (See Equation 6.2). Formation of ES, subsequently catalyses the irreversible










The rate at which P forms (d[P ]
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. [E]0 is the initial concentration of the enzyme E. KM is also
known as the Michaelis constant indicating the substrate concentration ([S]) at
which the reaction rate reaches Vmax
2
. The Michaelis-Menten (or Briggs-Haldane)
kinetics would be applicable to all enzymatic reactions in Figures 6.3 and 6.4,
except the reaction catalysed by RibH. The RibH reaction has two substrates
(DHBP and ArU) producing one product (DMRL), which Equation 6.2 does not
support.
The following chemical equations show an example of two substrates going
through enzymatic reactions to produce one product. It is assumed that S1 and S2
are independent of each other in binding to the enzyme E. Hence, the association
(kf1) and dissociation (kr1) rates of S1 to E are unaffected regardless of whether
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kcat−−→ P + E
(6.4)
The law of mass action [78] gives rise to the following ordinary differential equations




= −kf1[S1][E] + kr1[S1E]− kf1[S2E][S1] + kr1[S1S2E]
d[S2]
dt
= −kf2[S2][E] + kr2[S2E]− kf2[S1E][S2] + kr2[S1S2E]
d[S1E]
dt
= kf1[E][S1] + kr2[S1S2E]− kr1[S1E]− kf2[S1E][S2]
d[S2E]
dt
= kf2[E][S2] + kr1[S1S2E]− kr2[S2E]− kf1[S2E][S1]
d[E]
dt
= −kf1[E][S1] + kr1[S1E]− kf2[E][S2] + kr2[S2E] + kcat[S1S2E]
d[S1S2E]
dt





Applying the Michaelis-Menten assumption of equilibrium between substrates and
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The initial enzyme concentration at t0, denoted [E]0, can be given by the law of
enzyme conservation as follows.
[E]0 = [E] + [S1E] + [S2E] + [S1S2E]
→ [E] = [E]0 − [S1E]− [S2E] + [S1S2E]
(6.7)
Combining the equilibrium conditions from Equation 6.6 to 6.7 gives the following
equation:







































































































in Equation 6.10 respectively represent the dissociation
constants for substrate-enzyme complexes S1E and S2E. These terms can be
interchanged for KM values in light of the quasi-steady-state assumption made in













→ [S1S2E] = [E]0[S1][S2]
(KM2 + [S2]) · (KM1 + [S1])
(6.11)
Provided with Equation 6.11, the rate of enzymatic reaction, denoted v, can be







(KM2 + [S2]) · (KM1 + [S1])
=
Vmax[S1][S2]
(KM2 + [S2]) · (KM1 + [S1])
(6.12)
, where Vmax = kcat[E]0. In its canonical form supporting an arbitrary number (n)





i=1 (KMi + [S]i)
(6.13)
Equation 6.13 supports irreversible non-modulated non-interacting multi-reactant
enzymes. The rate laws expressed by Equation 6.13 and Equation 6.12 respec-
tively correspond to the Systems Biology Ontology (SBO) [42] catalogued terms
SBO:0000150 and SBO:0000151, a special case of SBO:0000150.
An enzyme database such as BRENDA [34] serves to be a good resource to
find out about experimentally verified parameter values for KMi and kcat. Using
the parameter values from BRENDA along with the above derived rate equations,
a SBML [91] model encapsulating the riboflavin metabolic pathway in B. subtilis,
as described in Figures 6.2, 6.3 and 6.4, was built in COPASI [87]. Figure 6.5
summarises the results obtained from simulating the model. It is shown that the
93
6. IN SILICO MODEL BASED DESIGN TO BRIDGE THE GAP


















Figure 6.5: SBML models examining flavin concentrations over time
Temporal changes in flavin concentration were examined with or without FMN inhibition
on the rib operon in B. subtilis: (a) Timecourse analysis with FMN regulatory feedback
enabled, (b) Timecourse analysis with FMN regulatory feedback disabled, (c) FMN
inhibiting the transcription of the rib operon corresponding to the result in (a), and (d)
Uninhibited transcription of the rib operon corresponding to the result in (b).
simulation exhibited approximately about a four-fold difference in the riboflavin
biosynthesis depending on whether the inhibitory regulation of FMN on the rib
operon is available or not. The difference in the expression level of of the rib operon
corresponding to the FMN concentration further explains the effect of such an in-
hibitory feedback control. Evidently, the use of dynamic modelling discussed here
allows detailed investigation of molecular dynamics, otherwise unfathomable. Nev-
ertheless, the computational complexity of dynamic models restricts the number of
reactions to be considered together. This makes it extremely challenging to apply
dynamic modelling at the genome-scale level.
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6.3.3 Constructing a genome-scale static model for metabolic
pathways
Static models can offer an alternative perspective to investigating metabolic path-
ways. Static modelling of metabolic pathways is epitomised by flux balance anal-
ysis (FBA). In comparison to dynamic modelling, FBA can tremendously reduce
the computational complexity involved in analysing the biochemical system of
metabolic networks. The reduction in complexity is attributed to the steady-state
conditions, resulting in the mathematical simplification, from considering the bio-
chemical system in equilibrium. This makes it reasonably possible, as opposed
to dynamic modelling, to apply FBA for modelling metabolic pathways in the
genome-scale level.
FBA defines a metabolic network using the following mathematical formalism:
S · v = 0 (6.14)
, where S denotes a stoichiometric matrix, v a vector of fluxes through all chemical
reactions, each of which fluxes is bound by vmini <= vi <= v
max
i . The value 0 on
the right hand side of the equation means that the metabolic network is in steady
state. A flux vector v is said to be in the null space of S, if the vector provides a
solution to satisfy this equation [133].
The biggest advantage of using FBA in modelling cellular systems is probably
the fact that the technique relies solely on stoichiometric characteristics without
the need of involving difficult-to-obtain kinetic parameters. The stoichiometry of
metabolic reactions can even be inferred bioinformatically by sequencing organ-
isms, blasting the sequence to identify proteins, and looking up the proteins on
databases such as KEGG, Uniprot, Reactome, or MetaCyc among others. The
downside of using FBA is that fluxes in FBA cannot be uniquely specified as a
function of regulatory mechanisms, due to the lack of kinetic parameters necessary
in determining the concentration of metabolites involved in regulation.
A metabolic network would typically contain more reactions than metabolites.
With respect to FBA, this means that there are more variables (i.e. fluxes) to be
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Table 6.1: Genome-scale reconstruction of metabolic network in Bacillus subtilis
PMID Strain Genes Metabolites Rxns Reference Year
17573341 unspecified 844 988 1020 [130] 2007
19555510 168 1103 1138 1437 [83] 2009
determined than there are equations (whose cardinality corresponds to the number
of metabolites), making the problem underdetermined. Underdetermined prob-
lems can be analysed by a technique called linear programming which can find
optimal solutions that satisfy certain objective functions. FBA's default choice
of objective function is the maximisation of biomass. Given such an objective
function, a linear solver can find a set of fluxes v leading to the maximisation of
biomass, representing the steady-state metabolic conditions of a cell undergoing
growth. FBA models should have a virtual reaction specifying the stoichiome-
try of metabolites (i.e. raw materials) needed in producing biomass. Alternative
objective functions can also be used including, for example, minimisation or max-
imisation of ATP production, energy currency production, or redox potential per
unit of glucose [102]. The energy currency involves metabolite species such as ATP
and NADPH, while redox potential involves NADH, NADPH, and FADH2. Often,
the values for vmini and v
max
i are unknown and set at arbitrary ranges. The lack of
precise ranges could affect the predictability of FBA, and it is sometimes needed
to fit models against the flux ranges of experimentally measurable reactions, such
as those involved in nutrient uptake and excretion.
6.3.3.1 Modelling riboflavin biosynthesis and metabolic pathways in
bacteria
Genome-scale metabolic models such as shown in Figure 6.6 enable two possibil-
ities. One is that they open the doors to using an uniform interface in taking a
holistic view on the entire metabolic reaction network that covers the biochem-
istry of both extracellular and cytosolic spaces. The other is that the uniform
interface can be manipulated programmatically. This would mean that extensive
numerical surveys can be conducted to elucidate the relationships between genes





Figure 6.6: Graph-based visualisation of the metabolic network of B. subtilis 168
A reconstructed model of the genome-scale B. subtilis metabolic pathways from the
second entry in Table 6.1 was used in the visualisation. The green and red nodes in the
zoomed-in pane represent metabolites and reactions respectively, and the edges represent
the participation of connected metabolites in reactions.
tions. As such, FBA together with genome-scale metabolic models offers to be a
good framework for systematic investigation of the theoretical limits of metabolic
reactions, in the context of DEA.
6.3.3.2 Metabolic pathway model simulation
A proof-of-concept FBA was performed to compare the theoretical limits of ri-
boflavin biosynthesis rates in B. subtilis under different nutrient conditions1. Fig-
1Please refer to Appendix A.1 for details on the experimental setup, code bases, and access
to other archived resources.
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(a) (b)
Figure 6.7: Applying FBA on the genome-scale metabolic pathway model of B. subtilis
Flux balance analysis (FBA) was performed on the genome-scale metabolic pathway
model of B. subtilis 168 (Table 6.1), with minimal media (M9) and rich media (LB),
given biomass maximisation as objectives: (a) Shown in blue solid line is the result of
robustness analysis on the biomass vs riboflavin fluxes in M9. The red-circled dot shows
a point where riboflavin production is optimal, with approximate biomass and riboflavin
fluxes of about 0.29 and 1.65 mmolgDW ·h respectively. (b) Shown in green broken line is the
result of robustness analysis on the biomass vs riboflavin fluxes in LB. The red-circled
dot shows a point where riboflavin production is optimal, with approximate biomass and
riboflavin fluxes of about 1.05 and 27.39 mmolgDW ·h respectively. The M9 result shown in
solid blue is the same plot as in (a) at a different scale to match that of LB.
ure 6.7 summarises the results of robustness analysis of biomass versus riboflavin
fluxes under minimal (M9) and rich (LB) nutrient conditions. As expected, it was
shown that the rich media dwarfs the minimal media in the resulting riboflavin
biosynthesis rates as well as the growth rates (Figure 6.7b).
It is noteworthy that the units used here for both the biomass and riboflavin fluxes
are in mmol
gDW ·h , where gDW denotes grams of dry cell weight. In general, biomass
fluxes are bluntly declared to be growth rates in units of h−1 [1] without clear





) is a rate of a kind, hence the dimension h−1, the fractional term
mmol
gDW
should not be neglected as it bears a special meaning in interpreting any flux
values. This fractional term indicates the amount of metabolite molecules (mmol)
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partaking in the corresponding metabolic reaction per unit biomass produced in
gram weights (gDW ). Given the relative molar mass1 of metabolites of concern,
mole units can be converted into weights. Such conversion cancels the fractional
term as part of the unit and reduces it to a scalar constant adjunct to a rate unit
(h−1).
In the example case of riboflavin biosynthesis catalysed by RibB in B. subtilis,
the metabolic reaction is defined as:
2 ·DMRL RibB−−−→ RIBF + ArU (6.15)
, where DMRL: 6,7-dimethyl-8-ribityl-lumazine, RIBF: riboflavin, and ArU: 5-
amino-6-ribityl-aminouracil.
When it is claimed that the unit of biomass fluxes is h−1, it would need to be
assumed that mmol
gDW
= 1. What this assumption entails is that the virtual metabolic
product of biomass, as part of the biomass reaction in a genome-scale metabolic
model, needs to be defined with the relative molar mass of 1000 g
mol
. This way,
the unit conversion of 1mmol = 1g holds true for the biomass reaction, to end up
reducing the flux unit neatly into h−1.
In order to verify if this was the case with the genome-scale metabolic model
discussed here, the mass balance of the biomass reactions defined in that model
was assessed in full2. The biomass reactions were scrutinised in light of the relative
molar mass of all reactants and products defined. Table 6.2 enlists the information
on compounds that are part of the biomass reactions defined by the genome-scale
metabolic model. The estimated relative molar mass (RMM) for DNA, mRNA,
proteins, cell wall, lipid, and lipoteichoic acid compositions (LAC) were calculated
based on respective biosynthesis reactions (See Appendix A.6). According to
the calculation shown here, the biomass reaction of the genome-scale metabolic
pathway model was defined with a RMM value of 1100.78 g mol−1, instead of the
1The technically more proper term of relative molar mass was used in lieu of the more popular
term of molecular weight, as the old term is in the process of getting deprecated.
2Please refer to the following for the meanings of abbreviated terms used in Table 6.2. ACP:
Acyl-carrier protein, RMM: relative molar mass, NMW: normalised molecular weight. Nor-
malised molecular weight is the molecular weight of compounds required in producing 1mol of
the main product as part of the metabolic reaction, in this case, to produce biomass.
99
6. IN SILICO MODEL BASED DESIGN TO BRIDGE THE GAP
IN THE DUAL-EVOLUTIONARY DOMAINS
Table 6.2: Composition of biomass reaction of B. subtilis genome-scale metabolic
model: information leading to estimation of biomass' relative molar mass.
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd00001 105 reactant metabolite H2O 18.02 1892.1
cpd00002 105.003371 reactant metabolite C10H13N5O13P3 504.16 52938.49952
cpd00003 0.01822 reactant metabolite C21H26N7O14P2 662.42 12.0692924
cpd00005 0.0002367 reactant metabolite C21H27N7O17P3 742.40 0.17572608
cpd00006 0.001053 reactant metabolite C21H26N7O17P3 741.39 0.78068367
cpd00010 0.000127618 reactant metabolite C21H33N7O16P3S 764.51 0.097565237
cpd00012 0.0008548 reactant metabolite H2O7P2 175.96 0.150410608
cpd00018 0.005253 reactant metabolite C10H13N5O7P 346.21 1.81864113
cpd00031 0.0002215 reactant metabolite C10H13N5O11P2 441.18 0.09772137
cpd00038 0.0004883 reactant metabolite C10H13N5O14P3 520.16 0.253994128
cpd00046 0.001153 reactant metabolite C9H13N3O8P 322.19 0.37148507
cpd00052 0.0006105 reactant metabolite C9H13N3O14P3 480.13 0.293119365
cpd00096 0.0002924 reactant metabolite C9H13N3O11P2 401.16 0.117299184
cpd00126 0.0005939 reactant metabolite C10H13N5O8P 362.21 0.215116519
cpd00201 0.000206831 reactant metabolite C20H21N7O7 471.42 0.09750427
cpd11451 0.00014977 reactant metabolite C46H66O2 651.01 0.097501768
cpd00063 0.002983 reactant metal ion Ca 40.08 0.11955864
cpd00205 0.6576 reactant metal ion K 39.10 25.71216
cpd00254 0.09474 reactant metal ion Mg 24.31 2.3031294
cpd10516 0.003209 reactant metal ion Fe 55.85 0.17922265
cpd11493 0.000273109 reactant ACP C11H21N2O7PS-R 356.33 0.09731693
cpd11461 0.026 reactant DNA N/A 955.24 24.83623204
cpd11462 0.0655 reactant mRNA N/A 950.99 62.28989327
cpd11463 0.5284 reactant Protein N/A 998.67 527.6992058
cpd15664 0.2242 reactant Cell wall N/A 997.32 223.5995288
cpd15670 0.0304 reactant LAC N/A 996.94 30.3068812
cpd15800 0.076 reactant Lipid N/A 995.92 75.69027691
cpd00008 104.9971 by-product metabolite C10H13N5O10P2 425.18 44642.66698
cpd00009 104.9866 by-product metabolite HO4P 95.98 10076.61387
cpd12370 0.000273109 by-product Apo-[ACP] HO-R 17.01 0.004645584
cpd11416 1 product Biomass N/A 1100.78 1100.783498
commonly assumed value of 1000 g mol−1. It is noteworthy that it would be tech-
nically correct to have this kind of aberration accounted for, for example via using
normalisation, when interpreting FBA results and their flux values.
6.3.4 Modelling the dynamics of mutagenesis
Mutagenesis cannot be considered in full by means of simple rate values, as
the stochastic process gives rise to complex time-dependent population dynamics
among different mutants. In order to gain further insight into the time-dependent
dynamics of mutant populations, a realistic bacterial growth model was needed.
Generally, the de facto mathematical model often discussed for bacterial growth
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takes the form of logistic curves, as given by Equation 6.16. Nmax is the limit of
the maximum population, referred to as the carrying capacity of the environment
representing an asymptote (See Figure 6.8a).
dN/dt = rN(1−N/Nmax) (6.16)
The pitfall in using the conventional logistic growth model (Eq. 6.16) is that it












































Figure 6.8: Comparison of growth curves by two logistic models
(a) A growth curve (shown in red) exhibited by the logistic model in Eq. 6.16, where
r = 2.2, and Nmax = 10
8.8. The blue horizontal asymptote represents log(Nmax). The
logistic model lacks the lag phase of growth typical in bacterial growth. (b) A growth
curve (shown in green) exhibited by the Fujikawa model (Eq. 6.17), where r = 2.2,
Nmax = 10
8.8, Nmin = 0.99999, and c = 0.74. There is a lag phase to the curve before
entering the logarithmic phase of growth.
lacks the lag phase of bacterial growth, rendering the model unrealistic at best.
Fujikawa and his colleagues introduced a modification to the logistic model to
incorporate the lag phase into the growth curve [68] (See Equation 6.17 and Figure
6.8b):
dN/dt = rN(1−N/Nmax)(1−Nmin/N)c (6.17)
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, where c >= 0 is an adjustment factor. Fujikawa model as shown in Equation 6.17
can provide accurate growth patterns of bacterial culture as a whole, and be used
to predict the total population level after a certain time has elapsed. However, it
cannot be used to predict the population levels of individual mutants sprouting up
as a result of growth. A new growth model was needed to accommodate the notion
of mutagenesis and to model the dynamics of mutant populations as a function
of time. As opposed to Fujikawa model's use of Nmax as a constant, the new
model, dubbed the name Enveloped growth model, defines the maximum term as a
variable, denoted N
′
max (See Equation 6.18). N
′
max is a variable defining the limit
(or envelop) of growth of an individual mutant as a result of other competing cells
in the culture. The time-dependent nature of N
′
max is due to the term Nenv, an
integral of the ordinary differential equation of Fujikawa model (Equation 6.17)


















, where Nenv is the integral of Equation 6.17 with respect to time up to the current
time point tc, and Pf is a congestion factor used for adjusting the magnitude of
dampened growth of a mutant population Nm, and 0 6 Pf < 1.0. Given N
′
max, the
ordinary differential equation of Enveloped growth model for a mutant population












, where r is a growth rate, Nmin > 0, and c is an adjustment factor proportional
to the duration of the lag phase of growth.
Figure 6.10 shows how Enveloped growth model (Equation 6.19) improves upon
Fujikawa model (Equation 6.17) in that the predicted mutant population does not
end up representing 100 % of the total cell population, which would be un-natural
if so happened. This so-called mutant population saturation issue associated to
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Fujikawa model is evident in Figure 6.9.



























Figure 6.9: Mutant population prediction by applying Fujikawa model as is
The growth curve shown in broken red shows the total population as determined by
Fujikawa model in Eq.6.17, where t0 = 0, r = 2.2, Nmin = 0.99999, Nmax = 10
8.8,
and c = 0.74. The blue growth curve represents a mutant population shown in loga-
rithmic scale, log(Nm), where t0 = 3, and was calculated using Fujikawa model (i.e.
unenveloped). Due to the lack of enveloping to dampen the mutant growth as its curve
gets close to the total population, the mutant population ends up saturating the entirety
of the total population towards the end (t = 15.0). This saturation problem makes
the unenveloped growth model invalid for predicting mutant populations in a realistic
manner.
As per Section 5.1.2, the mutagenesis rate (θ) of bacterial cells can, for instance,
be defined as 10−3 mutation per replication, or a SNP per 1000 cells replicated.
Given θ, the number of mutation events Nθ at time t, denoted Nθ(t), can be
predicted by tracking the temporal change in the total cell population:
Nθ(t) = ∆N · θ
∆N = N(t)−N(t− 1)
(6.20)
, where N is the total cell population calculable by integrating Equation 6.17 with
respect to time. Figure 6.11 shows a plot of Nθ(t) based on the same Fujikawa
growth curve used in deducing the total cell population in Figure 6.10.
Now, Nθ(t) provides a ground for modelling the population dynamics of in-
dividual mutants, by suggesting a firm numerical reference to how many SNP
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Figure 6.10: Dampened mutant populations in Enveloped growth model
(a) The growth curves at varying starting time points (shown in green) were calculated
using the enveloped growth model (Eq. 6.18), where r = 2.2, Nmax = 10
8.8, Nmin =
0.99999, c = 1.0, and Pf = 0.7. The larger value for c results in longer lag phases. Mutant
growth is further retarded as it reaches close to the total population, while the degree
of retardation is less when the growth level is farther away from the total population
level. For example, the curve with t0 = 7 at t = 15 is dampened less in comparison to
the curve with t0 = 1 at t = 15. (b) The growth curves with identical parameter values
except the congestion factor, Pf = 0.0. The dampening effect due to congestion is milder
in comparison to the curves with Pf = 0.7.
events may occur at any given time point. Combining the information from Nθ(t)
and the temporal estimation of mutant population from Nm(t) (Equation 6.19),
we have all the modelling elements necessary for materialising individual mutants
and calculating their contributions towards the total population at any time point.
Let's say a set of Nθ(t) mutants arising at time t is denoted Sθ(t) ∈ Sm, where
Sm is a set of all mutant sets Sθ(t) throughout a span of time from t0 upto the
current time tc. Any individual mutant mω ∈
⋃
Sm has the time of inception,
tα, associated with it. At any moment in time t > tα, the mutant population
continues to change due to growth. The estimated mutant population Nm at a
current time point tc of an individual mutant that was given rise to at tα is an
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Figure 6.11: Predicting the occurrence of mutation events.
The growth curve shown in broken red shows the total population as determined by
Fujikawa model in Eq.6.17, where t0 = 0, r = 2.2, Nmin = 0.99999, Nmax = 10
8.8,
and c = 0.74. This growth curve serves as the basis for calculating ∆N as shown in
Equation 6.20. The blue curve represents the number of occurrences of mutation events
as a function of time (Nθ(t)).













Any individual mutant mω ∈
⋃
Sm has its identity specified by the cardinal
variable denoted by ω ∈ {0, 1, 2, · · · , NΩ}, where NΩ = |
⋃
Sm| − 1. In fact, the
mutant with ω = 0 represents a mother cell, or a wildtype cell with zero mutation,
hence m0 = ∅. The mutant set
⋃tc
t=0 Sm represents all the cell genotypes available
in the culture upto the time point tc, and any cell mω ∈
⋃tc
t=0Sm may serve as a
template for a new mutant genotype with the probability defined as:




, where X is a random variable such that 0 6 X ∈ Z 6 NΩ; ω is a positive integer
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representing the cardinal variable to specify an individual mutant mω, given rise to
at tα; Nenv(t) is the total cell population envelop from Equation 6.18; and Nm(tα, t)
is the population of mutant mω from Equation 6.21. P (X = 0), the probability of
a new mutant arising from the mother cell, is defined as:
P (X = 0)(t) = 1−
NΩ∑
ω=1
P (X = ω)(t) (6.23)
In this mutant population model, a mutant mω, once assigned a membership
to a cardinal value ω or a genotype, does not change its membership. Such a mem-
bership arrangement was based on the assumptions that mutations only happen
during replication, and only affect daughter cells. These somewhat naive assump-
tions, discounting mutagenesis factors other than replication errors, were enough
for a proof-of-concept modelling to study a simple mutagenesis dynamics.
The bar graph in Figure 6.12 shows the mean population levels versus SNP
counts per cell as a result of running simulations (n = 4) according to the novel
mutagenesis model discussed so far. Figure 6.10b shows the corresponding mutant
growth curves used in the simulations. The simulations were based on a single
mother cell grown on 1 mL media for 15 hours under conditions allowing a maxi-
mum growth upto about 108.8 cells. This cell density is a little less than an OD600
equivalent value of 1.0 which is about 8 · 108 E. coli cells/mL according to litera-
ture [153]. The results showed that mutants comprise only a small proportion of
the entire cell population, and that double SNPs with respect to the mother cell's
genotype seem to be the practical limit to the mutagenesis achievable in a single
mutant, within the given growth timeframe. The unique mutant count results
revealed that the mutagenesis covered on average 4261 different kinds of unique
SNPs for the single-SNP mutants, and 444 unique double SNPs for the double-SNP
mutants. The number 4261 corresponds to the total number of CDSs available in
the B. subtilis 168 genome sequence (Genbank accession ID AL009126.3 [105])
used as part of the simulations here. This means that the given mutagenesis time-
frame was enough to explore all of the coding sequence basis in the organism of
interest, as far as single-SNP mutations are concerned. A spatio-temporal analysis
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Figure 6.12: Mean populations and unique mutant counts for cells with varying SNP
counts
of mutagenesis as a nested function of changing population such as shown here is
a novel attempt. This analysis method has a potential to be applied in estimating
optimal culture volumes and time lengths required in the evolutionary rounds of
the in vivo domain, for achieving a targeted SNP count. This estimation can pro-
vide the ground for determining an efficient load share between the in vivo and in
silico evolutionary domains.
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6.4 Mitigating the curse of combinatorial explo-
sion
6.4.1 The grand challenge
One of the primary challenges in genome-scale design is the lack of effective ways
to mitigate the immensity of its combinatorial search space. The size of search
space can be estimated by looking at the number of SNPs (µ) out of the total





Each SNP, for the example case of riboflavin enzymatic pathways, may induce
different flux changes in the relevant metabolic pathway step. Let's say a SNP
may result in three different effects in the relevant enzymatic flux: flux reduction,
flux increase, or no change. The set of possible phenotypic changes in the flux is
denoted Φ, and its cardinality |Φ|. Hence, |Φ| = 3 in this example case. For each
combination defined as part of C(Ω, µ), there are |Φ|µ possible permutations with
repetition to be considered in going over phenotypic changes in metabolic fluxes.
From these numbers, a simple metric to estimate the size of search space (NX)
was given by the following equation:
NX = |Φ|µ · C(Ω, µ) (6.25)
The problem of dealing with immense search space being addressed here is two-
fold. Firstly, the size of search space (estimated by NX) increases exponentially
as design complexity (i.e. the length of SNP combinations, µ, under considera-
tion) increases linearly (See Figure 6.13). Secondly, it becomes increasingly more
difficult to introduce additional SNPs into a single cell, as evident in Figure 6.12.
The former problem cannot be bypassed as there is no way to change the physical
nature of combinatorial explosion. The latter is a throughput issue which can be
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Figure 6.13: Estimation of state space size with respect to SNP counts
The size of state space was estimated in terms of NX for varying SNP counts (µ) and
gene counts (Ω) per cell. The phenotype count of |Φ| = 3 was used in all calculations as
per Equation 6.25.
overcome, to a limited extent, by increasing the mutation rate (See θ in Equation
6.20). Nevertheless, such an in vivo level countermeasure alone is still far from
ameliorating the curse of combinatorial explosion.
6.4.2 Data exchange strategies for the cross-domain inter-
face
The premise of the efficiency gain from harnessing the dual-evolutionary approach
requires that the cross-domain gap be bridged. The primary data medium, used by
the evolutionary process in the in vivo domain, is defined at the genotypic level.
This medium, once sequenced and analysed, can be transferred to the in silico
domain, in the form of SNP data, as explained in Chapter 5. On the contrary, the
primary data medium in the in silico domain is defined at the phenotypic level, as
a function of in silico fitness evaluation. The conceptual differences between geno-
typic and phenotypic elements attribute to the cross-domain gap in merging their
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data. The advantage of adopting a genome-scale FBA model, like that detailed
in this study, is that there is a model-level support to link phenotypes to genes.
The SNP data obtained from the in vivo domain can feed directly into the in
silico fitness evaluation model defined in terms of FBA. The in silico domain can
stipulate certain constraints on the flux of relevant enzyme(s) (i.e. phenotypes) in
the FBA data model to reflect potential implications of having a certain SNP on
a gene. Any downstream simulations of the in silico model would then be affected
by the SNP data from the in vivo domain.
Data can flow in the reverse direction as well, going from the in silico domain
to the in vivo domain. A combinatorial exploration, by the in silico EA, of apply-
ing different flux constraints in the FBA model would result in optimal solutions
defined in sets of key enzymatic constraints. Such in silico findings can be trans-
lated to influence in vivo genetic manipulation decisions such as a gene knock-out,
or a random mutagenesis scheme targeted to a particular gene of interest. The
smorgasbord of genotypic manipulations on key target genes can be included in
the construction of the next mother mutant to start the subsequent round of it-
erations in the dual evolutionary cycle. The suggested cross-domain interface, by
means of enabling two-way data exchange, can help close the cross-domain gap.
6.4.3 Bridging the in vivo-in silico gap
As demonstrated in Figure 6.13, a higher number of SNP counts can harbour
exponentially larger solution space. At the SNP count of 9, for instance, the
number of different solutions in the search space already outnumbers the total
number of stars in the observable universe [88] which is roughly estimated to be
around 1029. At the SNP count of 23, a figure less than treble the former SNP
count, the search space can hold as many solutions as there are atoms in the
universe [183]. These are numbers rather too large for any search operations to
finish going through within a reasonable time span. The in vivo search operation,
especially considering the throughput limiting nature of the mutation rate θ, a
finite amount of culture volume and time given, can only explore so far in the
solution space.
Figure 6.12 illustrates this point further by showing that only a little number
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of unique double-SNP solutions (444) had been encountered within 15 hours of
evolution in 1 mL culture volume. That is to say, only a tiny fraction ( 444
1.8e7
) of
the available search space was explored. By increasing the volume, let's say by
about three orders of magnitude higher, to 1 L culture, the in vivo search operation
would still have only scratched the surface by covering about 2.5 % of the solution
space. Any numbers regarding triple-SNP solutions have not even been part of
the discussion yet. Though, it seems probable that double-SNP solutions are the
practical limit to the in vivo operation, searchable within reasonable amounts of
time and culture volume. The obvious question to be asked here, as far as DEA
is concerned, is whether it is possible for the in silico operation to help speed up
the solutions search. If so, how?
The variant analysis pipeline explained as part of the in vivo domain can in-
form the in silico EA domain about any non-silent mutations that may provide
significant contribution towards meeting the design goal of interest. For the rea-
sons that have just been discussed, this information would be limited to double- or
single-SNP solutions. In order to find out if such information can be exploited to
reduce the search space of higher order solutions having SNP counts larger than
two, a hypothetical solution was considered, out of a total of 2000 hypothetical
genes in a cell (i.e. Ω = 2000), based on the following solution criteria.
Table 6.3: The criteria for a hypothetical solution, based on Ω = 2000 and µ = 9
Name solution SNP count (µ) hint pool size unit hint size limit upfront knowledge (µ0)
0to9 9 6 2 0
The numbers in Table 6.3 was designed to indicate, to a limited extend, the
search complexity of a target solution. The solution SNP count (µ) shows how
many SNPs any hypothetical solution befitting the criteria may consists of.
The hint pool size shows an aggregate total number of SNPs that can be possi-
bly elucidated by the in vivo search domain, with respect to a given phenotype of
interest. It is a sum of of SNP set sizes, limited by unit hint size limit, hypothet-
ically made available by processes, such as variant analysis discussed in Chapter
5. The size limit of 2, here, corresponds to the information limit offered by sub-
optimal solutions comprising single- or double-SNP(s). The evolutionary domains
can potentially use these intermediary, local solutions, to help find higher order so-
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lutions, consisting of µ >> 2 SNPs. The upfront knowledge, µ0, shows the amount
of information at hand, before the solution search is initiated by either domain.
The distance to solution, µ − µ0, is a simple factor indicating the likely search
complexity.
Table 6.4: The hypothetical solution (iv) used in the study and its intermediary
hint pool (i,ii,iii)





Arbitrary choices were made, with respect to satisfying the above criteria,
namely '0to9', to come up with a hypothetical solution shown in Table 6.4. The
hypothetical solution featured sub-optimal solutions (i, ii, iii) embedded as part of
the global solution (iv), each of which was associated to a phenotype from the set
Φ = {0, 1, 2} explained earlier, and a fitness score. For example, the sub-optimal
solution i, had a double SNP, at genes {900, 995} ⊂ {1, 2, · · · ,Ω}, harbouring their
respective phenotypes (2 and 1). Each solution's fitness score was given by the
values following the second colons in the table. The partial solutions i, ii, iii were
given a fitness score of 0.2 each, and the global solution iv was given 1.0. These
scores were evaluated in an additive manner, so the maximum fitness scorable by
the solution iv would be 1.6, due to the partial solutions embedded within it.
A set of in silico experiments were devised to study the conceptual differences
between DEA and a single domain framework such as directed evolution, based
on a GA developed using Python and DEAP [51] (See Figure 6.14). The following
assumptions were made. That characteristic model bacterial organisms such as E.
coli or B. subtilis, when applying directed evolution without intermittent human
interventions and the conjugation factor, would be taking an evolutionary strat-
egy, functionally equivalent to a mathematical optimisation method known as Hill
Climbing (HC) [95]. Therefore, HC was used as a simulated proxy for directed
evolution in this experiments, constituting the in vivo half of the DEA framework.
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Specific values used in the simulation
N = 3000, M = 2000,
L = flux phenotypes,
L ∈ {0,+,−, ∗},
where ∗ means 'any'
Ss =deap.tools.selTournament,







0.01 or larger for EA
0.001 for HC as proxy
fitness criteria as per Table 6.4,
G = 100
Figure 6.14: Overview of GA steps, decisions, and models used in this study
The left half of the figure is a flowchart showing the steps and decisions taken by the GA
used as part of simulating the proof-of-concept test scenario. The specific parameters
used in the simulation are shown on the right half. The Markov chain, shown in the lower
right corner, provided the mutagenesis policy for phenotypic as well as genotypic state
transitions in each gene as a function of the mutation probability Pm. Four phenotypes
were used in the study, namely 0,+,−, and ∗, respectively representing enzymatic flux
constraints resulting from mutations: zero flux, positive flux, negative flux, and 'any'
(to mean unconstrained). In this Markov chain, two types of transition probabilities, Pt
and Pr were defined. Pt was used to specify the probability of any given state to change
to a different state, and Pr was used to specify the probability of any given state to
stay the same. The GA setup shown here was used for simulating the concept of both
Evolutionary Algorithm (EA) and Hill Climbing (HC). The EA simulations had the step
S4 in the flowchart enabled with Pc = 0.5, and the HC skipped S4 by setting the value
of Pc, the crossover probability, to zero.
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'exp_cycle ':[{'seqid': 1, 'domain ':'invivo ', 'ngen': 100, 'pheno_threshold '
:1.0, 'geno_threshold ':0.9, 'CXPB':0.0, 'MUTPB':0.001 , 'domain_error '
:0.0} ,]
} }
The experimental setup of HC shown here defined the notion of directed evolu-
tion, upon using the GA framework depicted in Figure 6.14 as part of simulating
the DEA concept entirely in silico. One noteworthy parameter setting, in light of
directed evolution, was CXPB, the crossover probability. This field was set to zero
in all HC experiments, by definition of single-cellular systems taking evolutionary
strategies in solitude. Likewise, the domain_error field was as important a con-
cept to HC as it was critical to have the field switched off in the simulated in vivo
domain. The domain_error parameter was used to account for any uncertainties
associated to fitness evaluation in silico due to potential knowledge errors in the
evaluation system. It would be a reasonable assumption to make that in vivo
systems do not suffer from errors in their fitness evaluation as a result of poor un-
derstanding of cellular dynamics. By virtue of HC being used here as a proxy for
an in vivo system, the domain_error field was set to zero for all HC experiments.
Other parameter settings, including tot_iteration, seqid, domain, ngen,
pheno_threshold, and geno_threshold, bore commonly needed functions and
usages, along with the experimental definitions of DEA. For example, ngen was
used to set the number of generations for which any mutant population was subject
to evolutionary changes. The respective parameters of pheno_threshold and
geno_threshold were used to set acceptable fitness levels in the phenotype and
the genotype of a mutant.
In light of the experimental setups introduced so far and in Figure 6.14, a data
model was designed to support the in silico state space representation of a single
mutant cell (See Figure 6.15). It was non-trivial, with respect to the research
questions being answered, to design an efficient data model supporting the feature
completeness of the simulated DEA.
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Figure 6.15: The data model used in simulated DEA to represent the state space
of a single mutant cell supporting efficient in silico fitness evaluation
A 4000-bit-long sequence of alternating eight 1's and eight 0's was arbitrarily chosen
as a genome sequence template. Nd denotes the number of mismatching bits against
the genome sequence template, obtained from taking XOR between two bitmaps. In this
hypothetical genome, a single gene was made of a single nucleotide, represented by using 2
bits. The 4000-bit-long sequence bitmap, therefore, accommodated 2000 2-bit-long genes
indexed by i0, i1, ..., iN , where N = 1999. The look-up-table (LUT) was a list of tuples
consisting of a gene index and an integer specifying the phenotypic state of the gene.
For simplicity, the bit patterns ({00, 01, 10, 11}) used for respectively representing four
phenotypic states ({0,+,−, ∗}) were directly converted to corresponding genotypes and
their bit patterns (A = 00, T = 01, G = 10, C = 11). For example, the nine genes making
up the pre-agreed solution in LUT, with the gene index values of 1, 100, 200, 900, 940,
994, 995, 998, and 1954, were respectively associated to T, A, T, G, A, A, T, T, and A, and
were respectively mapped to the phenotypic state combination [+, 0,+,−, 0, 0,−,−, 0].
The bitmap of a mutant can be compared to LUT and the genome sequence template
to determine the mutant's phenotypic fitness (Sf1) and genotypic fitness (Sf2). The
respective fitness evaluation functions, denoted f1 and f2 can accommodate random
errors specified by Pe1 and Pe2.
As depicted in Figure 6.15, fitness evaluation was performed with respect to
the two functions f1 and f2, each of which respectively calculates the phenotypic
(Sf1) and the genotypic (Sf2) fitnesses. The fitness calculations can accommodate
random errors occurring with probabilities Pe1 and Pe2, or Pe, where Pe1 = Pe2.
115
6. IN SILICO MODEL BASED DESIGN TO BRIDGE THE GAP
IN THE DUAL-EVOLUTIONARY DOMAINS
Each mutant was represented with a bitmap data structure that can minimally
encode the state space, using two bits per gene or phenotype (cf. |L| = 4, where
L ∈ {0,+,−, ∗}). For Ω = 2000, it required 4000 bits to encode 2000 genes (cf.
iN = 1999 in the bitmap) per mutant. Performing the bitwise XOR operation on
the bitmap data structure representing each mutant against two answer templates
enabled the fitness evaluation for both Sf1 and Sf2. The genome template, serving
the purpose of a hypothetical organism's genome sequence, was arbitrarily chosen
to be an alternating sequence of eight 1's and eight 0's, as depicted above. The
genotype to phenotype conversion, with respect to having the hypothetical solution
(LUT) encoded into this genome sequence, was done by assuming a direct one-to-
one match between the genomic and the phenotypic state spaces. For example,
each gene out of 2000 was assumed to consist of a single nucleotide (i.e. A, T, G,
or C). As far as the current study was concerned, the arbitrary genes 1, 100, 200,
900, 940, 994, 995, 998, and 1954 were the only ones with any significance in their
specific phenotypes, as per LUT constructed from the pre-agreed answersheet in
Table 6.4. For the sake of simplicity, the four single nucleotides of their genes
were directly mapped to their four phenotypic states respectively representing
L ∈ {0,+,−, ∗}. The LUT and the total gene count, given by Ω, formed the
basis of calculating Sf1 and Sf2. Sf1 was a simple look-up-table (LUT) operation
against the answersheet values, and Sf2 =
2Ω−Nd
2Ω
, where Nd denotes the number
of mismatching bits against the genome sequence template.
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Non-converging fitnesses over generations by HC-based
policy akin to directed evolution




















Figure 6.16: 24 out of 24 mutant colonies failed to achieve the phenotypic objective,
by relying on an evolutionary strategy based on HC
The mean fitness scores of 24 mutant colonies were plotted over 100 generations. Each
mutant colony consisted of 3000 mutants that evolved based on the HC strategy. The
solid lines on the bottom half of the plot represent phenotypic fitness scores Sf1, and the
broken lines on the top part of the plot represent genotypic fitness scores. The mutant
populations' genotypic integrity was maintained to a high standard, but their phenotypic
fitnesses failed to reach the evolutionary objective. The pheno_threshold was set at 1.0,
and the geno_threshold at 0.9.
Figure 6.16 shows the result of HC experiments conducted on 24 mutant
colonies, each consisting of 3000 mutants evolved for 100 generations. These were
proxy experiments in lieu of directed evolution in vivo. All the mutant colonies
taking the evolutionary strategy provided by HC failed to achieve the pheno-
typic objective (i.e. the phenotypic fitness level above pheno_threshold). They
were all dwelling on the local optima of high genotypic fitness levels, driven by
geno_threshold.
117
6. IN SILICO MODEL BASED DESIGN TO BRIDGE THE GAP
IN THE DUAL-EVOLUTIONARY DOMAINS





{'seqid': 1, 'domain ':'invivo ', 'ngen': 30, 'pheno_threshold ':1.0, '
geno_threshold ':0.9, 'CXPB':0.0, 'MUTPB':0.001 , 'domain_error ':0.0} ,
{'seqid': 2, 'domain ':'insilico ', 'ngen': 40, 'pheno_threshold ':1.0, '
geno_threshold ':0.9, 'CXPB':0.5, 'MUTPB':0.01, 'domain_error ':0.0} ,
{'seqid': 3, 'domain ':'invivo ', 'ngen': 30, 'pheno_threshold ':1.0, '
geno_threshold ':0.9, 'CXPB':0.0, 'MUTPB':0.001 , 'domain_error ':0.0} ,
]
} }
The experimental definition of DEA assuming a probability of 0.3 for random in





{'seqid': 1, 'domain ':'invivo ', 'ngen': 30, 'pheno_threshold ':1.0, '
geno_threshold ':0.9, 'CXPB':0.0, 'MUTPB':0.001 , 'domain_error ':0.0} ,
{'seqid': 2, 'domain ':'insilico ', 'ngen': 40, 'pheno_threshold ':1.0, '
geno_threshold ':0.9, 'CXPB':0.5, 'MUTPB':0.01, 'domain_error ':0.3} ,
{'seqid': 3, 'domain ':'invivo ', 'ngen': 30, 'pheno_threshold ':1.0, '
geno_threshold ':0.9, 'CXPB':0.0, 'MUTPB':0.001 , 'domain_error ':0.0} ,
]
} }
Different to the HC experimental definition discussed earlier, the two simu-
lated DEA experiments had the experimental cycle (exp_cycle) defined in multi-
ple steps. Each step was given a seqid value for noting the sequential order of its
execution. In the three steps defined for both DEA categories, the domain field
was used to define alternating evolutionary strategies, switching from taking the
HC, to taking the EA, and back to taking the HC again. This alternating domain
parameter setup was for simulating the iterative design cycle in the dual domains
of the DEA framework. Also, the MUTPB field was set to alternate between 0.001
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and 0.01. This was done to reflect in the simulations the flexibility of the in sil-
ico domain in setting the mutation rate or the rate at which different solutions
are explored. A higher mutation rate would enable a faster exploration of diverse
mutants in a population at the expense of the stability of desirable mutants. Bio-
logical systems in nature have evolved to put a hard limit on increasing this value,
as high mutation rates can pose an immediate threat to the functional integrity
of their genome base, limiting their survival chances. The primary objective of
biological systems is to maximise the chance of survival. The primary objective
of the in silico domain, in the context of DEA, is to find solution(s) conferring
desired phenotypes as quickly as possible. The survival of an organism of interest,
as far as the in silico domain is concerned, would only be secondary an objective.
The capability of efficiently making crossover mutations is another useful fea-
ture offered by the in silico domain. Crossover mutations could unlock hidden
solutions via a mechanism known in the mathematical optimisation community as
implicit parallelism. The value of 0.5 was used for CXPB on all in silico simula-
tions. The error-prone DEA was defined with a probability of random errors in
the in silico system's assessment of fitness scores. This experimental setup was
introduced to serve not only as a control, but also as a main comparison point
to assess the potential feasibility of a real-world DEA system. This experimental
setup along with the corresponding results presented in Figure 6.18 formed the ba-
sis of discussing how errors in in silico fitness evaluation may affect the integrity
of the DEA framework.
Figure 6.17 shows the result of simulated DEA experiments conducted on 24
mutant colonies, each with 3000 mutants evolved for 100 generations. In the
DEA and the HC experiments, the duality of two fitness evaluation categories,
phenotypic and genotypic fitnesses introduced in Figure 6.15, was acting as a
push-pull driving force for directing mutations. The mutually conflicting dual
objectives biased selection events for directing mutants to acquire mutations that
would provide an optimal balance between the two objectives. The two types of
evolutionary pressure acting in opposite directions had more pronounced effects
in DEA experiments than they did in HC experiments. It can be seen in Figure
6.17 that the phenotypic objective affected mutants to take upward trajectories in
phenotypic fitnesses at the expense of decreasing genotypic fitnesses, while being
119
6. IN SILICO MODEL BASED DESIGN TO BRIDGE THE GAP
IN THE DUAL-EVOLUTIONARY DOMAINS
Converging fitnesses over generations by error-free DEA
taking short interlaced evolutionary runs





















Figure 6.17: 7 out of 24 mutant colonies succeeded in achieving the phenotypic
objective, based on error-free DEA
The mean fitness scores of 24 mutant colonies, each consisting of 3000 mutants, evolved
based on the error-free DEA strategy, were plotted over 100 generations. The mutant
populations' genotypic integrity was somewhat challenged but was successfully main-
tained, while resulting in 7 phenotypically successful colonies.
The solid lines on the bottom half of the plot represent mean phenotypic fitness scores
Sf1, and the broken lines on the top part of the plot represent mean genotypic fitness
scores Sf2. The threshold values of 1.0 and 0.9 were respectively set for pheno_threshold
and geno_threshold.
resisted by the genotypic objective.
Also evident was the different mode of evolutionary trajectories exhibited by
DEA in comparison to the results from HC. The modal change occurred when
mutant colonies switched from the simulated in vivo domain to the in silico evo-
lutionary domain in generation 30 (See Figure 6.17). The tug of war between
the two fitness criteria started tilting towards favouring phenotypic changes over
genomic stability. This was indicated by the fast paced decline in the genotypic
fitnesses and by the sudden appearances of fast converging mutant colonies mak-
ing steep turns upwards in the fitness landscape, between the generations of 30
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Converging fitnesses over generations by error-prone
DEA taking short interlaced evolutionary runs, amid
errors in fitness evaluation




















Figure 6.18: 6 out of 24 mutant colonies succeeded in achieving the phenotypic
objective, based on error-prone DEA
The mean fitness scores of 24 mutant colonies, each consisting of 3000 mutants, evolved
based on the error-prone DEA strategy, were plotted over 100 generations. Fitness eval-
uation errors, with a random occurrence probability of 0.3, were plaguing the in silico
evolutionary decisions. The mutant populations' genotypic integrity was severely chal-
lenged but was impressively defended and maintained, while also resulting in 6 phenotyp-
ically successful colonies. The solid lines on the bottom half of the plot represent mean
phenotypic fitness scores Sf1, and the broken lines on the top part of the plot represent
mean genotypic fitness scores Sf2. The threshold values of 1.0 and 0.9 were respectively
set for pheno_threshold and geno_threshold.
and 70. This period coincided with the generations governed by the evolutionary
strategies of the in silico domain, as specified to be so in the experimental defini-
tion of the simulated DEA. It appears that the in silico domain, in contributing
to find converging mutants, took a full advantage of the higher mutation rate as
well as crossover mutations. The accelerated mutant maneuver went back to the
initial conservative characteristics of HC at generation 70, but only after optimal
converging solutions had been found by multiple mutant colonies.
Figure 6.18 shows the result of experiments on simulated DEA with the pres-
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ence of random errors in in silico fitness evaluation. The two mutually conflicting
fitness criteria were acting against each other just like in the previous two cases.
The increase in the mutation rate upon entering the in silico domain was reflected
on the accelerated decline in the genomic fitness by all mutant colonies. The in
silico fitness evaluation error, due to the domain switch at generation 30, had
severely affected the fitness scores, causing huge drops among all mutant colonies
between generations 30 and 70. The sudden drops in mean fitnesses happened
in both genotypic and phenotypic categories. At first, it seemed as though the
fitness evaluation error only had adverse effects on both fitness categories in the
short run. However, the error must have also induced some positive effects on
some mutant colonies, perhaps by nudging them out of stagnation, or by forcing
them to take uncharted evolutionary trajectories. After all, the in silico domain
seemed to have primed mutants in such a way that some colonies started achiev-
ing the phenotypic objective shortly after switching back to the in vivo domain in
generation 70. The accelerated mutant maneuver went back to the initial conser-
vative characteristics of HC, as expected. However, the error-prone DEA exhibited
remarkable resilience not only in terms of error recovery but also in its success in
driving mutant colonies to achieve the dual objectives in the hands of the in vivo
step supposedly taking a conservative evolutionary stance. Given the fact that a
real-world DEA would most likely suffer from errors in in silico fitness evaluation,
the results shown here further corroborated the idea that DEA can be useful in
facilitating in vivo solution search.
6.5 Discussion
This chapter covered a wide range of ideas with respect to the focus on their
modelling aspects. Be it concepts from in silico or in vivo domains, the emphasis
was given to their modelling aspects.
A comprehensive model was developed to convey many of the concepts compris-
ing the DEA framework. The plausibility of the DEA framework was investigated
using the simulation of the model. The simulated DEA resulted in converging
mutant colonies. This can be interpreted as the framework's capability of finding
solutions within the limited timeframe. This result was contrasted by the simu-
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lated directed evolution not beig able to solely resolve any solutions given the same
timeframe. These results were in agreement with the idea that hiring the in silico
domain can increase the search efficiency of the in vivo domain, or vice versa, like
that envisioned by DEA. Given the assumption that time to solution is positively
correlated to design complexity, this study successfully corroborated the idea that
the DEA framework offers to be an effective means to mitigate design complexity.
Throughout the study involving the in silico domain, many novel methods were
developed. These include the enveloped growth model (Equation 6.19) and the
novel way of analysing the spatio-temporal population dynamics of mutants. These
methods can potentially be used in the estimation of parameters such as optimal
culture volume and evolution time, crucial to in vivo experiments in minimising
evolutionary overheads. Minimising evolutionary overheads as such is directly
relevant to reducing the time to solution, to closing the cross-domain gap, and to
the capability of dealing with complex designs.
With hindsight, the gap between the dichotomous evolutionary domains was
bridged in various angles. The use of variant analysis to make the information
exchange compatible between the two domains was one such angle. The decision to
adopt the genome-scale FBA, as a suggested means for in silico fitness evaluation,
was for addressing the primary concern of using a model as closely compatible to
SNP data as possible. This suggestion was driven by the thought that the adoption
of in silico models closely resembling the real world would be the only effective
way to minimise errors that may potentially plague the cross-domain interface to
end up exacerbating the gap. Without doubt, the point being made was rational.
However, the error-prone DEA experiments cast an interesting view point with
respect to maintaining the cross-domain integrity, amid errors in in silico fitness
evaluation. It is a view point suggesting that in silico errors can be effectively
mitigated, in a more systematic manner, via in situ corrections provided by the
in vivo evolutionary domain. The results presented in Figure 6.18 hinted at this
possibility, where the error-prone DEA was able to cope with in silico fitness
evaluation error, upon switching the domain to the in vivo counterpart. This is
suggestive of the idea that the resilience of the in vivo domain may render the
cross-domain gap a non-issue, at least to a certain extent.
Now, these discussions about seemingly eclectic subject matters involving evo-
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lution and design appear excessively intertwined. Yet, they also converge at
the focal point of achieving design automation. One principle adamantly held
up throughout this study was concerning automation, such that methodological
choices deemed unfit for automation were simply ruled out. Automation is per-
haps the single most important element in increasing the data exchange through-
put between the two domains. The throughput increase would in turn contribute
towards bridging the gap from whole another angle, let alone the contribution it
would have on reducing the time to solution. In Chapter 7, the discussion will shift
gears more towards bolstering the automation aspect of realising the DEA frame-
work, via introducing a series of ideas underpinning single-cell-level microfluidics.
These microfluidic techniques certainly attributed towards closing the gap from a








Synthetic biology is aimed at developing organisms with novel functionalities. As
part of realising this aim, DEA was suggested [80], and its proof-of-concept imple-
mentation ideas were tested in Chapter 5 and 6. In the DEA framework concerning
phenotypic characterisation, however, there still exists a disconnect between the
two domains in the properties perceivable by measurement. Such discrepancy
arises, in part, from the incompatibility of phenotypic data obtainable in the two
domains. For instance, measurable properties in the in silico domain are often
modelled on a single-cell basis as shown in Chapter 6, whereas actual measure-
ments in the in vivo counterpart are usually taken on populations of cells due
to limitations in conventional lab techniques. Colony- or population-level mea-
surements may end up obscuring the identification and characterisation of rare,
stochastic cellular events occurring at single-cell levels [163]. Single-cell based in
vivo measurement and analysis techniques are needed to close this gap.
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While flow cytometry can offer single-cell-level measurements, it is limited to
measurements at a single time point, and therefore is incapable of measuring single-
cell-level events in a time series. Studies claiming time-series measurement of single
cells using flow cytometry [162] are, in fact, based on time-series measurements
of populations of cells and reporting single-cell-level statistics by calculating the
population mean values.
Synthetic biology and systems biology have constantly increasing needs for
true single-cell-level time-lapse measurements, as temporal variation is integral to
cellular properties. Microfluidics is promising in terms of developing novel
measurement systems that can measure the temporal dynamics of single-cell-level
cellular events, prone to cancelling out in population based measurement systems.
Photolithography techniques [191] as well as programmatic image analysis [81, 149]
underpin the development of sub-micron scale microfluidic systems for carrying out
time-lapse measurements at fine granularities. Synthetic biology, especially with
respect to DEA, is an area of research that can greatly benefit from this kind of
novel measurement systems.
However, the current practice of designing single-cell-level microfluidic devices
relying on designers' ad-hoc intuition is subject to expensive trial-and-error cycles.
It is not unusual for human designers to mistakenly apply their understanding
of the macroscopic world to the microfluidic world where liquid behaves rather
strangely due to the physics of low Reynold number conditions [24]. A model-based
approach [146] to designing microfluidics devices would help reduce such human
errors. Working with models before finalising device designs not only improves the
validity of designs but also reduces the overall production cost.
Discussed in the following are a number of microfluidic designs that support
single-cell-level measurements. The purpose of presenting these design examples
are mainly two fold. Firstly, they exemplify the usecases of single-cell-level mi-
crofluidics to assist with design automation in light of DEA in synthetic biology.
Secondly, they show the successful application of model-based engineering of mi-
crofluidic devices.
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7.2 Fabrication of sub-micron features
One of the biggest challenges in this work in producing microfluidic designs capable
of single-cell level analysis was achieving sub-micron sized features as part of the
fabrication process. The fabrication of submicron-level, high-resolution features
can be directly achieved by using electron-beam lithography (e-beam). However,
applying e-beam is not cost-effective for lengthy and repetitive feature types span-
ning a large surface area, due to low-throughput sequential e-beam head movement
[178]. A photolithography method along with etching was successfully applied
in building lengthy and repetitive sub-micron features, in the fabrication of the
single-cell chemostat by Cluzel's group [123]. While the use of photolithography
was more suitable for the feature types this work involved, the minimum feature
width reliably attainable by photolithography in the multiple foundries consulted
for the work was only about 2.0 µm, due to the diffraction limited nature of their
photolithography setup. Apart from the need for achieving submicron feature
widths, the microfluidics design introduced here also required a uniform feature
depth of 1.5 µm across all small features. Etching is a common technical choice
in the fabrication process to attain these features [89, 123]. However, it was not
possible to reliably control etching to terminate at a depth of 1.5 µm in practice
without rounds of costly optimisation runs. The etching rate can vary depending
on how exposed the surface area of a feature is due to etching anisotropy [89],
leading to variable etching depths - the wider the feature width, the higher the
etching rate.
The photolithography method used in fabricating the single-cell chemostat [123]
was adapted to develop a new method as illustrated in Figure 7.1. The use of
Deep Reactive Ion Etching (DRIE) along with SiO2 was desirable for meeting
the design requirements in this study. Using DRIE, the etching process can be
controlled to be substrate specific. For example, the etching can be selective only
towards SiO2, or towards Si, depending on the choice of a gas mixture. Given such
control and the use of SiO2, instead of Si, as the substrate of choice for microfluidic
structures, it was immediately possible to reliably etch the depth of 1.5 µm without
optimisation, regardless of feature widths. The etching depth control was achieved
by depositing a 1.5 µm silicon oxide layer on silicon wafers (Figure 7.1a step 1).
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The SiO2 deposition is much easier a task than directly controlling the etching
depth of Si.
Oxide backfill was used as a measure for improving upon the 2.0 µm resolution
limit arising from the use of contact photolithography (Figure 7.1a steps 11 and
12). The combination of these methodological choices, as described further in the
following, enabled the fabrication of lengthy submicron features in a manner that
is not only cost-effective, but also reliable. The microfluidics fabrication process
consisted of three main parts, and was performed by Lionix BV, The Netherlands.
The first part was the lithography of small features having a minimum feature
width of 2.0 µm, and a uniform feature height of 1.5 µm. The second part was the
lithography of large features having feature widths between 50µm and 100µm, and
a feature height of 40µm. Lastly, the third part was the backfill steps for reducing
the 2.0 µm minimum feature width to a submicron level.
7.2.1 Lithography of small features
Thermal oxidation was used to introduce a 1.5 µm layer of SiO2 on 4-inch silicon
wafers (See Figure 7.1a step 1). The wafers were spin coated with photoresist
Fujifilm Oir 906/12, at a thickness of 1.2 µm and were soft baked (step 2). The
photoresist layer acts as a protective layer from DRIE. For each wafer, a small-
feature photo mask was overlaid on the photoresist layer using a vacuum to tighten
the contact (step 3). The wafer was then exposed to UV light (step 4), and
developed (step 5). A post-exposure hard baking was performed in order to densify
the developed photoresist on the wafers (step 6). DRIE was performed to etch
small features using a CHF3 and O2 gas mixture, (step 7). After exhausting the
gas chamber (step 8), O2 plasma followed by HNO3 gas was used for stripping the
photoresist layer (step 9). The gas was exhausted afterwards. (step 10).
7.2.2 Lithography of large features
The lithography of large features was done by repeating steps 2 through 10 (Figure
7.1a) as in the lithography of small features, using a variation of the photoresist
and gas mixtures. In step 2, a Fujifilm Oir 908/35 layer was spin-coated at the





Figure 7.1: Fabrication protocol of submicron-scale microfluidic structures
(a) Fabrication processes: 1. Thermal oxidation for introducing 1.5 µm of SiO2 2. Spin
coating of photoresist, followed by soft baking. 3. Contact overlay of the photo mask
(shown in brown) using vacuum. 4. Exposure to UV light. 5. Development 6. Hard
baking to densify the developed photoresist 7. DRIE of the oxide layer. 8. Exhaust 9.
O2 plasma followed by 100% HNO3 gas for stripping the photoresist layer. 10. Exhaust
11. Deposition of TEOS for 0.8 µm backfill. 12. Thermal treatment for conversion to
SiO2 (b) A low magnification SEM image from the top of a chip fabricated using this
protocol. (c) A high magnification SEM image of the chip at a tilted angle. The dark
cavity feature is 40 µm deep, and the small trench features are 1.5 µm deep.
In step 7, a gas mixture of C4F8 and CH4 was applied for stripping the 1.5 µm
layer of SiO2, and a mixture of C4F8 and SF6 for etching 40µm deep cavities into
the silicon material (See Figure 7.1b,7.1c).
7.2.3 Oxide backfill for reaching submicron resolutions
Tetra-ethyl orthosilicate (TEOS) was deposited on the wafers at a thickness of
0.8 µm, reducing the overall feature widths by a total of 1.6 µm (step 11). For
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example, a 2.0 µm wide feature would become 0.4 µm wide. The TEOS deposition
does not affect the depths of features. The deposited TEOS was then thermally
treated to be converted into SiO2 (step 12).
7.3 Microfluidics for single-cell-level measurement
and analysis
Discussed in the following are designs for microfluidics to support the measurement
of cellular properties at the single-cell level. These designs exemplify microfluidic
elements to form the basis of building automated measurement and analysis sys-
tems. Automation at this level will play vital roles in closing the gap between the
in vivo and in silico domains discussed as part of the DEA framework, and in
achieving the ultimate goal of design automation in synthetic biology.
7.3.1 Growth rate vs marker fluorescence chip
The microfluidic designs shown in Figure 7.2b and 7.2c have structural support for
promoting bacterial growth in the direction of channels. Together with a software
component to automate the microscopy and image analysis, they can be used
in measuring single-cell-level growth rate and fluorescence as part of the DEA
framework.
A silicon wafer fabricated using the method in Figure 7.1 was cast with Poly-
dimethylsiloxane (PDMS) to make intermediate moulds. The intermediate moulds
were used, in turn, to cast agarose gel slabs replicating the imprints of the submi-
cron channels of the initial wafer. The gel slabs and their channel imprints were
used to trap and grow bacterial cells. The gel slabs were encased in a PDMS
chamber to which defined growth media were programmatically delivered via a
pneumatic pump control unit. The agarose-based microfluidic chip can accom-
modate a large number of uniquely labelled locations, each of which hosts the
growth of a small number of cell clusters. Figure 7.11e shows one of many such
locations in a single microfluidic chip at two different time points t0 and t1. A
motorized microscope stage (Nikon Ti-E) and motorized shutters (Sutter) were





Figure 7.2: SEM images of agarose-based microfluidics chip designs
Agarose-based microfluidics chips were designed for (a) investigating biofilm formation,
and for (b,c) growth rate vs marker fluorescence measurement.
to acquire multi-dimensional (bright field and fluorescent field) images in multiple
locations and time points. The images were processed via a sequence of steps
to determine cell boundaries, as shown in Figure 7.11f. In this case the process-
ing steps involved the Fiji commands, sharpen, contrast, log, contrast, make
binary, erode, dilate, watershed, and analyze particles (for finding regions
of interest or ROIs). However, the processing steps may vary depending on cell
types and imaging conditions.
For each segmented cell in each image, a cell node was created in a local graph-
based database (Rexster Tinkergraph). Cells that form clusters were grouped
together into a cluster node. Each cell node stored properties such as a bounding
polygon, a cluster membership and references to the bitmap data of relevant phase
contrast and fluorescence images. Pairs of temporally corresponding cluster nodes
were connected by edges indicating relationships. Finding temporal correspon-
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dences between images required that the images be spatially aligned across time.
This image-to-image alignment was implemented by including a temporally invari-
ant landmark as a cue to map local coordinate space to global coordinate space.
Temporal correspondence between single cells was established in consecutive time
frames according to the algorithm described in Section 7.4.1. The same steps can
be repeated for an arbitrarily long temporal image series. Given a time series of
length N , for example, information about the temporal correspondence of single
cells can be obtained by repeating the calculation of pair-wise connections at time
points [t1, t2], [t2, t3] . . . [tN−1, tN ].
Single-cell-level time-series data were extracted (as detailed in Section 7.4.1)
and stored in the database. Important statistics regarding the analysis of cellular
events over time can then be gathered by querying the database (See Figure 7.13).
The software to perform this analysis was customised for the characterisation of
fluorescent markers in bacterial cells, including Escherichia coli and Bacillus sub-
tilis, but can be applied to the analysis of any other cell types, once the appropriate
image processing steps for segmentation are identified.
7.3.2 Model-driven design of microfluidics
The versatile lens of model-driven engineering (MDE) also proved its worth in
designing microfluidics chips in this study. The microfluidics designs featured in
Section 7.3.3, 7.3.4, and 7.3.5 were subject to model checks before finalising their
designs for fabrication. This design practice was cost-effective in minimising the
fabrication cost. The modelling was done using a multi-physics simulation software
package (COMSOL v4.2), based on the parameter settings in Table 7.1.
7.3.3 Chemical gradient generator
The microfluidic device shown in Figure 7.3 was designed to generate a chemical
gradient out of two input liquids in laminar flow. Liquids exhibiting laminar flow
do not mix well, as modelled1 in the blue and red liquids flowing in parallel without
lateral mixing between the y-axis segment of 310µm and 380µm in Figure 7.3a.
1The liquid-structure dynamics was modelled using COMSOL
132
Table 7.1: COMSOL parameters used in this study:
Category Property Settings
Material definition Water Standard library definition
(Entire domain)
Silicone [solid] Standard library definition
(Boundaries except inlet and outlet)
Physics packages Laminar Flow Temperature (T); 293.15[K]
Fluid properties: Water
Compressible flow (Ma<0.3)
Transport of Dilute Species Velocity field u = spf/fp1
Diffusion coefficient[m2/s] Dc = 1e− 10
Global definitions inlet pressures p1 = 70000[Pa]
two inlet concentrations pure water and 1mM chemical solution
Mesh definition size Extra fine
type free triangular
Linear solver Solver type PARDISO




Multithreaded forward and backward solve Disabled
Pivoting perturbation 1.00E − 08
Nonlinear method Automatic (Newton)
Initial damping factor 0.01
Minimum damping factor 1.00E − 06
Shown in the y-axis segment of 240µm and 310µm of Figure 7.3a is a gradient
generator model designed to disrupt the laminar flow and expedite the mixing of
the two liquids. The liquid-structure dynamics due to the gradient generator model
successfully formed a chemical gradient, as evidenced by the spread of rainbow
colours in Figure 7.3a towards the bottom of the y-axis. After the model-based
verification of expected behaviours of the design, an actual chip was fabricated
using the method from Section 7.2. In order to verify the quality of fabrication
results, Scanning Electron Microscopy (SEM) (Tescan Vega 3LMU) was performed
at Electron Microscopy Research Services, Newcastle University.
It was qualitatively shown in the SEM image in comparison to the CAD image
of the corresponding design in Figure 7.3b that the sub-micron features of the chip
design resolved as expected. This SEM result warranted that the fabrication of
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Figure 7.3: Gradient Generator model vs end-product
the chip as far as structural elements are concerned was successful. The successful
fabrication of sub-micron features was confirmed quantitatively via measurements
of control features (Appendix C.2).
A gradient generator chip was made by curing PDMS directly on the silicon
wafer, followed by plasma bonding the PDMS layer onto a glass coverslip (#1
thickness) for use in microscopy. The chip was tested for fluid dynamics to see if the
structural design could function as a gradient generator as predicted in the model.
0.1 % (w/v) solution of fluorescent brightener 28, also known as Calcofluor White
M2R, was made by dissolving 0.01 g of Calcofluor White in 10 mL of MilliQ water.
The solution was titrated using NaOH till the solution turned from opaque white
to clear champagne colour. The final pH of the solution reached approximately
about 11. Excitation light in the wavelength range of 365 nm and 395 nm incident
on Calcofluor White produces emission light at the wavelength of 420 nm. The
chip was staged on an epi-fluorescence microscopy (Nikon Ti-E) set up with a
DAPI filter. DAPI can pick up fluorescence at the emission wavelength of the
Calcofluor White solution. The excitation UV light was generated by using Nikon
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Intensilight C-HGFI. MilliQ water was injected into the left inlet of the chip at 1
psi of pressure, and the 0.1 % (w/v) Calcofluor White solution into the right inlet
at 1 psi of pressure. The chip was left running for 30 min at room temperature in
order to give it some time to form a stable laminar flow. Images were acquired
in the bright-field and fluorescent channels, using an image acquisition software
(MicroManager), a 40x objective (Nikon) and a CCD camera (QImaging Retiga
2000R).
Figure 7.4 summarises the characterisation results of the gradient generator
chip from analysing the fluorescence of the Calcofluor White solution. The PDMS
pillar structures visible throughout the bright field image (a) were used as ref-
erences to make a mask for filtering out background fluorescence in (c) due to
PDMS structures. The (b) was the resulting mask showing pillars with elevated
levels of background fluorescence. The overall background fluorescence in (c) was
estimated by fitting the entire field of view against the background fluorescence
from (b). The fitted result was shown in (d). The raw fluorescence image (c)
was normalised against the estimated background fluorescence (d), to result in (f).
Normalised fluorescence levels across the x-axis in (f) were sampled on four y-axis
locations (the red horizontal lines numbered 0, 1, 2, and 3). These fluorescence
levels were plotted in (e) for all labelled y-axis locations. The y-axis of the plot
shows fluorescence in arbitrary unit (AU) and the x-axis shows horizontal loca-
tions matching those of the image field in micrometre unit. Going from right to
left along the x-axis of the plot in (e), the fluorescence level at the y-axis location
labelled 0 showed a sharp drop, because the fluorescent solution injected from the
right would exhibit a laminar flow against the water injected from the left. Upon
nearing the bottom (y-axis locations 2 and 3), the fluorescence gradient became
much less steep, indicating that the laminar flow started mixing well to form a
continuous gradient field. The fluctuation of fluorescence levels in y-axis loca-
tion labelled 3 was caused by the honeycomb structures in the gradient generator.
Overall, the gradient generator chip seemed to function as intended, according to
this simple experiment. More extensive characterisation was left for future studies,
due to time constraints in the project.
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Figure 7.4: Gradient generator characterisation
(a) Bright field, (b) PDMS channel support pillars with elevated background fluores-
cence, (c) Fluorescence field (DAPI), (d) A heat map showing background fluorescence
across the chip fitted from the background fluorescence of the support pillars, (e) Nor-
malised fluorescence (AU) profiles across x-axis (µm) of four y-axis locations, (f) Nor-
malised fluorescence field.
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7.3.4 Chemical-gradient-passthrough decision tree
Microfluidic channels resembling a decision tree as shown in Figure 7.5 was de-
signed for measuring bacterial chemotaxis-like behaviours. The design can be used
for testing if cells would prefer growing in the direction of increasing or decreasing
chemical concentrations. One of the obstacles in the design of the microfluidic
decision tree was that the structure resembles that of the chemical gradient gen-
erator. This means that the decision tree structure would disrupt the chemical
gradient of the fluid flowed into it as the fluid travels further down the tree.
As a remedy to this issue, channels in the shape of waves running down verti-
cally were introduced into the decision tree structure (See the SEM image in Figure
7.5). The decision tree structure featuring these wavy passthrough channels was
dubbed the name chemical gradient passthrough decision tree.
Figure 7.5: Passthrough decision tree
In fact, this chemical gradient passthrough channel design was finalised by mod-
elling numerable structural variations. The COMSOL simulation result shown in
Figure 7.6 revealed that this passthrough channel design is effective in neutralising
the adverse effect of the decision tree structure on chemical gradient.
With respect to automation, there was another critical design aspect to be
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Figure 7.6: Modelling of the passthrough decision tree
considered in the making of the decision tree. The dimensions of the area occupied
by the decision tree channels were approximately about 1000µm by 1000µm. An
area this size is rather too large to be covered as a whole by microscopy using
high magnification objectives (e.g. 100x or 40x). At the same time, using high
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magnification objectives is necessary in acquiring microscopy data suitable for
image analysis. Microscopic barcodes were designed as shown in Figure 7.7 for
labelling multiple microfluidic locations. Each labelled location was designed to
be small enough to fit into the field of view of high magnification microscopy. This
would allow for the use of high power microscopy along with this chip design.
The area of the structural feature representing one bit was designed to be 1 µm2.
Given that the chip design was already crowded with small features, fabricating
the wafer to cleanly resolve all those tiny details was non-trivial. This kind of
tiny features in microfluidics design was putting the fabrication method discussed
in Section 7.2 to a truly stringent test. The success in fabricating those features
using this method, as can be seen in the SEM image of Figure 7.5, was a significant
achievement. A microscopic barcode design such as this would become one of
the essential features in the design of sub-micron-scale microfluidic devices for
supporting lab automation.
Figure 7.7: Microscopic barcodes to label locations in microfluidics
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7.3.5 Quorum communication tester
(a) (b)
Figure 7.8: COMSOL simulation of fluid dynamics in the quorum sensing assay
chip
A PDMS-based microfluidics assay chip was designed to be used in experiments for
investigating microbial quorum sensing. The COMSOL simulation showed liquid velocity
and concentration gradient profiles with respect to the chip's liquid-structure interaction
dynamics. (a) The liquid velocity profile of the fluidic channels, given 70,000 Pa of
pressure on the two inlets. (b) The concentration gradient of the fluidic channels when
water was injected through inlet1 and 1 mM concentration of inducer molecule was
injected through inlet2.
Yet another class of microfluidics-based measurement device was designed to
allow for experiments involving quorum communication behaviours in cellular sys-
tems. As were the cases in previous microfluidics designs, finalising this chip design
was a result of subjecting different structural variations to extensive modelling and
simulation. Figure 7.8 shows a fluid dynamics simulation result of the quorum com-
munication tester chip. The chip was designed to accept two input fluid flows with
different chemical compositions, and to form chemical interfaces between the two
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fluids at the perpendicular channels connecting the two main inlets. The perpen-
dicular channels were designed to allow the exchange of chemicals via diffusion.
The result shown in Figure 7.8b assured that the chemical concentration injected
into the right hand side channel (inlet2) does not affect the left hand side channel
(inlet1). The only places in the chip where the two fluid types exchanged chemical
compositions were the perpendicular channels.
(a) (b)
Figure 7.9: COMSOL simulation of concentration gradients in the quorum sensing
assay chip
A comparison of the COMSOL simulation of concentration gradients was performed to
see if there are location specific differences in the gradient profile of the microfluidics
assay chip. The given design was confirmed to support the desirable property of exhibit-
ing a consistent concentration gradient profile invariant to the difference in the y-axis
coordinate locations. (a) A close-up view of the concentration gradient field shown in
Figure 7.8b. (b) Comparison of the concentration gradient across the x-axis between
two locations (Top & Bottom) separated by about 6000µm in the y-axis direction.
Figure 7.9 shows close-up views of the perpendicular channels exhibiting diffu-
sive chemical exchange between the two inlets. In the experimental setup of this
simulation, a glucose solution in 1 mM concentration was injected into inlet2, and
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Figure 7.10: An SEM image showing the fabrication result of the quorum commu-
nication tester chip
water was injected into inlet1. Figure 7.9b shows a graph comparing the glucose
concentration profile across the x-axis of perpendicular channels in two different
y-axis locations separated by about 6000µm (Top vs Bottom). The graph con-
firmed three desired properties of the microfluidic design: that the inlet2 glucose
concentration did not affect inlet1, that the perpendicular channels provided an
interface for diffusive chemical exchange, and that the y-axis location of perpen-
dicular channels did not affect the chemical diffusion characteristics.
The quorum communication tester chip was fabricated using the methods in
Section 7.2. Figure 7.10 shows an SEM image of the fabrication result. Disre-
garding the minor blemishes visible on the top part of the image, likely to be
dirt particles inadvertently introduced in preparing for the SEM samples, the sub-
micron features of the chip design were successfully fabricated, from inspecting
the SEM image qualitatively. The in vitro characterisation of the chip was not
attempted due to time constraints in the project. However, the same experimental
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setup used in the in vitro characterisation of the gradient generator chip (Section
7.3.3) can be used for the characterisation of this chip as well.
7.4 Programmatic image processing and analysis
Using a microfluidic platform for observing bacteria at single-cell and single-lineage
levels typically involves time-lapse microscopy, which can generate a large amount
of image data. Image data in their raw form require much pre-processing before
any quantifiable data can be extracted for analysis. Typical image processing
steps involve, for instance, the identification of cell boundaries (segmentation),
gathering statistics on cell sizes and fluorescence levels, and tracking temporally
corresponding cells in time series. Not only are these tasks computationally ex-
pensive, they also generate large amounts of single-cell data, making manual data
curation cumbersome and error-prone. Dealing with large volumes of data as such
necessitates the use of integrated and automated image analysis pipelines that can
process image data as they are generated with accuracy and speed.
There are many tools available for image analysis in the biological sciences,
including MicrobeTracker [70], TLMTracker [100], CellProfiler [28], and ImageJ
[151]. While these tools are widely used, they require significant manual interven-
tion in the analysis process, and they are not designed to process large numbers
of images in a systematic, parallel and automated fashion. MicrobeTracker is
popular among biologists for image analysis. However, the software is GUI-based
and primarily intended for manual use. Furthermore, MicrobeTracker is written
in Matlab, requiring a commercial license to be able to use its code base. CellPro-
filer is probably one of the strongest contenders for providing flexible, parallelisable
pipelines. However, this tool is still primarily intended for manual use, with a GUI-
based interface. Although CellProfiler provides a headless operation mode without
the GUI interface, the mode is intended, not for being integrated as part of auto-
mated microscopy, but for a postexperimental batch image processing. There is no
API-level support that would allow other software to easily invoke CellProfiler and
retrieve results in a modular fashion. The architecture of ImageJ and its sibling
Fiji [150] is noteworthy as it allows the software's core library full of useful image
processing algorithms to be readily reused.
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An image analysis pipeline, employing Fiji's core library for much of the image
processing needs, was developed with the goal of having the pipeline integrated
as part of the microfluidic platform for automated time-lapse microscopy. One
of the key advantages of using an integrated system such as this is that a full
automation, from image acquisition to analysis, can be achieved. This also means
that the results of image analysis can be used to determine the way in which
image acquisition is done, as part of an active feedback loop. This capability
is especially useful in dealing with large sample sizes. If need be, a rule-based
filtering algorithm can be implemented depending upon analysis results, to reduce
the number of samples being observed to those exhibiting phenotypes of interest.
7.4.1 Correspondence algorithm: an overview
Dealing with time-series cellular microscopy data via using a computerised logic is
non-trivial, largely due to the difficulty in establishing the spatio-temporal cor-
respondence between cellular data sets. A pattern recognition algorithm was
needed in order to extract cellular image features suitable for uniquely identi-
fying cells undergoing growth in space and time. Introduced in the following is
a novel correspondence algorithm that can process time-series images featuring
bacterial growths. The algorithm can extract single cell data, and track each cell
spatio-temporally. The algorithm consists of two parts: establishing cluster-level
correspondence followed by establishing single-cell level correspondence.
7.4.2 Establishing cluster correspondence
Consider a set B consisting of single cells from multiple time points, and a set P
consisting of subsets of single cells from B satisfying the condition L. The condition
L, used to qualify cells for belonging to the same subset, is a predicate for testing
cells to see if they coincide in the same spatio-temporally isolated cluster. These
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sets can be defined1 as:
B = {x | x is a single cell at time points t ∈ {1, 2, 3 . . . }}
P = {x ⊆ B | x satisfies L} is a partition set of B, fulfilling
∀x1, x2 ∈ P, x1 6= x2 6= ∅, x1 ∩ x2 = ∅, and
⋃
P = B
L : ∀y ∈ x is in the same spatio-temporally isolated cluster
(7.1)
P (t) is a subset of P , defining a set of cell clusters co-occurring at time t, hence
corresponding to the collective information of single cells captured by microscopy
image(s) at time t. In addition, E(t) is a set of ordered pairs of clusters having
temporal correspondence from time t to t+ 1, defined as:
P (t) = {x ∈ P | x is a cluster of cells at time t}
E(t) = {(x, y) ∈ P (t)× P (t+ 1) | x temporally corresponds to y}
(7.2)
, where the cluster temporal correspondence is defined by clusters x and y having
spatial overlap with respect to the global coordinate space.
The transitive closure of E(t), denoted ET (t) can be defined as,
ET (t) = {(x, z) ∈ Pp(t)× Pp(t) | ∃Y ⊆ Pp(t) satisfying W},
where (x, z) = (z, x) and Pp(t) = P (t) ∪ P (t+ 1)




) denotes the degree of relatedness in cluster correspondence between
clusters y and y
′
, or the minimum number of corresponding pairs p ∈ E(t) required
1The convention for mathematical notations used here adheres to that of Set Theory and
Logic.
⋃
P , for example, refers to the union set of all members of set P . The notation ∅ refers
to an empty set, unless noted otherwise.
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to associate cluster y to cluster y
′




(∣∣∣{(x, x′) ∈ E(t) | ∃R ⊆ Pp(t), satisfying K}∣∣∣)
K : ∀x ∈ {R ∪ {y, y′}},∃x′ ∈ {R ∪ {y, y′}}, such that





0, if R = ∅ ∧ (y, y′) 3 E(t)
1, if (y, y
′
) ∈ E(t)




) = 0 means clusters y and y
′
are not associated in terms of cluster
correspondence. fd(y, y
′
) = 1 means a single cluster, y, at time t, is directly
associated with a single cluster at time t+1, namely y
′
(Figure 7.11a). fd(y, y
′
) = n,
where n > 1, means cluster y at time t is associated with cluster y
′
at time t+ 1,
via a minimum of n number of cluster pairs p ∈ E(t). Having the number n > 1
signifies one of the following events: multiple clusters at time t merged to a single
cluster at time t + 1 (Figure 7.11c), a single cluster at time t split into multiple
clusters at time t+ 1 (Figure 7.11b), or both (Figure 7.11d).
It can be said that clusters y ∈ P (t) and y′ ∈ P (t + 1) have cluster corre-
spondence if the binary relation, y ET (t) y
′
exists, by evaluating the predicate Q
(See Eq.7.5). In the events of clusters merging or splitting, ET (t) can also be used
to decide, for instance, if clusters y and y
′
at the same time frame t have cluster
correspondence, by asserting the predicate Q.
Q
[




True, if ∃(y, y
′
) ∈ ET (t)
False, otherwise
(7.5)
C(t) is a partition set of P (t) consisting of a set of non-empty, mutually exclu-
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sive subsets of P (t):
C(t) ={x ⊆ P (t) | x satisfies J}, fulfilling
∀x1, x2 ∈ C(t), x1 6= x2 6= ∅, x1 ∩ x2 6= ∅,
⋃
C(t) = P (t)
J : (∀xi, xj ∈ x,Q[xiET (t)xj] is True) ∨ (| x |= 1)
(7.6)
Establishing one-to-one temporal correspondences between members of C(t)
and C(t+1) can be provided by the injective function fc : x ∈ C(t) 7→ y ∈ C(t+1)
defined in terms of a set of mapping pairs,
fc : x ∈ C(t) 7→ y ∈ C(t+ 1) =
{(x, y) | ∀xi ∈ x & ∀yj ∈ y,Q[xiET (t)yj] is True}
(7.7)
7.4.3 Establishing single-cell-level correspondence
Provided that C1 ∈ C(t) and C2 ∈ C(t+1) have a temporal correspondence via fc :
C1 7→ C2, it becomes relatively trivial to establish single-cell-level correspondences
between ci ∈
⋃
C1 and cj ∈
⋃
C2, as follows:
Let a single cell c (e.g. ci or cj) have a geometrical representation of a bounding
polygon cP given by a set of NV vertices,
cP ={v0, v1, . . . , vNV −1} (7.8)
The minimum bounding box of cP , denoted B(cP ), is a set of four vertices that
forms a rectangle to enclose the polygon in two-dimensional coordinate space:
B(cP ) ={vˆ0, vˆ1, vˆ2, vˆ3}, where
vˆ0 = [xmin ymin], vˆ1 = [xmax ymin]
vˆ2 = [xmin ymax], vˆ3 = [xmax ymax]
(7.9)
Given the minimum bounding boxes of cP (i) and cP (j), cP (j) is scaled to match
the dimensions of cP (i) by finding the dot products of the individual vertices of
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cP (j) and the transformation matrix A:
c
′


















Now that B(cP (i)) and B(c
′
P (j)) have the same dimensions sizewise, cP (i) and
c
′
P (j) can be directly compared to evaluate the geometrical differences between
the two polygons (See Figure 7.11g).
Sweeping a horizontal line across the y-axis to scan and sample NL number of
lines that fill a polygon can be done for both cP (i) and c
′
P (j). The sweeping line
S0S1k at position k is defined by two vertices S0 and S1 with respect to k and the
polygon's minimum bounding box:
S0 =
(NL − 1− k)vˆ0 + kvˆ2
NL − 1 S1 =
(NL − 1− k)vˆ1 + kvˆ3
NL − 1
, where 0 ≤ k ∈ Z ≤ NL − 1
(7.11)
The line segment S0S1k intersects a polygon cP at two vertices P0 and P1, where
P0 may or may not coincide with P1. Given two polygons cP (i) and c
′
P (j), there
exists a sequence of four intersecting vertices, (P0(i), P1(i), P0(j), P1(j)), at y = k.
When sorted in the descending order of the vertices' x-axis coordinate component,
the ordered sequence can be re-labelled and defined as (vk(0), vk(1), vk(2), vk(3)).
Then, the MSE of geometrical differences between the polygons cP (i) and c
′
P (j)















Given Eq.7.12 as a cost function, the problem of finding temporal correspon-
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Figure 7.11: Overview of the image processing pipeline to compare cells for tem-
poral correspondence
(a,b,c,d) Clusters at two timepoints having different geometrical patterns. (e) Two pairs
of phase contrast and fluorescence images, at time points t0 (left) and t1 (right), of
E. coli constitutively expressing GFP. The cell cluster highlighted in cyan at t0 cor-
responds to the cluster in cyan at t1. (f) From left to right: a series of Fiji's com-
mands sharpen, contrast, log, contrast, make binary, erode, dilate, watershed,
and analyze particles. (g) Two cell clusters from successive time points are shown.
The upper half shows the image processing steps involved in sampling polygonal data
representative of a single cell at time t0, and so does the bottom half for a single cell at
time t1. The single cell being sampled at time t1 is subject to an extra step of scaling its
dimension to match that of the cell at time t0 before data sampling and comparison can
take place.
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dence can effectively be considered in light of the general assignment problem.
Assignment problems, in general, can be solved by the algorithm known as the
Hungarian method [104].
In order to minimise the calculation of paring costs, the potential assignment
of a single cell ci ∈
⋃
C1 at time t can be limited to a subset of
⋃
C2, where
the two cluster sets C1 ∈ C(t) and C2 ∈ C(t + 1) have an one-to-one temporal
correspondence according to Eq.7.7. For example, if
⋃
C1 = {ci | i ∈ {0, 1, 2, 3}}
and
⋃
C2 = {cj | j ∈ {0, 1, 2, 3, 4, 5}} are sets of corresponding cells in time t and
t + 1 respectively, four cells in
⋃
C1 need to be matched to six cells in
⋃
C2 (See
Figure 7.12b). Provided that images are taken at intervals small enough to ensure
the cell divisions for cells in
⋃
C1 at time t to occur at most once at time t + 1,
the following cost matrix can be constructed for solving the assignment problem
via the Hungarian algorithm, where c[i][j] = fMSE(cP (i), c
′
P (j)) and c
′
P (j+ j+1) =
c
′
P (j) ∪ c′P (j + 1).

c[0][0] ∞ ∞ ∞
c[0][0+1] ∞ ∞ ∞
∞ c[1][1] ∞ ∞
∞ c[1][1+2] ∞ ∞
∞ c[1][2] c[2][2] ∞
∞ c[1][2+3] c[2][2+3] ∞
∞ ∞ c[2][3] c[3][3]
∞ ∞ c[2][3+4] c[3][3+4]
∞ ∞ c[2][4] c[3][4]
∞ ∞ c[2][4+5] c[3][4+5]
∞ ∞ ∞ c[3][5]

Cell pairs with the infinity sign (∞) are invalid matches that would leave unmatch-
able cells in the clusters, and hence are given the maximum cost value without any
calculation. The cost functions highlighted in red denote cell pair matches that
would leave unmatchable cells in the clusters due to boundary conditions, and
therefore can also be given the maximum cost value without any calculation. The
cost functions shown in black are the possible matches that would result in success-
ful correspondence matches satisfying all cells in the clusters, and therefore need
to be calculated. Unfortunately, the Hungarian algorithm does not scale well. Its
most efficient implementation known to date has a time complexity of O(n3) [94].
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(a) (b)
Figure 7.12: A graph-encoded assignment problem, and its Dijkstra path as a
solution
(a) The assignment problem of corresponding cells can be encoded into a weighted,
directed graph. Currently shown is an example of a cluster of four cells at time t0 being
matched to a cluster of six cells at time t1. Nodes represent possible correspondence
matches, and weighted edges the costs of respective matches. For instance, the node





1 at time t1. Each edge connecting two nodes carries a weight, whose value indicates
the cost of the next matching pair of cells between the two clusters. The nodes and
edges highlighted in red represent the best matches, or the matches with the smallest
total MSE, searchable by finding the Dijkstra's shortest weighted path of the graph. (b)
The phase contrast images of E. coli cell clusters at time t0 and t1 used for building the
weighted directed graph. The black arrows connecting the segmented cells between the
two clusters are deduced from the graph path highlighted in red.
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In the cell to cell matching case, the cardinal number n in discussing the time
complexity can be determined by adding the cell count at time t (|⋃C1|), and the
counts of individual cells (|⋃C2|) and merged cells (|⋃C2|−1) at time t+1, hence
n = |⋃C1|+ 2 · |⋃C2| − 1 [140].
In fact, the assignment problem can also be encoded into a weighted graph,
where the cost function (Eq.7.12) provides the weights. Having the problem en-
coded in a graph allows graph search algorithms such as Dijkstra's algorithm to
be used to find solutions for the assignment problem, at a more scalable time com-
plexity of O(|E|+|V |log|V |). This approach is different from applying the shortest
augmenting paths based approach [94] in solving an assignment problem, in that
the algorithm shown here only needs a single calculation of Dijkstra's shortest
path per assignment problem as opposed to many iterations of path calculations
required by the augmenting paths method.
For example, in the case of four cells being matched to six cells (Figure 7.12b),
a weighted graph representing all permutations of possible cell matches (nodes)
along with the costs of the matches (edges) can be constructed (Figure 7.12a). Us-
ing Dijkstra's algorithm [54], the graph can then be solved for the shortest path,
or the path with the minimum total cost (highlighted in red), from which single-
cell-level temporal correspondences can easily be deduced. Interestingly, Dijkstra's
explanation of using graph structures in shortest path problems [54] is in agreement
with Richard Bellman's idea of Principle of Optimality [17], a necessary condition
for dynamic programming. Bellman's concept of dynamic programming is a math-
ematical optimisation achieved by breaking down a complex problem into simpler
sub-problems, via offering a simple incremental handle to deal with combinatorial
complexity. Having such an element of algorithmic compatibility would mean that
the graph search problem can be transformed to an optimisation problem defined
in terms of dynamic programming, or vice versa. For problems requiring small
input sizes, such as that demonstrated here, adopting dynamic programming in
lieu of Dijkstra's graph-based method would have no dire consequences. However,
doing so in a general sense, shall need to be approached with caution. Dynamic
programming may end up with performance penalties, as it is known to exhibit
a pseudo-polynomial time complexity with respect to the input bit length, unlike
Dijkstra's graph-based approach regardlessly offering a polynomial time complex-
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ity.
7.4.4 Application of the correspondence algorithm in syn-
thetic biology
A set of time-lapse images were acquired using the microfluidic system as described
in Section 7.3.1, and were analysed via the image processing pipelines and algo-
rithms as detailed in Section 7.4.2 and 7.4.3. Bacillus subtilis 168, chromosomally
modified to constitutively express GFP, was used to test the system. Figure 7.13a
shows an example of the generations of a cell lineage, with respect to a mother cell,
being tracked using the system developed in this study. It was possible for the sys-
tem to gather statistics much like those offered by flow cytometry (Figure 7.13b).
Statistics available from flow cytometry lack temporal dimensions at the single-cell
level. The only possible way to incorporate a temporal dimension into the mea-
surements in flow cytometry is to use biological replicates from different static time
points. In doing so, however, flow cytometry loses single-cell-level details in the
temporal dimension, and is restricted to gathering population-level statistics. This
microfluidics-based system was capable of tracking single cells over time, including
cellular events such as the growth and splitting of cells. The stochastic nature
of single cells may result in inter-cellular variabilities in the time of occurrence of
certain cellular events. For example, the cellular event of reaching the fifth gen-
eration from the mother cell took place at different time points for different cells
(See the cells highlighted in red in Figure 7.13a). Therefore, for single-cell-level
analyses involving temporal dimensions, it is important to differentiate the kinds
of statistics based on static time points (i.e. when measurements were taken) from
those based on cellular events (i.e. when something important happened). The
measurements shown in Figure 7.13c were from the cells five generations away from
those of Figure 7.13b. The collection of these generation-based statistics demon-
strate that this novel system was successful not only in incorporating temporal
dimensions into single-cell-level statistics, but also in capturing statistics based on
cellular events rather than on static time points.
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Figure 7.13: Single-cell-level statistics based on cell lineages and generations
(a) An example lineage of B. subtilis cells. The cells highlighted in red are in their fifth
generation. (b) An example analytic data showing the scatter plot of fluorescence vs
size of single cells (B. subtilis) at their first generation. (c) An example analytic data
showing the scatter plot of fluorescence vs size of single cells (B. subtilis) at their fifth
generation.
7.5 Discussion
One of the primary achievements worthy of mentioning as part of this research
work in microfluidics was the development of a fabrication protocol that can pro-
duce submicron features without relying on costly etching optimisation runs. This
fabrication protocol was a product of extreme scrutiny of various intermediate pro-
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tocols given the constrains of the budget and time in the project. The protocol
was what made it possible, in the first place, to successfully fabricate all the chip
designs featured in this study. The innovations shown here would not have been
possible without this fabrication protocol.
As a rewarding consequence, the single-cell-level microfluidic measurement de-
vices shown in this work opened up many possibilities in terms of achieving lab
automation. The possibilities were especially promising as the programmatic im-
age analysis was demonstrated to work successfully in conjunction with single-cell
level measurements. As much as the single-cell level measurements are useful, they
can generate copious amounts of data, rendering manual analysis infeasible. To
this end, the programmatic analysis of measurement data using the software de-
veloped in this research work played a crucial role. In the real-world automation
scenario, there would be a need for the mass acquisition of single-cell-level mea-
surement data from many different coordinate points on a microfluidics chip. In
order to be braced for such highly parallel experimental cases, a one of a kind mi-
crofluidic barcode system was invented to help label and identify the coordinates
of locations on chips.
Another major achievement in this work was the development of a microfluidic
measurement system capable of performing true time-lapse measurements of the
fluorescence of individual cells. The benefit of having such a measurement system
is quite a significant one in that the system allows the investigation of rare cellular
events at the single-cell-level with which direct comparisons to the findings from
single-cell-level in silico models can be made. This is yet another realisation of an
idea that can close the gap in the dual evolutionary approach.
The novelty in introducing such a single-cell-level measurement system in con-
junction with the programmatic data analysis necessitated the development of a
novel algorithm to calculate spatio-temporal correspondences at the single-cell-
level. The development of the correspondence algorithm was based on the clever
concept of transforming an assignment problem into a graph search problem. This
was a noteworthy achievement in such a way that the general principles of the
algorithm could potentially find other uses in different fields of science or engi-
neering. Another achievement as part of this work in microfluidics was that it
served to be a good example of MDE in designing microfluidic systems, forming
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an uncanny counterpoint to the maxim of DEA: using models to help better the
reality.
As it stands at the current moment, however, it takes a considerable amount
of effort just to have a microfluidics chip made to be ready for a time-lapse mi-
croscopy run. What this entails is a call for future studies centered towards an
integration effort to develop, based on the working pieces shown here, a measure-




Proof-of-concept implementations of various research ideas shown throughout Chap-
ter 5, 6, and 7 were a concerted effort in an attempt to accomplish enabling tech-
nologies for the dual evolutionary approach. This work resulted in a well-defined
methodological framework that can be extended for exploring the two solution do-
mains to find converging solutions in a format the two domains can readily share.
Implementations involving molecular devices and programmatic sequence analysis
pipelines, shown in Chapter 5, addressed many important aspects with respect
to realising the in vivo half of the framework. The work detailed in Chapter 6
provided comprehensive modelling methods that can be used in bridging the gap
between the two domains. Microfluidics techniques detailed in Chapter 7 explored
areas in which process automation can be achieved to gain automated control of
experimental processes at the single cell level. The collective research work de-
tailed in these chapters would serve to be an example to suggest how DEA can
be realised in the future not only for an efficient exploration of the in vivo solu-
tion space, but also for facilitating cross-domain data transfer in a manner highly
amenable to automation. While there were drawbacks in some implementations,
other more successful aspects of the work showed promising results, enough to
demonstrate the plausibility of the suggested methodological framework.
I believe the research work presented here established a good starting point
for adopting the DEA framework to address the ultimate concern of dealing with
design complexity in synthetic biology as well as of achieving automation. One
of the key aspects explored in this study, was to define the search space of design.
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The two domains of DEA rely on different conceptual perspectives to see design,
hence their search spaces had to be defined from different conceptual elements.
For instance, the in vivo domain would use genetic sequences as a primary handle
to explore different genotypic possibilities (See Note 17 in Figure 3.1). So the
unknown here are the phenotypes to be unveiled after applying changes to genetic
sequences. On the contrary, the in silico domain would take the opposite direc-
tion, by working on model parameters that can change phenotypes (See Note 16
in Figure 3.1) before reasoning about genetic constructs that conform to the phe-
notypic changes. So the unknown are the sequences. These conceptual differences
were reflected in the adoption of the molecular device for controlling random mu-
tagenesis (i.e. the solution generator) as a primary means to explore the in vivo
genotypic solution space (Section 5.2.3), and that of the genome-scale FBA as a
primary means to explore the in silico phenotypic solution space (Section 6.3.3).
These differences attributed to the gap in interpreting and consolidating their
search results. The cross-domain gap can be bridged by building compatible data
interfaces between the two domains to make the task of resolving the differences
in their search results straightforward. I investigated measurement technologies
combining molecular biology, software and microfluidics to provide a way to merge
these differences. This resulted in the development of variant analysis pipelines
(Section 5.3.2.2) for measuring genotypes, and the microfluidic (Chapter 7) or the
molecular (Section 5.2.2) means for measuring phenotypes. The consolidation of
genotypic measurements (i.e. SNPs) and phenotypic measurements was briefly
discussed in Section 6.4.2. However, a further investigation is still needed to sug-
gest implementation-level details, as to how conclusions can be drawn on potential
correlations between genes and phenotypes. This was left for future studies.
The molecular phenotypic measurement device was designed to enable a high-
throughput assessment of fitness criteria in random in vivo solutions (Section 5.2).
The molecular device was used to incorporate the function of evaluating environ-
mental incentives or fitness landscape (Note 3, 11 in Figure 3.1) into a single
mutant cell. Such a molecular technique can enable the screening of putative in
vivo solutions in a massively parallel manner. Sequencing the genomes of putative
solutions, in turn, can transfer the solutions resident in vivo to the in silico design
domain (Note 21 in Figure 3.1). To help streamline this important, yet time-
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consuming process, software pipelines were developed to automate the genome
sequence assembly (Section 5.3.2.1).
In fact, the design of the molecular phenotypic measurement device suggested
in this study has a huge drawback, in that its design is highly prone to false-positive
measurements due to accumulating mutations on the measurement device. While
the automated assembly and variant analysis pipelines can, in principle, be used
to weed out false positives, having to deal with many false positives would be
severely burdensome in practice. This shortcoming could potentially be overcome
if a plasmid-based device was used instead of the chromosomally integrated de-
vice featured in this study. The stability of plasmid-based devices, unlike that
of chromosomally integrated devices, is short-lived allowing mutant cells to lose
the molecular device over a number of generations. Gram positive cells such as B.
subtilis are known to exhibit low plasmid retention rates, and are naturally compe-
tent. This means that the cells can easily be made to lose or to take up plasmids by
adjusting growth conditions. Such bacterial properties can be exploited to replen-
ish mutant cells with fresh plasmids free of undesirable false-positive mutations
during the course of evolutionary cycles. The investigation of this promising idea
was left for future studies.
It was shown that bridging the gap between the two domains can increase the
search efficiency of design problems in synthetic biology (Section 6.4.3). The in-
crease in search efficiency would, in effect, amount to the reduction of search space
or time to design. The DEA framework, as a consequence of such gain, would have
a higher capacity for dealing with design complexity and provide a ground for mit-
igating the search space explosion issue discussed earlier. Having said this, one of
the main argument points in this study was that partial solutions made available
via in vivo evolutionary processes could be combined in silico, and vice versa, to
achieve design optimisation requiring more complex solutions (Figure 6.18). It
might be argued, though, that DEA is too cumbersome without offering any gains
over directed evolution, given the discussion in Chapter 5 which presented directed
evolution as an efficient means to facilitate the in vivo solution search. However,
employing such an in vivo strategy alone is conceptually equivalent to the mathe-
matical optimisation strategy called Stochastic Hill Climbing [95]. Such a strategy,
according to the simulations presented in Chapter 6, would be a poor choice for
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complex time-constrained problems that have combinatorially challenging search
spaces.
In a similar vein, it is worth noting that the advantage of using EA over
Hill Climbing (HC) was discussed in the mathematical optimisation context by
Mitchell, Holland and Forrest [122]. Holland postulated [77, 85] that the power of
EA lies at implicit parallelism, whereby making crossovers in the population can
reduce the time to search for optimal solutions compared to only using random
mutations. While the initial discussion of Holland was confined to the theory of
mathematical optimisation in the context of computing science, the idea, in my
opinion, can be transposed to synthetic biology without loss of generality. My
research, at least in part, demonstrated that the general principle of Holland's
argument about EA over HC still holds to be true in the context of adopting DEA
over directed evolution in finding synthetic biological design solutions (Section
6.4.3).
In light of this argument, the DEA framework is a real-world case of EA,
in which the concept of implicit parallelism was incorporated into the in vivo
domain via the capability of recombining solutions in the in silico domain. This
theorisation is also directly in line with the reasoning behind the idea that DEA
would offer to be a more efficient platform than employing directed evolution in the
in vivo domain alone. As such, this study established a groundwork for bolstering
the premise that DEA is a powerful framework for design automation in synthetic
biology.
Accomplishing the integration of different working concepts shown in this study
to function together is significantly challenging a project in and of itself. Due to
time constraints, much of the integration effort was reserved for future studies.
For example, the fitness evaluation to guide the in silico domain, in the real-
world scenario, would need to take the form of executing FBA on the genome-
scale metabolic pathway model, as shown in Section 6.3.3.2. In lieu of FBA, the
fitness evaluation in the proof-of-concept experiments was done by using a look-
up table (LUT) out of the pre-agreed answersheet from Table 6.4. Nevertheless,
this test case was enough for evaluating the validity of the DEA framework. It
was evident from the simulation results (Figure 6.17) that the in silico domain
could offer an efficient means to conduct population mating, which the in vivo
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domain lacked. The in silico search could effectively recombine partial solutions
to successfully explore the search space, leading to a high SNP count solution,
otherwise unachievable. The in silico domain was able to reach SNP counts that
the in vivo domain alone could not reach given the limited timeframe (Figure 6.18
vs 6.16). The results shown here are strongly suggestive of the possibility that the
dual-evolutionary strategy, if its two domains were bridged to exchange SNP-level
information in short iterative cycles, can mitigate the combinatorial explosion of
solution space to a significant degree.
Single-cell-level spatio-temporal measurements demonstrated in this study would
play an important role in evaluating the exit condition in the iterative design cy-
cle of the DEA framework. The caveat is that single-cell-level measurements can
produce high volumes of data, too cumbersome for manual curation and analysis.
Motivated by this, the microfluidic measurement and analysis platform developed
in this study was designed with an end-to-end lab automation in mind. To this
end, I believe lab automation will serve to be one of the most important enabling
technologies for design automation in synthetic biology in the future soon to come.
Lab automation would be accomplished not by building microfluidic devices alone,
but by incorporating software intelligence for the programmatic execution of device
control and data analysis. This led to the development of microfluidic devices with
structural features, such as microscopic barcode (Figure 7.7), specially designed
to facilitate the development of software intelligence for use in highly parallel ex-
perimental automation. The microfluidics research done as part of this study was
a clear demonstration that software research is indispensable to achieving lab au-
tomation. Hence, software should be an integral part of microfluidics research
aimed at design automation in synthetic biology.
It was argued throughout this study that we need to shift gears in synthetic
biology towards pursuing design automation. This study successfully highlighted
some of the key technologies with which to envisage an automatic platform for
designing complex synthetic biological systems. Driven by strong commercial in-
terests, synthetic biology has been gravitating towards applications in metabolic
engineering. Such a trend has made the line between metabolic engineering and
synthetic biology quite blurry. My investigation too looked at an example of
metabolic engineering in discussing design automation in synthetic biology. It
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needs to be clarified though, that metabolic engineering is not synthetic biology
but a subset of which. Synthetic biology, as a ground for a greater set of biological
design problems, should be bracing for a higher level of complexity than that suited
for metabolic engineering. To this end of supporting yet higher levels of design
complexity, a fully automated synthetic biology design cycle is not an option but
a necessity. This requisite calls for future studies on a plethora of subjects that
have not been addressed in this study.
Some of the future works needed regarding this include, but are not limited
to, the following. DNA sequence data, at the whole-genome scale, can be over-
whelming, and the analysis of which requires significant amounts of computing
power. Dealing with complex designs will necessarily result in the inundation of
sequence data, pouring out of the in vivo design domain. It will be critically im-
portant to be able to support parallelism in the data analysis pipelines in order to
help increase the data exchange throughput between the two evolutionary design
domains. Also, a microfluidic platform supporting the programmatic execution
of general-purpose lab protocols such as Gibson assembly would be highly desir-
able. As part of such a platform, it would greatly help to have a software control
stack providing an API-level access to the platform. Building a microfluidics plat-
form that supports automated execution of a suite of experiments required by the
DEA framework would be considered a significant milestone to be achieved in the
future. Provided with such a feature-complete lab automation platform together
with a well-defined API, the design practice in synthetic biology will be completely
redefined as envisioned in my research work.
In closing, the significance of this research work lies in developing and demon-
strating key technologies that can, when extended and put together, embody
what's ultimately envisioned by the DEA framework for accomplishing design au-






A.1 The genome-scale FBA in B. subtilis
The source code used in the study of genome-scale FBA was made available via
the git repository: https://bitbucket.org/sungshic/mpa.git.
Downloading the source code:
$ git clone https :// bitbucket.org/sungshic/mpa.git
Installing library dependencies on Ubuntu 14.04:
$ sudo apt -get update
$ sudo sh -c "echo 'deb http :// download.opensuse.org/repositories/home:/ fbergman :/ libsbml/xUbuntu_14 .04/ /'
>> /etc/apt/sources.list.d/python -libsbml.list"
$ sudo apt -get update
$ sudo apt -get install python -libsbml
$ sudo apt -get install libglpk -dev
$ sudo apt -get install python -glpk
$ sudo apt -get install python -matplotlib
$ sudo apt -get install python -numpy
$ sudo apt -get install python -scipy
$ sudo pip install cobra
$ sudo sh -c "echo 'deb http :// downloads.skewed.de/apt/trusty trusty universe
deb -src http :// downloads.skewed.de/apt/trusty trusty universe ' >> /etc/apt/sources.list"
$ sudo add -apt -repository ppa:ubuntu -toolchain -r/test
$ sudo apt -get update
$ sudo apt -get install python -graph -tool
$ sudo apt -get install python -reportlab
$ sudo pip install PyPDF2
$ sudo pip install pdfrw
$ sudo pip install rdflib
$ sudo apt -get install openjdk -7-jre -headless # need this for installing CPLEX
#install CPLEX package v12 .6.3 # it is available from IBM , free for academic use.
$ cd /opt/ibm/ILOG/CPLEX_Studio1263/cplex/python /2.6/x86 -64 _linux/
$ sudo python setup.py install
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A.2 NGS assembly and variant analysis pipelines
The source code used in the study of NGS assembly and variant analysis was made
available via the following git repository:
https://bitbucket.org/sungshic/dea_hybrid_assembler.git.
Downloading the source code:
$ git clone https :// bitbucket.org/sungshic/dea_hybrid_assembler.git
ADocker image (sungshic/dea_hybrid_assembler:1.1) was created to demon-
strate how the assembly and variant analysis pipelines shown in Section 5.3.2 can
be used for verifying the genomic correctness of the EVOt2 clone (Section 5.2.5).
Executing the following in bash shell would pull the Docker image from Docker
Hub to a local host, and make a folder (assembly) under the home directory.
Docker version 1.12.3 (build 6b644ec) was used for the following tutorial.
Invoking a docker container for NGS assembly and variant analysis pipelines:
$ sudo docker pull sungshic/dea_hybrid_assembler :1.1
$ cd # go to the home directory
$ mkdir assembly # and make a folder to store assembly results
The following command will run the bash command-line prompt on a docker
container from the base image sungshic/dea_hybrid_assembler:1.1 located at
Docker Hub. This command, with the -v option, will also mount the local host
folder ~/assembly to the working directory in the container.
$ sudo docker run -it -v ~/ assembly :/root/workspace/dea_hybrid_assembler/genomeassemblypipeline/data/gandalf/
basespace/bsb1_evot2/assembly sungshic/dea_hybrid_assembler :1.1 /bin/bash
A.3 Processing cytometry data
The source code used in the study of programmatic processing of cytometry data
was made available via the following git repository:
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https://bitbucket.org/sungshic/fcs_analysis.git.
Downloading the source code:
$ git clone https :// bitbucket.org/sungshic/fcs_analysis.git
A.4 Evolutionary algorithm in silico
The source code used in the study of applying evolutionary algorithm in the in
silico design domain was made available via the following git repository:
https://bitbucket.org/sungshic/idea_silico.git.
Downloading the source code:
$ git clone https :// bitbucket.org/sungshic/idea_silico.git
A.5 Graph-based image analysis for single-cell-level microflu-
idics
The source code used in the study of applying graph-based image analysis tech-
niques in single-cell-level microfluidics was made available via the following git
repository:
https://bitbucket.org/sungshic/gbimageanalyzer.git.
Downloading the source code:
$ git clone https :// bitbucket.org/sungshic/gbimageanalyzer.git
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A.6 Estimating relative molar mass of macro-molecules in
biomass reaction
Table A.1: Composition of peptidoglycan polymer reaction of B. subtilis genome-
scale metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd03495 1 reactant met polymer C95H152N8O28P2 1916.20 1916.2
cpd15666 1 reactant met polymer C40H63N8O21R 991.97 991.97
cpd02229 1 by-product met polymer C55H90O7P2 925.24 925.24
cpd15665 1 product met polymer C80H125N16O42R 1982.93 1982.93
Table A.2: Composition of cell wall synthesis reaction of B. subtilis genome-scale
metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd11459 0.0145 reactant met polymer C420H692N30O391P30 13347.14 193.53353
cpd15665 0.453 reactant met polymer C80H125N16O42R 1982.93 898.26729
cpd15667 0.016 reactant met polymer C191H359N10O259P46R 8364.59 133.83344
cpd15668 0.0112 reactant met polymer C326H584N55O304P46R 11563.08 129.506496
cpd15669 0.00808 reactant met polymer C461H809N10O484P46R 15660.90 126.540072
cpd15666 0.48828 by-product met polymer C40H63N8O21R 991.97 484.3591116
cpd15664 1 product Cell wall N/A 997.32 997.3217164
Table A.3: Composition of protein synthesis reaction of B. subtilis genome-scale
metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd00023 0.4928 reactant L-glu C5H8NO4 146.12 72.007936
cpd00033 0.7723 reactant L-gly C2H5NO2 75.07 57.976561
cpd00035 0.5051 reactant L-ala C3H7NO2 89.09 44.999359
cpd00039 0.6114 reactant L-lys C6H15N2O2 147.19 89.991966
cpd00041 0.2801 reactant L-asp C4H6NO4 132.09 36.998409
cpd00051 0.3653 reactant L-arg C6H15N4O2 175.21 64.004213
cpd00053 0.4928 reactant L-gln C5H10N2O3 146.14 72.017792
cpd00054 0.4091 reactant L-ser C3H7NO3 105.09 42.992319
cpd00060 0.2145 reactant L-met C5H11NO2S 149.21 32.005545
cpd00065 0.1028 reactant L-trp C11H12N2O2 204.22 20.993816
cpd00066 0.3329 reactant L-phe C9H11NO2 165.19 54.991751
cpd00069 0.2097 reactant L-tyr C9H11NO3 181.19 37.995543
cpd00084 0.1073 reactant L-cys C3H7NO2S 121.16 13.000468
cpd00107 0.6555 reactant L-leu C6H13NO2 131.17 85.981935
cpd00119 0.1546 reactant L-his C6H9N3O2 155.15 23.98619
cpd00129 0.3041 reactant L-pro C5H8NO2 114.12 34.703892
cpd00132 0.2801 reactant L-asn C4H8N2O3 132.12 37.006812
cpd00156 0.5807 reactant L-val C5H11NO2 117.15 68.029005
cpd00161 0.3526 reactant L-thr C4H9NO3 119.12 42.001712
cpd00322 0.5107 reactant L-ile C6H13NO2 131.17 66.988519
cpd11463 1 product Protein N/A 998.67 998.673743
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Table A.4: Composition of lipid synthesis reaction of B. subtilis genome-scale
metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd15529 0.01816 reactant metabolite C33H66NO8P 635.85 11.547036
cpd15531 0.07327 reactant metabolite C37H74NO8P 691.96 50.6999092
cpd15533 0.02483 reactant metabolite C41H82NO8P 748.06 18.5743298
cpd15536 0.005699 reactant metabolite C34H66O10P 665.85 3.79467915
cpd15538 0.02308 reactant metabolite C38H74O10P 721.96 16.6628368
cpd15540 0.007846 reactant metabolite C42H82O10P 778.07 6.10473722
cpd15695 0.05369 reactant metabolite C39H78NO8P 720.01 38.6573369
cpd15696 0.1262 reactant metabolite C39H78NO8P 720.01 90.865262
cpd15697 0.008684 reactant metabolite C33H66NO8P 635.85 5.5217214
cpd15698 0.1459 reactant metabolite C35H70NO8P 663.90 96.86301
cpd15699 0.2473 reactant metabolite C35H70NO8P 663.90 164.18247
cpd15700 0.0341 reactant metabolite C37H74NO8P 691.96 23.595836
cpd15707 0.008709 reactant metabolite C53H98O20 1055.33 9.19086897
cpd15708 0.002095 reactant metabolite C49H90O20 999.22 2.0933659
cpd15709 0.003029 reactant metabolite C57H106O20 1111.44 3.36655176
cpd15710 0.006468 reactant metabolite C55H102O20 1083.38 7.00730184
cpd15711 0.0152 reactant metabolite C55H102O20 1083.38 16.467376
cpd15712 0.001002 reactant metabolite C49H90O20 999.22 1.00121844
cpd15713 0.0171 reactant metabolite C51H94O20 1027.28 17.566488
cpd15714 0.02897 reactant metabolite C51H94O20 1027.28 29.7603016
cpd15715 0.004053 reactant metabolite C53H98O20 1055.33 4.27725249
cpd15722 0.01694 reactant metabolite C40H78O10P 750.01 12.7051694
cpd15723 0.03982 reactant metabolite C40H78O10P 750.01 29.8653982
cpd15724 0.002726 reactant metabolite C34H66O10P 665.85 1.8151071
cpd15725 0.04589 reactant metabolite C36H70O10P 693.91 31.8435299
cpd15726 0.07776 reactant metabolite C36H70O10P 693.91 53.9584416
cpd15727 0.01074 reactant metabolite C38H74O10P 721.96 7.7538504
cpd15728 0.01447 reactant metabolite C47H88O15 893.19 12.9244593
cpd15729 0.003517 reactant metabolite C43H80O15 837.08 2.94401036
cpd15730 0.004989 reactant metabolite C51H96O15 949.30 4.7360577
cpd15731 0.0107 reactant metabolite C49H92O15 921.24 9.857268
cpd15732 0.02515 reactant metabolite C49H92O15 921.24 23.169186
cpd15733 0.001682 reactant metabolite C43H80O15 837.08 1.40796856
cpd15734 0.02855 reactant metabolite C45H84O15 865.14 24.699747
cpd15735 0.04838 reactant metabolite C45H84O15 865.14 41.8554732
cpd15736 0.006735 reactant metabolite C47H88O15 893.19 6.01563465
cpd15737 0.01119 reactant metabolite C41H78O10 731.05 8.1804495
cpd15738 0.00276 reactant metabolite C37H70O10 674.94 1.8628344
cpd15739 0.003807 reactant metabolite C45H86O10 787.15 2.99668005
cpd15740 0.008216 reactant metabolite C43H82O10 759.10 6.2367656
cpd15741 0.01931 reactant metabolite C43H82O10 759.10 14.658221
cpd15742 0.00132 reactant metabolite C37H70O10 674.94 0.8909208
cpd15743 0.02224 reactant metabolite C39H74O10 703.00 15.63472
cpd15744 0.03768 reactant metabolite C39H74O10 703.00 26.48904
cpd15745 0.005208 reactant metabolite C41H78O10 731.05 3.8073084
cpd15782 0.002845 reactant metabolite C44H88N2O11P 852.15 2.42436675
cpd15783 0.0006934 reactant metabolite C40H80N2O11P 796.04 0.551974136
cpd15784 0.0009777 reactant metabolite C48H96N2O11P 908.25 0.887996025
cpd15785 0.0021 reactant metabolite C46H92N2O11P 880.20 1.84842
cpd15786 0.004935 reactant metabolite C46H92N2O11P 880.20 4.343787
cpd15787 0.0003316 reactant metabolite C40H80N2O11P 796.04 0.263966864
cpd15788 0.005621 reactant metabolite C42H84N2O11P 824.09 4.63220989
cpd15789 0.009523 reactant metabolite C42H84N2O11P 824.09 7.84780907
cpd15790 0.001324 reactant metabolite C44H88N2O11P 852.15 1.1282466
cpd15791 0.0005977 reactant metabolite C73H140O17P2 1351.82 0.807982814
cpd15792 0.0001484 reactant metabolite C65H124O17P2 1239.61 0.183958124
cpd15793 0.0002022 reactant metabolite C81H156O17P2 1464.04 0.296028888
cpd15794 0.0004375 reactant metabolite C77H148O17P2 1407.93 0.615969375
cpd15795 0.001028 reactant metabolite C77H148O17P2 1407.93 1.44735204
cpd15797 0.001192 reactant metabolite C69H132O17P2 1295.72 1.54449824
cpd15798 0.002019 reactant metabolite C69H132O17P2 1295.72 2.61605868
cpd15799 0.0002781 reactant metabolite C73H140O17P2 1351.82 0.375941142
cpd15800 1 product Lipid N/A 995.92 995.9246962
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Table A.5: Composition of LAC synthesis reaction of B. subtilis genome-scale
metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd15746 0.004866 reactant metabolite C119H232O135P24 4566.40 22.2201024
cpd15747 0.001122 reactant metabolite C115H224O135P24 4510.29 5.06054538
cpd15748 0.001761 reactant metabolite C123H240O135P24 4622.50 8.1402225
cpd15749 0.003687 reactant metabolite C121H236O135P24 4594.45 16.93973715
cpd15750 0.008667 reactant metabolite C121H236O135P24 4594.45 39.82009815
cpd15751 0.0005365 reactant metabolite C115H224O135P24 4510.29 2.419770585
cpd15752 0.009356 reactant metabolite C117H228O135P24 4538.34 42.46070904
cpd15753 0.01585 reactant metabolite C117H228O135P24 4538.34 71.932689
cpd15754 0.002264 reactant metabolite C119H232O135P24 4566.40 10.3383296
cpd15755 0.002269 reactant metabolite C263H472O255P24 8457.76 19.19065744
cpd15756 0.0005201 reactant metabolite C259H464O255P24 8401.66 4.369703366
cpd15757 0.0008257 reactant metabolite C267H480O255P24 8513.87 7.029902459
cpd15758 0.001724 reactant metabolite C265H476O255P24 8485.81 14.62953644
cpd15759 0.004053 reactant metabolite C265H476O255P24 8485.81 34.39298793
cpd15760 0.0002488 reactant metabolite C259H464O255P24 8401.66 2.090333008
cpd15761 0.00435 reactant metabolite C261H468O255P24 8429.71 36.6692385
cpd15762 0.00737 reactant metabolite C261H468O255P24 8429.71 62.1269627
cpd15763 0.001056 reactant metabolite C263H472O255P24 8457.76 8.93139456
cpd15764 0.002032 reactant metabolite C311H544N24O255P24 9443.00 19.188176
cpd15765 0.0004655 reactant metabolite C307H536N24O255P24 9386.90 4.36960195
cpd15766 0.0007401 reactant metabolite C315H552N24O255P24 9499.11 7.030291311
cpd15767 0.001545 reactant metabolite C313H548N24O255P24 9471.06 14.6327877
cpd15768 0.003631 reactant metabolite C313H548N24O255P24 9471.06 34.38941886
cpd15769 0.0002227 reactant metabolite C307H536N24O255P24 9386.90 2.09046263
cpd15770 0.003895 reactant metabolite C309H540N24O255P24 9414.95 36.67123025
cpd15771 0.006599 reactant metabolite C309H540N24O255P24 9414.95 62.12925505
cpd15772 0.0009457 reactant metabolite C311H544N24O255P24 9443.00 8.9302451
cpd15773 0.006441 reactant metabolite C191H352N24O159P24 6272.26 40.39962666
cpd15774 0.00148 reactant metabolite C187H342N24O159P24 6214.14 9.1969272
cpd15775 0.002339 reactant metabolite C195H360N24O159P24 6328.37 14.80205743
cpd15776 0.004889 reactant metabolite C193H356N24O159P24 6300.31 30.80221559
cpd15777 0.01149 reactant metabolite C193H356N24O159P24 6300.31 72.3905619
cpd15778 0.0007078 reactant metabolite C187H344N24O159P24 6216.16 4.399798048
cpd15779 0.01236 reactant metabolite C189H348N24O159P24 6244.21 77.1784356
cpd15780 0.02094 reactant metabolite C189H349N24O159P24 6245.22 130.7749068
cpd15781 0.002997 reactant metabolite C191H352N24O159P24 6272.26 18.79796322
cpd15670 1 product LAC N/A 996.94 996.9368815
Table A.6: Composition of DNA synthesis reaction of B. subtilis genome-scale
metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd00115 0.884 reactant dATP C10H13N5O12P3 488.16 431.53344
cpd00241 0.6692 reactant dGTP C10H13N5O13P3 504.16 337.383872
cpd00356 0.6684 reactant dCTP C9H13N3O13P3 464.13 310.224492
cpd00357 0.8807 reactant dTTP C10H14N2O14P3 479.14 421.978598
cpd00012 3.1023 by-product PPi H2O7P2 175.96 545.880708
cpd11461 1 product DNA N/A 955.24 955.239694
Table A.7: Composition of mRNA synthesis reaction of B. subtilis genome-scale
metabolic model
Cmp ID Stoichiometry Rxn role Kind Molecular formula RMMg/mol NMWg/molprod
cpd00002 0.7706 reactant ATP C10H13N5O13P3 504.16 388.505696
cpd00038 0.9496 reactant GTP C10H13N5O14P3 520.16 493.943936
cpd00052 0.5853 reactant CTP C9H13N3O14P3 480.13 281.020089
cpd00062 0.6331 reactant UTP C9H12N2O15P3 481.12 304.597072
cpd00012 2.9386 by-product PPi H2O7P2 175.96 517.076056
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B Appendix B
B.1 The evo_insert construct
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B.2 The pMUTIN4 plasmid vector



























































Figure B.1: The pMUTIN4 plasmid map
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B.3 The pSG1729 plasmid vector




































































Figure B.2: The pSG1729 plasmid map
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B.4 Primers used for colony PCR
Table B.1: Primers used for colony PCR of B. subtilis BSB1 with pMUTIN4_evo
Primer ID Oligo sequence Length GC(%) Tm(°C)
evo_insert_fwd1 AGCGTTACATGGAGCTGGTGCG 22 59 73
evo_insert_rev1 CGTCCAATAATGCAACTAGGCGGC 24 54 71
Table B.2: Primers used for colony PCR of B. subtilis BSB1 with pSG1729_EVOt2
Primer ID Oligo sequence Length GC(%) Tm(°C)
pEVOt2_colpcr_fwd AGAGTGTGATGATAAGTGG 19 42 56
pEVOt2_colpcr_rev TTGAATTCCTCCTTTTCGTC 20 40 58
colpcr_pSG_spec_cds_fwd CTGAACCAAATAGATATACTCC 22 36 56
colpcr_amyE_3p_end_rev AAGTATTTCACATTTATATTGTGC 24 25 55
B.5 Media recipes
B.5.1 Spizizen Minimal Media (SMM) - per 1 L solution
 2.0 g ammonium sulphate ((NH4)2SO4)
 14.0 g dipotassium hydrogen phosphate (K2HPO4)
 6.0 g potassium dihydrogen phosphate (KH2PO4)
 1.0 g sodium citrate dehydrate (trisodium citrate), (Na3.citrate.2H2O)
 0.2 g magnesium sulphate, (MgSO4.7H2O)
 Make up to 1 L using MilliQ H2O, and use a hotplate-stirrer to mix and
dissolve the ingredients.
 Split the solution into 5X 200 mL bottles, and autoclave them using a sensi-
tive cycle.
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B.5.2 MM competence media - per 5 mL
This media needs to be prepared just prior to use.
 5 mL SMM media (see B.5.1)
 62.5 µL Solution E (40 % glucose)
 50µL tryptophan solution1
 30µL Solution F (1 M MgSO4 or MnSO4)
 5 µL casamino acid
 2.5 µL FeNH4 citrate
B.5.3 Starvation media - per 5 mL
This media needs to be prepared just prior to use.
 5 mL SMM media (see B.5.1)
 62.5 µL Solution E (40 % glucose)
 30µL Solution F (1 M MgSO4 or MnSO4)
1Necessary for 168, a tryptophan auxotroph strain
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C Appendix C
C.1 Analysis of sub-micron microfluidics wafer design and
production
The production of microfluidics chips requires a complex design and manufacture
process. This process is increasingly more complex when sub-micron features are
required within the chip. Designs for microfluidics chips were produced using
L-edit software, with a constant channel depth across the designs of 1.4 µm. The
designs were used to manufacture a wafer mask and subsequently produce a silicon
wafer with the design etched upon it with lithography techniques.
In order to achieve sub-micron scale features two masks were prepared: one for
shallow features (i.e. 1.4 µm) and one for deep features (i.e. 40µm). The wafers
were then prepared using the process described in Figure 7.1 and Section 7.2.
This novel production process was meticulously designed to minimise the costly
optimisation need at the foundry. One of the fabricated silicon wafers was charac-
terised using electron microscopy, in order to determine whether this novel process
can successfully produce the intended feature dimensions of my sub-micron scale
microfluidics design.
The silicon wafer was cleaned by soaking in the order of isopropanol, acetone,
and isopropanol. An intermediate mould was made using a thin layer of hard-
PDMS for the microfluidic features and a thick layer of soft-PDMS as a support.
Please refer to Section C.3 for the details on the wafer cleaning and the mould
making protocols. Then, the intermediate mould was surface salinized, and cast
with soft-PDMS to make a reverse mould. This reverse mould was prepared for
analysis on the scanning electron microscope (SEM). Microfluidics designs to be
analysed were selected from across the wafer as shown in Figure C.1.
The reverse mould was diced up using a scalpel and samples with a maximum
size of 15 mm by 15 mm were cut out. Chip samples were cut diagonally across
the design to expose a cross section, for depth measurements. Samples were gold
plated after being mounted onto circular SEM stubs using carbon tapes (Electron
Microscopy Research services, Newcastle University). The samples were mounted
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Figure C.1: The SEM sample locations on the wafer: a bird's eye view
into the SEM (Cambridge Stereoscan 240) and images taken of the top surface of
the samples. SEM samples were then tilted to allow images showing the channel
depths to be taken. Sample images were then measured using ImageJ software.
The scale bar was measured first and the scale applied to the rest of the image.
Features of interest were then measured by applying lines to the image at high
magnification and using the measurement function.
For depth measurements, measured lines from the corresponding flat image
were transposed onto the same feature in the tilted image to compare the distortion
caused by perspective when looking at a three dimensional image (the scale bar at
the top of the tilted images is only accurate at the point of focus, due to the effect
of perspective). A series of lines were then drawn to assist with the measurement
and the measurement function used for final measurements. All lines drawn and
measurements taken appear on the images in the following section.
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(a) (b)
Figure C.2: Chip 1: design view vs product SEM view
(a) Design of one square repeat panel within Chip 1, including measurements of expected
final channel widths. (b) Overview SEM image showing the square panels repeating
across Chip 1, with deep gutters between rows of square panels.
C.2 Measurements of wafer mould samples
C.2.1 Chip 1
The width of the channels was designed to be 2.2 µm, 2.3 µm and 2.4 µm in a
repeating pattern. The backfill depth was 0.8 µm of oxide from each surface. This
gives final channel widths of 0.6 µm, 0.7 µm and 0.8 µm (Figure C.2). The depth
of the shallow channels was designed to be 1.4 µm.
The SEM images in Figure C.3 shows the channel width and depth measure-
ments. The depth of channels within Chip 1 was measured at 1.2 µm. The width
measurements were summarised in Figure C.4 to have respective mean channel
widths of 0.63µm, 0.71µm and 0.78µm.
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(a) (b)
Figure C.3: Chip 1: SEM images with line overlays
The lines were overlaid in ImageJ to show measurements of channel widths (a) and





















Figure C.4: Chip 1: comparison of fabricated vs designed channel width lengths
C.2.2 Chip 7
The width of the channels was designed to be 3.4 µm, 3.6µm and 3.8 µm in a
repeating pattern, with one closed end and the other opening onto the channel.
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(a) (b)
Figure C.5: Chip 7: design view vs product SEM view
(a) Design of one square repeat panel within Chip 7, including measurements of expected
final channel widths. (b) Overview SEM image showing the square panels repeating
across Chip 7, with deep gutters between rows of square panels.
The backfill depth was 0.8 µm of oxide from each surface. This gives final channel
widths of 1.8 µm, 2.0 µm and 2.2 µm (Figure C.5). The depth of the channel was
designed to be 1.4 µm. The large fluid flow gutter depth is designed to be 40µm.
The SEM image in Figure C.6 shows the measurements of channel width and
depth. The depth of channels within Chip07 was measured at 1.1 µm. Figure
C.7 summarises the respective mean channel widths to be 1.54µm, 1.64µm and




Figure C.6: Chip 7: SEM images with line overlays
The lines were overlaid in ImageJ to show measurements of channel widths ((a)) and
























Figure C.7: Chip 7: comparison of fabricated vs designed channel width lengths
C.2.3 Chip 8
The width of the channels was designed to be 2.2 µm, 2.3µm and 2.4 µm in a
repeating pattern, with one closed end and the other opening onto the channel.
185
(a) (b)
Figure C.8: Chip 8: design view vs product SEM view
(a) Design of one square repeat panel within Chip 8, including measurements of expected
final channel widths. (b) Overview SEM image showing the square panels repeating
across Chip 8, with deep gutters between rows of square panels.
Circular features are present at the closed end of the channels and at intervals along
the channel. The diameter of the circle was designed to be 4.0 µm. The backfill
depth was 0.8 µm of oxide from each surface. This gives final channel widths of
0.6 µm, 0.7 µm and 0.8 µm, and a circle diameter of 2.4 µm (Figure C.8). The
depth of the channel was designed to be 1.4 µm. The large fluid flow gutter depth
is designed to be 40µm. The SEM image in Figure C.9 shows the measurements
of channel width. The circle diameter measured between 1.9 µm and 1.962µm.
Channel widths in this case measured as expected, though the circular features
diameters measured less than expected. Some damage can be seen to the circular
features in Figure C.9a It is not clear whether this is as a result of a blemish in the
original wafer or if it occurred during the production of the intermediate wafer.
The depth of channels within Chip08 could not be measured due to the lack of
appropriate SEM images. Figure C.9b summarises the respective mean channel























Figure C.9: Chip 8: SEM images with line overlays
(a) SEM images with line overlays from ImageJ to show measurements of channel widths.
(b) Comparison of fabricated vs designed channel width lengths.
C.2.4 Chip 10
The width of the channels was designed to be 2.2 µm, 2.3µm and 2.4 µm in a
repeating pattern, with one closed end and the other opening onto the channel.
The dimensions of the diamond were designed to be 6.0 µm by 10.0 µm. The
backfill depth was 0.8 µm of oxide from each surface. This gives final channel
widths of 0.6 µm, 0.7 µm and 0.8 µm, and diamond dimensions of 4.4 µm by 8.4 µm
(Figure C.10). The depth of the channel was designed to be 1.4 µm. The large fluid
flow gutter depth is designed to be 40µm. The SEM image in Figure C.11 shows
the measurements of channel width. The shorter of the two diamond dimensions
measured between 3.417µm and 3.473µm. The depth of channels within Chip
10 could not be measured due to the lack of appropriate SEM images. Figure




Figure C.10: Chip 10: design view vs product SEM view
(a) Design of one square repeat panel within Chip 10, including measurements of ex-
pected final channel widths. (b) Overview SEM image showing the square panels re-























Figure C.11: Chip 10: SEM images with line overlays
(a) SEM images with line overlays from ImageJ to show measurements of channel widths.
(b) Comparison of fabricated vs designed channel width lengths.
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C.2.5 Wafer fabrication control features
Test features with a range of sizes and shapes were included in four corner positions




Figure C.12: SEM images of control features for wafer fabrication and their mea-
surements
(a) SEM images with line overlays from ImageJ to show measurements of the rectangular
test features. (b) Comparison of fabricated vs designed control feature lengths. (c) SEM
images with line overlays from ImageJ to show measurements of the square test features.
(d) Comparison of fabricated vs designed control feature lengths.
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C.3 Wafer cleaning and microfluidics mould production pro-
tocols
The following protocols were adapted from that of Cluzel's lab [123].
Reagents and items:
 Copolymer 1: (7-8% Vinylmethylsiloxane)-(dimethylsiloxane) copolymer; Gelest;
VDT-731
or Vinylmethylsiloxane-dimethylsiloxane copolymer, trimethysiloxy termi-
nated cSt 800-1200; Fluorochem Ltd.; VDT-731
 Copolymer 2: (25-30% methylhydrosiloxane) - dimethylsiloxane copolymer,
hydride terminated, 30-50 cst; Gelest; HMS-H271
or Methylhydrosiloxane- dimethylsiloxane copolymer, hydride terminated
cSt 30-50; Fluorochem Ltd.; HMS-HM271
 Modulator: 1,3,5,7-Tetramethyltetravinylcyclotetrasiloxane; Sigma; 396281
or 1,3,5,7-Tetravinyl tertamethylcyclotetrasiloxane; Fluorochem Ltd; S16500
 Catalyst: Platinum divinyl-tetramethyl-disiloxane; Gelest; SIP6839.3
or Platinum-divinyltetramethyldisiloxane complex in vinyl terminated poly-
dimethylsiloxane; Fluorochem Ltd; SIP6830.3
 Solvent: Hexane
 Sylgard 184 PDMS; Ellsworth
 Tridecafluoro-1,1,2,2-tetrahydrooctyl-1-trichlorosilane; United Chemical Tech-
nology;T2492
or 1H,1H,2H,2H-perfluorooctyltricholosilane; Fluorochem Ltd; S13125
 Isopropanol; VWR; BDH1133-4LP
 Acetone; VWR; BDH1101-4LP
 200 mL glass Borosilicate bottle
 200µL Pipette-man and tips
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 Disposable, plastic pipettes




 Printed silicon wafers
 Large glass petri dish to hold wafer
 Large glass petri dishes for chemical baths
 Kim wipes or lens cleaning tissue
 Plastic petri dish
 Dremmel drill with coffee frother adapter
 Scalpel
 Aluminum foil
 70 % Ethanol spray
 Blue tack
C.3.1 Preparing the wafer
Protocol:
 Rinse wafer in order with isopropanol, acetone, and then isopropanol in large
glass petri dishes. Take care not to let the residue from the gloves deposit
on the wafer.
 Let the wafer sit in room temperature to dry (optionally using an N2 air
blow gun).
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 Stick the wafer onto the inverted cap of a 14 mL culture tube using blue
tack and then onto the floor of the vacuum chamber in the fume hood. By
balancing the wafer on the cap, both sides of the wafer will be silanized. This
step prevents PDMS from sticking to the bottom of the wafer.
 Place 40µL of Tridecafluoro-1,1,2,2-tetrahydrooctyl-1-trichlorosilane on a
kim wipe placed in the bottom of a plastic petri dish. Place within the
vacuum chamber. This compound is corrosive, so take appropriate precau-
tions. Only silanize within the dedicated vacuum chamber in the hood.
 Apply vacuum using a vacuum pump, taking extra caution not to knock off
the wafer. If wafer tilts, stop and secure it.
 Allow the wafer to incubate for 30 minutes.
 Turn off house vacuum and slowly reintroduce air to the chamber. If air is
introduced too quickly, the wafer can be thrown against the chamber and be
damaged.
C.3.2 Preparing the aluminium wafer holder
Protocol:
 Clean any dust or residual PDMS from the glass dish to be used as a holder.
 Place a layer of aluminum foil (one piece) dull side up, on the bottom and
up the side walls of the holder. The layer of aluminum foil allows the PDMS
coated wafer to be easily removed from the holder, reducing the risk of
cracking the wafer in later steps.
C.3.3 Preparing the h-PDMS
Quantities are for a 6 inch wafer, though making this amount for a 4 inch wafer




 Add the following to a 200 mL Borosilicate bottle and mix well using the
Dremmel and coffee frother adapter at the lowest speed setting (5000 RPM).
 13.6 g copolymer 1 (pour directly from bottle).
 72µL catalyst (pipette slowly from bottle with 200µL tip; watch the
meniscus to make sure that the tip is filled.
 Add the following to the above mixture and mix well using the Dremmel and
coffee frother adapter at the lowest speed setting (5000 RPM).
 0.4 g modulator (use a disposable pipette to transfer this from the bot-
tle).
 4 g copolymer 2 (use a disposable pipette).
 2 g hexane (use a disposable pipette).
 Degas this mixture in the vacuum chamber for 5 minutes, increasing
and decreasing the pressure to pop the bubbles.
 A thin layer of bubbles may remain on the surface, as they will eventu-
ally disappear.
C.3.4 Creating the h-PDMS layer
Protocol:
 Heat hot plate to 65 ◦C (outside the vacuum chamber).
 While the h-PDMS is degassing, mount the wafer on the spin coater.
 Use the largest spin chuck.
 The aluminum foil from previous users may need to be removed to fit
the wafer in place.
 Following the instructions on the spin coater, create the following program:
 Speed: 100 RPM; Duration: 1 minute (Named program T)
 When the h-PDMS is done degassing, remove it from the vacuum chamber.
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 Start the spin coater, and gently pour the h-PDMS onto the spinning wafer.
 Start in the center and move outwards until the entire wafer is coated.
 Stop the spin coater when the wafer is completely coated.
 Gently remove the wafer and place it on a circular piece of paper towel.
 Place the wafer and towel in the vacuum chamber and degas for 3 minutes.
 After 1 minute bubbles should form on the surface of the wafer and
migrate to the surface.
 Take care not to spread PDMS on the bottom of the wafer as this will
interfere with the vacuum seal needed by the spin coater. PDMS can
be removed from the bottom of the wafer with a kim wipe.
 While the wafer is degassing, reprogram the spin coater with the following
program:
 500 RPM for 5 s followed by 1000 RPM for 40 s (Named program S)
 When the wafer is done degassing (3 minutes), place it on the spin coater
and run the above program, with the lid on.
 During the 3 minute degas step, the h-PDMS may have slowly withdrawn
from some of the external chips. Make a note of these chips on the blemish
chart, and at the end of the process discard the PDMS intermediates created
from them.
 Place the wafer in the glass petri dish and place the holder on the 65 ◦C hot
plate.
 Bake the wafer for 45 minutes.
 Begin the next step whilst baking is underway.
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C.3.5 Creating the s-PDMS support layer
Quantities are for a 6-inch wafer, if making a 4-inch wafer use the quantities in
brackets.
Protocol:
 Mix 70 g (50 g) of Sylgard 184 base with 7 g (5 g) of the Sylgard 184 curing
agent in a 200 mL Borosilicate bottle using the Dremmel and coffee frother
attachment.
 Degas for 30 minutes in a vacuum chamber.
 While the s-PDMS is degassing, place the wafer, in the aluminum wafer
holder, on a hot plate set at 65 ◦C.
 After the s-PDMS has degassed, remove the wafer holder from the hot plate,
and gently pour the s-PDMS onto the wafer.
 Allow the s-PDMS to settle and coat the wafer ( 5 minutes), and then place
the wafer holder back on the hot plate.
 Cover with the Pyrex cover and bake overnight. A more solid mould can be
obtained by extending the bake step to 24 hours.
C.3.6 Removing the PDMS intermediate mould from the wafer
Protocol:
 When done baking, remove the wafer holder from the hot plate and allow to
cool to room temperature.
 In the following steps be very careful to never bend or apply pressure to the
silicon wafer. It will crack under gentle pressure.
 Gently remove the side wall of the wafer holder. The PDMS intermediates,
the wafer, and the bottom layer of aluminum foil will come off with the side
wall.
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 Gently flip over the side wall/wafer/PDMS intermediate and slowly remove
the aluminum foil.
 Gently insert a scalpel between the PDMS intermediate and the aluminum
side wall. Run the scalpel around the edge of the intermediate to dislodge
the intermediate from the side wall.
 Remove any PDMS that has leaked under the wafer by running the scalpel
along the edge of the wafer.
 Flip the intermediate and the wafer over so that the wafer is lying flat on
the table.
 Gently peel the PDMS intermediate from the wafer.
 Move very slowly. The entire process should take at least 5 minutes. Re-
moving the intermediate too quickly will damage the intermediate and will
leave residual PDMS on the surface of the wafer.
 Once the intermediate has been removed, wash the wafer with isopropanol,
acetone, and isopropanol, as above, and dry with N2. Return the wafer to
its plastic storage disk.




CAD Computer Aided Design. 81, 85, 133
NGS Next Generation Sequencing. 6972





DEA Dual-evolutionary algorithm or dual-evolutionary approach. 710, 17, 19
22, 66, 67, 6971, 78, 97, 111, 112, 114, 115, 118126, 130, 156162
DNA Deoxyribonucleic acid. 19, 53, 56, 69, 79, 162, 170
DRIE Deep Reactive Ion Etching. 127129
EA Evolutionary algorithm. 20, 71, 110, 111, 118, 160
EtBr Ethidium bromide. 25, 48
FAD Flavin adenine dinucleotide. 59
FBA Flux Balance Analysis. 9598, 110, 123, 160
FMN Flavin mononucleotide. 59, 61, 62, 64, 68, 69, 72
GA Genetic algorithm. 112
LAC Lipoteichoic acid. 170
MDE Model-driven engineering. 6, 132, 155
mRNA Ribonucleic acid. 170
MSE Mean Squared Error. 148, 151
ODE Ordinary Differential Equation. 93
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Glossary (Nomenclature)
PDMS Polydimethylsiloxane. 130, 180, 193197
RBS Ribosome binding site or Shine-Dalgarno sequence. 61
ROI Region of interest. 131
SEM Scanning Electron Microscopy. 129, 133, 137, 139, 142
SNP Single-nucleotide polymorphism. 56, 71, 72, 103, 106112, 123, 161
TEOS Tetra-ethyl orthosilicate. 129, 130
202
References
[1] Roi Adadi, Benjamin Volkmer, Ron Milo, Matthias Heinemann,
and Tomer Shlomi. Prediction of microbial growth rate versus biomass
yield by a metabolic network with kinetic parameters. PLoS Computational
Biology, 8[7]:e1002575e1002575, January 2012. 98
[2] Rudolf Adlung and Hamid Mamdouh. How to Design Trade Agree-
ments in Services: Top Down or Bottom Up? SSRN Electronic Journal, jun
2013. 4
[3] Alessandra M. Albertini and Alessandro Galizzi. The sequence
of the trp operon of Bacillus subtilis 168 (trpC2) revisited. Microbiology,
145[12]:33193320, dec 1999. 75
[4] G Alterovitz, T Muso, and M F Ramoni. The challenges of informatics
in synthetic biology: from biomolecular networks to artificial organisms.
Briefings in bioinformatics, 11[1]:8095, January 2010. 13
[5] Ernesto Andrianantoandro, Subhayu Basu, David K Karig, and
Ron Weiss. Synthetic biology: new engineering rules for an emerging dis-
cipline. Molecular systems biology, 2:20060028, January 2006. 2, 11
[6] Narayana Annaluru, Héloïse Muller, Leslie A Mitchell,
Sivaprakash Ramalingam, Giovanni Stracquadanio, Sarah M
Richardson, Jessica S Dymond, Zheng Kuang, Lisa Z Scheifele,
Eric M Cooper, Yizhi Cai, Karen Zeller, Neta Agmon, Jef-
frey S Han, Michalis Hadjithomas, Jennifer Tullman, Katrina
203
REFERENCES
Caravelli, Kimberly Cirelli, Zheyuan Guo, Viktoriya London,
Apurva Yeluru, Sindurathy Murugan, Karthikeyan Kandav-
elou, Nicolas Agier, Gilles Fischer, Kun Yang, J Andrew Mar-
tin, Murat Bilgel, Pavlo Bohutski, Kristin M Boulier, Brian J
Capaldo, Joy Chang, Kristie Charoen, Woo Jin Choi, Peter
Deng, James E DiCarlo, Judy Doong, Jessilyn Dunn, Jason I
Feinberg, Christopher Fernandez, Charlotte E Floria, David
Gladowski, Pasha Hadidi, Isabel Ishizuka, Javaneh Jabbari,
Calvin Y L Lau, Pablo A Lee, Sean Li, Denise Lin, Matthias E
Linder, Jonathan Ling, Jaime Liu, Jonathan Liu, Mariya Lon-
don, Henry Ma, Jessica Mao, Jessica E McDade, Alexan-
dra McMillan, Aaron M Moore, Won Chan Oh, Yu Ouyang,
Ruchi Patel, Marina Paul, Laura C Paulsen, Judy Qiu, Alex
Rhee, Matthew G Rubashkin, Ina Y Soh, Nathaniel E Sotuyo,
Venkatesh Srinivas, Allison Suarez, Andy Wong, Remus Wong,
Wei Rose Xie, Yijie Xu, Allen T Yu, Romain Koszul, Joel S
Bader, Jef D Boeke, and Srinivasan Chandrasegaran. Total syn-
thesis of a functional designer eukaryotic chromosome. Science (New York,
NY), 344[6179]:5558, April 2014. 16
[7] Rutherford Aris. Mathematical modelling techniques. Courier Corpora-
tion, 2012. 83
[8] Timothy Arndt. Visual software tools for bioinformatics. Journal of
Visual Languages & Computing, 19[2]:291301, 2008. 67
[9] FH Arnold. Design by directed evolution. In FASEB JOURNAL,
11, pages A872A872. FEDERATION AMER SOC EXP BIOL 9650
ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA, 1997. 58
[10] A Bacher, S Eberhardt, M Fischer, and K Kis. Biosynthesis of
vitamin B2 (riboflavin). Annual Review of Nutrition, 2000. 87, 89
204
REFERENCES
[11] Manuel F Balandrin, James A Klocke, Eve Syrkin Wurtele, and
William Hugh Bollinger. Natural plant chemicals: sources of industrial
and medicinal materials. Science, 228[4704]:11541160, 1985. 58
[12] Anton Bankevich, Sergey Nurk, Dmitry Antipov, Alexey A
Gurevich, Mikhail Dvorkin, Alexander S Kulikov, Valery M
Lesin, Sergey I Nikolenko, Son Pham, Andrey D Prjibelski,
et al. Spades: a new genome assembly algorithm and its applications
to single-cell sequencing. Journal of computational biology, 19[5]:455477,
2012. 67
[13] Christopher D Bayliss and E Richard Moxon. Hypermutation and
bacterial adaptation. ASM news, 68[11], 2002. 56
[14] K. Beck, M. Beedle, A. van Bennekum, A. Cockburn, W. Cun-
ningham, M. Fowler, J. Grenning, J. Highsmith, A. Hunt, R. Jef-
fries, Jon Kern, Brian Marick, Robert C. Martin, Steve Mal-
lor, Ken Shwaber, and Jeff Sutherland. The agile manifesto. Tech-
nical report, The Agile Alliance, 2001. 5
[15] Kent Beck and Cynthia Andres. Extreme Programming Explained:
Embrace Change; 2nd ed. Addison-Wesley, Boston, MA, 2005. 5
[16] Richard Bellman. COMBINATORIAL PROCESSES AND DYNAMIC
PROGRAMMING. pages 1923, February 1958. 54
[17] Richard Bellman. Dynamic programming. Courier Corporation, 2013.
152
[18] Cristina Bicchieri. Rationality and game theory. The Oxford handbook
of rationality, pages 182205, 2004. 53
[19] L Bilitchenko, A Liu, S Cheung, E Weeding, and B Xia. Eugenea
domain specific language for specifying and constraining synthetic biological
parts, devices, and systems. PloS one, 2011. 14, 81
205
REFERENCES
[20] Ivana Bjedov, Olivier Tenaillon, Benedicte Gerard, Vale-
ria Souza, Erick Denamur, Miroslav Radman, François Tad-
dei, and Ivan Matic. Stress-induced mutagenesis in bacteria. Science,
300[5624]:14041409, 2003. 55
[21] Anthony M Bolger, Marc Lohse, and Bjoern Usadel. Trim-
momatic: a flexible trimmer for illumina sequence data. Bioinformatics,
30[15]:21142120, 2014. 67
[22] Monica Bordegoni and Caterina Rizzi. Innovation in product design:
from CAD to virtual prototyping. Springer, 2011. 81
[23] Eckard Bringmann and Andreas Kr. Model-Based Testing of Au-
tomotive Systems. In 2008 International Conference on Software Testing,
Verification, and Validation, pages 485493. IEEE, apr 2008. 6
[24] James P Brody, Paul Yager, Raymond E Goldstein, and
Robert H Austin. Biotechnology at low reynolds numbers. Biophysical
journal, 71[6]:34303441, 1996. 126
[25] Polly Brown. Cad: Do computers aid the design process after all? Inter-
sect: The Stanford Journal of Science, Technology and Society, 2[1]:5266,
2009. 85
[26] John Cairns, Julie Overbaugh, and Stephan Miller. The origin of
mutants. Nature, 335[6186]:142145, 1988. 55
[27] James M Carothers, Jonathan A Goler, Darmawi Juminaga, and
Jay D Keasling. Model-Driven Engineering of RNA Devices to Quantita-
tively Program Gene Expression. Science, 334[6063]:17161719, 2011. 6
[28] Anne Carpenter, Thouis Jones, Michael Lamprecht, Colin
Clarke, In Kang, Ola Friman, David Guertin, Joo Chang,
Robert Lindquist, Jason Moffat, Polina Golland, and David
Sabatini. CellProfiler: image analysis software for identifying and quanti-
fying cell phenotypes. Genome biology, 7[10]:R100, 2006. 143
206
REFERENCES
[29] Sean B Carroll. Genetics and the making of homo sapiens. Nature,
422[6934]:849857, 2003. 82
[30] Malcolm J. Casadaban and Stanley N. Cohen. Analysis of gene
control signals by DNA fusion and cloning in Escherichia coli. Journal of
Molecular Biology, 138[2]:179207, apr 1980. 23
[31] Jeronimo Cello, Aniko V Paul, and Eckard Wimmer. Chemical
synthesis of poliovirus cDNA: generation of infectious virus in the absence
of natural template. Science (New York, NY), 297[5583]:10161018, August
2002. 16
[32] L Y Chan, S Kosuri, and D Endy. Refactoring bacteriophage T7 -
Chan - 2005 - Molecular Systems Biology - Wiley Online Library. Molecular
systems biology, 2005. 16
[33] Deepak Chandran, Frank T Bergmann, and Herbert M Sauro.
Computer-aided design of biological circuits using tinkercell. Bioengineered
Bugs, 1[4]:276283, October 2014. 14, 81
[34] Antje Chang, Ida Schomburg, Sandra Placzek, Lisa Jeske,
Marcus Ulbrich, Mei Xiao, Christoph W Sensen, and Dietmar
Schomburg. BRENDA in 2015: exciting developments in its 25th year
of existence. Nucleic Acids Research, 43[Database issue]:D43946, January
2015. 93
[35] M. M. Y. Chen, C. D. Snow, C. L. Vizcarra, S. L. Mayo, and F. H.
Arnold. Comparison of random mutagenesis and semi-rational designed li-
braries for improved cytochrome P450 BM3-catalyzed hydroxylation of small
alkanes. Protein Engineering Design and Selection, 25[4]:171178, apr 2012.
57
[36] G Chotani, T Dodge, A Hsu, M Kumar, R LaDuca, D Trimbur,
W Weyler, and K Sanford. The commercial production of chemicals




[37] Edmund M. Clarke, Orna Grumberg, and David E. Long. Model
checking and abstraction. ACM Transactions on Programming Languages
and Systems, 16[5]:15121542, sep 1994. 6
[38] Peter JA Cock, Tiago Antao, Jeffrey T Chang, Brad A Chap-
man, Cymon J Cox, Andrew Dalke, Iddo Friedberg, Thomas
Hamelryck, Frank Kauff, Bartek Wilczynski, et al. Biopython:
freely available python tools for computational molecular biology and bioin-
formatics. Bioinformatics, 25[11]:14221423, 2009. 67
[39] M T Cooling, V Rouilly, G Misirli, J Lawson, T Yu, J Hallinan,
and A Wipat. Standard virtual biological parts: a repository of modular
modeling components for synthetic biology. Bioinformatics, 26[7]:925931,
April 2010. 83
[40] D Coquard, M Huecas, M Ott, J M Van Dijl, A P van Loon,
and H P Hohmann. Molecular cloning and characterisation of the ribC
gene from Bacillus subtilis: a point mutation in ribC results in riboflavin
overproduction. Molecular and General Genetics MGG, 254[1]:8184, March
1997. 59, 89
[41] Athel Cornish-Bowden. One hundred years of MichaelisMenten kinet-
ics. Perspectives in Science, 4:39, March 2015. 90
[42] Mélanie Courtot, Nick Juty, Christian Knüpfer, Dagmar Wal-
temath, Anna Zhukova, Andreas Dräger, Michel Dumontier,
Andrew Finney, Martin Golebiewski, Janna Hastings, Ste-
fan Hoops, Sarah Keating, Douglas B Kell, Samuel Kerrien,
James Lawson, Allyson Lister, James Lu, Rainer Machne, Pe-
dro Mendes, Matthew Pocock, Nicolas Rodriguez, Alice Vil-
leger, Darren J Wilkinson, Sarala Wimalaratne, Camille
Laibe, Michael Hucka, and Nicolas Le Novère. Controlled vocabu-




[43] Brian Cox and J. R. (Jeffrey Robert) Forshaw. The quantum uni-
verse : (and why anything that can happen, does). Da Capo Press, 2012.
1
[44] Valentino Crespi, Aram Galstyan, and Kristina Lerman. Top-
down vs bottom-up methodologies in multi-agent system design. Au-
tonomous Robots, 24[3]:303313, apr 2008. 4
[45] Francis Crick. Central dogma of molecular biology. Nature,
227[5258]:561563, 1970. 55
[46] P F Culverhouse. Constraining designers and their CAD tools. Design
Studies, 16[1]:81101, January 1995. 81, 86
[47] Kathleen A Curran and Hal S Alper. Expanding the chemical palate
of cells by combining systems biology and metabolic engineering. Metabolic
engineering, 14[4]:289297, July 2012. 15
[48] M J Czar, Y Cai, and J Peccoud. Writing DNA with GenoCADTM.
Nucleic Acids Research, 37[Web Server]:W40W47, June 2009. 14, 81
[49] Charles Darwin. On the Origin of Species by Means of Natural Selection.
Murray, London, 1859. or the Preservation of Favored Races in the Struggle
for Life. 54, 78
[50] Benedetto De Martino, Dharshan Kumaran, Ben Seymour, and
Raymond J Dolan. Frames, biases, and rational decision-making in the
human brain. Science (New York, NY), 313[5787]:684687, August 2006. 3
[51] François-Michel De Rainville, Félix-Antoine Fortin, Marc-
André Gardner, Marc Parizeau, and Christian Gagné. DEAP.
In the fourteenth international conference, page 85, New York, New York,
USA, 2012. ACM Press. 112




[53] Henry Winram. Dickinson. A Short History of the Steam Engine. Cam-
bridge University Press, 2011. 12
[54] Edsger W Dijkstra. A note on two problems in connexion with graphs.
Numerische mathematik, 1[1]:269271, 1959. 152
[55] Steve Dorus, Eric J Vallender, Patrick D Evans, Jeffrey R An-
derson, Sandra L Gilbert, Michael Mahowald, Gerald J Wyck-
off, Christine M Malcom, and Bruce T Lahn. Accelerated evolution
of nervous system genes in the origin of homo sapiens. Cell, 119[7]:1027
1040, 2004. 82
[56] John W Drake, Brian Charlesworth, Deborah Charlesworth,
and James F Crow. Rates of spontaneous mutation. Genetics,
148[4]:16671686, 1998. 55
[57] C L Dym. Engineering Design: A Synthesis of Views. page 1. Cambridge
University Press, New York, 1994. 2
[58] Arthur Edelstein, Nenad Amodaj, Karl Hoover, Ron Vale, and
Nico Stuurman. Computer Control of Microscopes Using MicroManager.
John Wiley & Sons, Inc., Hoboken, NJ, USA, May 2001. 130
[59] W Ernst Eder and Stanislav Hosnedl. Design engineering: a manual
for enhanced creativity. CRC Press, 2007. 1, 54
[60] W Ernst Eder and Stanislav Hosnedl. Introduction to design engi-
neering: systematic creativity and management. CRC Press, 2010. 54
[61] Lucy Eland, Anil Wipat, S Lee, Sungshic Park, and Ling Wu.
Microfluidics for bacterial imaging, pages 69111. Elsevier, Oct 2016. 9
[62] T Ellis, X Wang, and J Collins. Diversity-based, model-guided
construction of synthetic gene networks with predicted functions. Nature
biotechnology, 2009. 83
[63] R Ian Faulconbridge and Michael J Ryan. Managing complex tech-
nical projects: A systems engineering approach. Artech House, 2003. 83
210
REFERENCES
[64] Robert France and Bernhard Rumpe. Model-driven Development of
Complex Software: A Research Roadmap. In Future of Software Engineering
(FOSE '07), pages 3754. IEEE, may 2007. 6
[65] Peter Freeman and David Hart. A science of design for software-
intensive systems. Communications of the ACM, 47[8]:1921, August 2004.
2
[66] Jacob Frelinger, Thomas B Kepler, and Cliburn Chan. Flow:
Statistics, visualization and informatics for flow cytometry. Source Code for
Biology and Medicine, 3[1]:10, 2008. 67
[67] Errol C Friedberg, Graham C Walker, Wolfram Siede, and
Richard D Wood. DNA repair and mutagenesis. American Society for
Microbiology Press, 2005. 55
[68] Hiroshi Fujikawa, Akemi Kai, and Satoshi Morozumi. A new logistic
model for Escherichia coli growth at constant and dynamic temperatures.
Food Microbiology, 21[5]:501509, October 2004. 101
[69] M Galdzicki, K P Clancy, E Oberortner, and M Pocock. The
Synthetic Biology Open Language (SBOL) provides a community standard
for communicating designs in synthetic biology : Nature Biotechnology :
Nature Research. Nature, 2014. 3
[70] Ethan C Garner. MicrobeTracker: quantitative image analysis designed
for the smallest organisms. Molecular microbiology, 80[3]:577579, 2011. 143
[71] D Gärtner, M Geissendörfer, and W Hillen. Expression of the
Bacillus subtilis xyl operon is repressed at the level of transcription and is
induced by xylose. Journal of Bacteriology, 1988. 62
[72] M Geissendörfer and W Hillen. Regulated expression of heterologous
genes inBacillus subtilis using the Tn10 encodedtet regulatory elements. Appl
Microbiol Biotechnol, 1990. 62
[73] John Burdon Sanderson Haldane George Edward Briggs. A Note
on the Kinetics of Enzyme Action. Biochemical Journal, 19[2]:338, 1925. 90
211
REFERENCES
[74] D G Gibson, J I Glass, C Lartigue, V N Noskov, R Y Chuang, M A
Algire, G A Benders, M G Montague, L Ma, M MMoodie, C Mer-
ryman, S Vashee, R Krishnakumar, N Assad-Garcia, C Andrews-
Pfannkoch, E A Denisova, L Young, Z Q Qi, T H Segall-Shapiro,
C H Calvey, P P Parmar, C A Hutchison, H O Smith, and J C
Venter. Creation of a Bacterial Cell Controlled by a Chemically Synthe-
sized Genome. Science (New York, NY), 329[5987]:5256, July 2010. 16
[75] Thomas Gilovich, Dale Griffin, and Daniel Kahneman. Heuristics
and Biases. The Psychology of Intuitive Judgment. Cambridge University
Press, July 2002. 3
[76] F Ginetti, M Perego, A M Albertini, and A Galizzi. Bacillus sub-
tilis mutS mutL operon: identification, nucleotide sequence and mutagenesis.
Microbiology (Reading, England), 142 ( Pt 8):20212029, August 1996. 63
[77] David E Goldberg and John H Holland. Genetic algorithms and
machine learning. Machine learning, 3[2]:9599, 1988. 160
[78] Cato M Guldberg and Peter Waage. Studies concerning affinity. CM
Forhandlinger: Videnskabs-Selskabet i Christiana, 35[1864]:1864, 1864. 90,
91
[79] Armando Martin Haeberer and TSE Maibaum. Scientific rigour, an
answer to a pragmatic question: a linguistic framework for software engi-
neering. In Proceedings of the 23rd International Conference on Software
Engineering, pages 463472. IEEE Computer Society, 2001. 84
[80] J Hallinan, S Park, and A Wipat. Bridging the gap between design
and reality: A dual evolutionary strategy for the design of synthetic genetic
circuits. In BIOINFORMATICS 2012, pages 263268, 2012. 7, 9, 19, 54, 82,
83, 125
[81] Kyle IS Harrington, Timothy S Stiles, Lakshmi Venkatraman,
Claudia Prahst, and Katie Bentley. Functional image processing
with imagej/fiji. In BioImage Informatics Conference, 2015. 126
212
REFERENCES
[82] Matthias Heinemann and Sven Panke. Synthetic biologyputting
engineering into biology. Bioinformatics, 22[22]:27902799, 2006. 2, 11
[83] Christopher S Henry, Jenifer F Zinner, Matthew P Cohoon,
and Rick L Stevens. iBsu1103: a new genome-scale metabolic model of
Bacillus subtilis based on SEED annotations. Genome biology, 10[6]:R69,
2009. 96
[84] T A Hince and S Neale. A comparison of the mutagenic action of
the methyl and ethyl derivatives of nitrosamides and nitrosamidines on Es-
cherichia coli. Mutation research, 24[3]:3837, sep 1974. 55
[85] John Henry Holland et al. Adaptation in natural and artificial systems:
an introductory analysis with applications to biology, control, and artificial
intelligence. MIT press, 1992. 160
[86] Gerard J Holzmann. Conquering Complexity. Computer, 40[12]:111
113, 2007. 83
[87] S Hoops, S Sahle, R Gauges, C Lee, J Pahle, N Simus, M Sing-
hal, L Xu, P Mendes, and U Kummer. COPASIa COmplex PAthway
SImulator. Bioinformatics, 22[24]:30673074, December 2006. 93
[88] Elizabeth Howell and SPACE com Contributor. How many stars
are in the universe? Space. com, May, 31, 2014. 110
[89] Zhipeng Huang, Nadine Geyer, Peter Werner, Johannes
De Boor, and Ulrich Gösele. Metal-assisted chemical etching of silicon:
a review. Advanced materials, 23[2]:285308, 2011. 127
[90] Vladimir. Hubka and W. Ernst. Eder. Theory of Technical Systems :
a Total Concept Theory for Engineering Design. Springer Berlin Heidelberg,
1988. 1
[91] M Hucka, A Finney, H M Sauro, H Bolouri, J C Doyle, H Ki-
tano, , the rest of the SBML Forum, A P Arkin, B J Bornstein,
D Bray, A Cornish-Bowden, A A Cuellar, S Dronov, E D Gilles,
213
REFERENCES
M Ginkel, V Gor, I I Goryanin, W J Hedley, T C Hodgman,
J H Hofmeyr, P J Hunter, N S Juty, J L Kasberger, A Krem-
ling, U Kummer, N Le Novere, L M Loew, D Lucio, P Mendes,
E Minch, E D Mjolsness, Y Nakayama, M R Nelson, P F Nielsen,
T Sakurada, J C Schaff, B E Shapiro, T S Shimizu, H D Spence,
J Stelling, K Takahashi, M Tomita, J Wagner, and J Wang. The
systems biology markup language (SBML): a medium for representation and
exchange of biochemical network models. Bioinformatics, 19[4]:524531,
March 2003. 93
[92] Holger Jenke-Kodama, Rolf Müller, and Elke Dittmann. Evo-
lutionary mechanisms underlying secondary metabolite diversity. In Natural
Compounds as Drugs Volume I, pages 119140. Birkhäuser Basel, Basel,
2008. 15, 58
[93] Paul R. Jensen, Tracy J. Mincer, Philip G. Williams, and
William Fenical. Marine actinomycete diversity and natural product
discovery. Antonie van Leeuwenhoek, 87[1]:4348, jan 2005. 15
[94] R Jonker and A Volgenant. Ein Algorithmus mit kürzesten al-
ternierenden Wegen für dichte und dünne Zuordnungsprobleme. Computing,
38[4]:325340, December 1987. 150, 152
[95] Ari Juels and Martin Wattenberg. Stochastic hillclimbing as a base-
line method for evaluating genetic algorithms. In Advances in Neural Infor-
mation Processing Systems, pages 430436, 1996. 112, 159
[96] David J Kasik, William Buxton, and David R Ferguson. Ten cad
challenges. IEEE Computer Graphics and Applications, 25[2]:8192, 2005.
81, 85
[97] Jay D Keasling. Manufacturing molecules through metabolic engineering.
Science (New York, N.Y.), 330[6009]:13558, dec 2010. 6
[98] K. Keutzer, A.R. Newton, J.M. Rabaey, and A. Sangiovanni-
Vincentelli. System-level design: orthogonalization of concerns and
214
REFERENCES
platform-based design. IEEE Transactions on Computer-Aided Design of
Integrated Circuits and Systems, 19[12]:15231543, 2000. 4
[99] Ahmad S Khalil and James J Collins. Synthetic biology: applications
come of age. Nature Reviews Genetics, 11[5]:367379, May 2010. 2, 11
[100] Johannes Klein, Stefan Leupold, Ilona Biegler, Rebekka
Biedendieck, Richard Munch, and Dieter Jahn. Tlm-tracker: soft-
ware for cell segmentation, tracking and lineage analysis in time-lapse mi-
croscopy movies. Bioinformatics, 28[17]:22762277, 2012. 143
[101] Edward H Knight. Knights American Mechanical Dictionary. 1876. xv,
12
[102] A L Knorr, R Jain, and R Srivastava. Bayesian-based selection of
metabolic objective functions. Bioinformatics, 23[3]:351357, February 2007.
96
[103] Peter Kroes. Engineering design. pages 127161. Springer Netherlands,
Dordrecht, April 2012. 3
[104] H W Kuhn. The Hungarian method for the assignment problem. Naval
Research Logistics, 52[1]:721, February 2005. 150
[105] F Kunst, N Ogasawara, I Moszer, A M Albertini, G Alloni,
V Azevedo, M G Bertero, P Bessieres, A Bolotin, S Borchert,
R Borriss, L Boursier, A Brans, M Braun, S C Brignell, S Bron,
S Brouillet, C V Bruschi, B Caldwell, V Capuano, N M Carter,
S K Choi, J J Cordani, I F Connerton, N J Cummings, R A
Daniel, F Denziot, K M Devine, A Düsterhöft, S D Ehrlich,
P T Emmerson, K D Entian, J Errington, C Fabret, E Ferrari,
D Foulger, C Fritz, M Fujita, Y Fujita, S Fuma, A Galizzi,
N Galleron, S Y Ghim, P Glaser, A Goffeau, E J Golightly,
G Grandi, G Guiseppi, B J Guy, K Haga, J Haiech, C R Har-
wood, A Hènaut, H Hilbert, S Holsappel, S Hosono, M F Hullo,
215
REFERENCES
M Itaya, L Jones, B Joris, D Karamata, Y Kasahara, M Klaerr-
Blanchard, C Klein, Y Kobayashi, P Koetter, G Koningstein,
S Krogh, M Kumano, K Kurita, A Lapidus, S Lardinois, J Lauber,
V Lazarevic, S M Lee, A Levine, H Liu, S Masuda, C Mauël,
C Médigue, N Medina, R P Mellado, M Mizuno, D Moestl,
S Nakai, M Noback, D Noone, M O'Reilly, K Ogawa, A Ogi-
wara, B Oudega, S H Park, V Parro, T M Pohl, D Portelle,
S Porwollik, A M Prescott, E Presecan, P Pujic, B Purnelle,
G Rapoport, M Rey, S Reynolds, M Rieger, C Rivolta, E Rocha,
B Roche, M Rose, Y Sadaie, T Sato, E Scanlan, S Schleich,
R Schroeter, F Scoffone, J Sekiguchi, A Sekowska, S J Seror,
P Serror, B S Shin, B Soldo, A Sorokin, E Tacconi, T Takagi,
H Takahashi, K Takemaru, M Takeuchi, A Tamakoshi, T Tanaka,
P Terpstra, A Togoni, V Tosato, S Uchiyama, M Vandebol,
F Vannier, A Vassarotti, A Viari, R Wambutt, H Wedler,
T Weitzenegger, P Winters, A Wipat, H Yamamoto, K Yamane,
K Yasumoto, K Yata, K Yoshida, H F Yoshikawa, E Zumstein,
H Yoshikawa, and A Danchin. The complete genome sequence of
the gram-positive bacterium Bacillus subtilis. Nature, 390[6657]:249256,
November 1997. 61, 106
[106] John Laird. The law of parsimony. The Monist, pages 321344, 1919. 85
[107] Russell Lande. Natural selection and random genetic drift in phenotypic
evolution. Evolution, 30[2]:314334, 1976. 82
[108] Ben Langmead and Steven L Salzberg. Fast gapped-read alignment
with bowtie 2. Nature methods, 9[4]:357359, 2012. 67
[109] Yoann Le Breton, Nrusingh Prasad Mohapatra, and
WG Haldenwang. In vivo random mutagenesis of bacillus subtilis
by use of tnylb-1, a mariner-based transposon. Applied and environmental
microbiology, 72[1]:327333, 2006. 55
216
REFERENCES
[110] Elaine R Lee, Kenneth F Blount, and Ronald R Breaker. Rose-
oflavin is a natural antibacterial compound that binds to FMN riboswitches
and regulates gene expression. RNA biology, 6[2]:187194, 2009. 61
[111] David Lewis. How to define theoretical terms. The Journal of Philosophy,
67[13]:427446, 1970. 84
[112] P J Lewis and A L Marston. GFP vectors for controlled expression and
dual labelling of protein fusions in Bacillus subtilis. Gene, 227[1]:10110,
feb 1999. 24
[113] Heng Li, Bob Handsaker, Alec Wysoker, Tim Fennell, Jue Ruan,
Nils Homer, Gabor Marth, Goncalo Abecasis, and Richard
Durbin. The sequence alignment/map format and samtools. Bioinformat-
ics, 25[16]:20782079, 2009. 67
[114] Seong Han Lim, Jong Soo Choi, and Enoch Y Park. Microbial pro-
duction of riboflavin using riboflavin overproducers,Ashbya gossypii, Bacil-
lus subtilis, andCandida famate: An overview. Biotechnology and Bioprocess
Engineering, 6[2]:7588, April 2001. 59, 87
[115] Matthew W Lux, Brian W Bramlett, David A Ball, and Jean
Peccoud. Genetic design automation: engineering fantasy or scientific re-
newal? TRENDS in Biotechnology, 30[2]:120126, February 2012. 2, 8, 11,
14, 15
[116] M Mack, A Van Loon, and H Hohmann. Regulation of Riboflavin
Biosynthesis inBacillus subtilis Is Affected by the Activity of the Flavoki-
nase/Flavin Adenine Dinucleotide Synthetase Encoded byribC. Journal of
Bacteriology, 1998. 89
[117] P C Mangelsdorf and R G Reeves. The origin of maize. Proceedings
of the National Academy of Sciences, 1938. 11
[118] Aaron McKenna, Matthew Hanna, Eric Banks, Andrey
Sivachenko, Kristian Cibulskis, Andrew Kernytsky, Kiran
Garimella, David Altshuler, Stacey Gabriel, Mark Daly, et al.
217
REFERENCES
The genome analysis toolkit: a mapreduce framework for analyzing next-
generation dna sequencing data. Genome research, 20[9]:12971303, 2010.
67
[119] D Mérino, H Réglier Poupet, and P Berche. A hypermutator phe-
notype attenuates the virulence of Listeria monocytogenes in a mouse model
- Mérino - 2002 - Molecular Microbiology - Wiley Online Library. Molecular
Microbiology, 2002. 56
[120] L Michaelis and M L Menten. Die kinetik der invertinwirkung (The
Kinetics of Invertase Action). Biochem z, 1913. 90
[121] Alexander S Mironov, Ivan Gusarov, Ruslan Rafikov,
Lubov Errais Lopez, Konstantin Shatalin, Rimma A Kreneva,
Daniel A Perumov, and Evgeny Nudler. Sensing Small Molecules by
Nascent RNA. Cell, 111[5]:747756, November 2002. 87
[122] Melanie Mitchell, John H Holland, and Stephanie Forrest.
When will a genetic algorithm outperform hill climbing. In Advances in
neural information processing systems, pages 5158, 1994. 160
[123] J Moffitt, J Lee, and P Cluzel. The single-cell chemostat: an agarose-
based, microfluidic device for high-throughput, single-cell studies of bacteria
and bacterial communities. Lab on a Chip, 2012. 127, 191
[124] Tae Seok Moon, Chunbo Lou, Alvin Tamsir, Brynne C Stanton,
and Christopher A Voigt. Genetic programs constructed from layered
logic gates in single cells. Nature, 491[7423]:249253, November 2012. 13
[125] A.E. MUSSON. Industrial Motive Power in the United Kingdom, 180070.
The Economic History Review, 29[3]:415439, aug 1976. 11
[126] Pierre Nicolas, Ulrike Mäder, Etienne Dervyn, Tatiana
Rochat, Aurélie Leduc, Nathalie Pigeonneau, Elena Bidnenko,
Elodie Marchadier, Mark Hoebeke, Stéphane Aymerich, Dörte
Becher, Paola Bisicchia, Eric Botella, Olivier Delumeau, Ge-
off Doherty, Emma L Denham, Mark J Fogg, Vincent Fromion,
218
REFERENCES
Anne Goelzer, Annette Hansen, Elisabeth Härtig, Colin R Har-
wood, Georg Homuth, Hanne Jarmer, Matthieu Jules, Edda
Klipp, Ludovic Le Chat, François Lecointe, Peter Lewis, Wol-
fram Liebermeister, Anika March, Ruben A T Mars, Priyanka
Nannapaneni, David Noone, Susanne Pohl, Bernd Rinn, Frank
Rügheimer, Praveen K Sappa, Franck Samson, Marc Schaffer,
Benno Schwikowski, Leif Steil, Jörg Stülke, Thomas Wiegert,
Kevin M Devine, Anthony J Wilkinson, Jan Maarten van Dijl,
Michael Hecker, Uwe Völker, Philippe Bessières, and Philippe
Noirot. Condition-dependent transcriptome reveals high-level regulatory
architecture in Bacillus subtilis. Science (New York, N.Y.), 335[6072]:1103
6, mar 2012. 23
[127] Jens Nielsen and Jay D Keasling. Synergies between synthetic biol-
ogy and metabolic engineering. Nature biotechnology, 29[8]:693695, August
2011. 8, 15
[128] E Nudler. The riboswitch control of bacterial metabolism. Trends in
Biochemical Sciences, 29[1]:1117, January 2004. 89
[129] Bashar Nuseibeh and Steve Easterbrook. Requirements engineering:
a roadmap. In Proceedings of the Conference on the Future of Software
Engineering, pages 3546. ACM, 2000. 84
[130] You-Kwan Oh, Bernhard Ø Palsson, Sung M Park, Christophe H
Schilling, and Radhakrishnan Mahadevan. Genome-scale recon-
struction of metabolic network in Bacillus subtilis based on high-throughput
phenotyping and gene essentiality data. The Journal of biological chemistry,
282[39]:2879128799, September 2007. 96
[131] Konstantin Okonechnikov, Olga Golosova, Mikhail Fursov,
and UGENE team. Unipro ugene: a unified bioinformatics toolkit. Bioin-
formatics, 28[8]:11661167, 2012. 75
219
REFERENCES
[132] Antonio Oliver. Hypermutation in natural bacterial populations: conse-
quences for medical microbiology. Reviews in Medical Microbiology, 16[1]:25
32, 2005. 56
[133] Jeffrey D Orth, Ines Thiele, and Bernhard Ø Palsson. What is
flux balance analysis? Nature biotechnology, 28[3]:245248, March 2010. 95
[134] David Lorge Parnas. On the criteria to be used in decomposing systems
into modules. Communications of the ACM, 15[12]:10531058, 1972. 83
[135] Michael Pedersen and Andrew Phillips. Towards programming lan-
guages for genetic engineering of living cells. Journal of The Royal Society
Interface, 6[Suppl 4]:S437S450, August 2009. 14, 81
[136] J Perkins, A Sloma, and T Hermann. Genetic engineering of Bacillus
subtilis for the commercial production of riboflavin. Journal of Industrial
Microbiology and Biotechnology, 1999. 89
[137] M. Pizka and A. Bauer. A brief top-down and bottom-up philosophy on
software evolution. In Proceedings. 7th International Workshop on Principles
of Software Evolution, 2004., pages 131136. IEEE. 4
[138] György Pósfai, Guy Plunkett, Tamás Fehér, David Frisch,
Günther M Keil, Kinga Umenhoffer, Vitaliy Kolisnychenko,
Buffy Stahl, Shamik S Sharma, Monika de Arruda, Valerie Bur-
land, Sarah W Harcum, and Frederick R Blattner. Emergent
properties of reduced-genome Escherichia coli. Science (New York, NY),
312[5776]:10441046, May 2006. 16
[139] Nathan D Price, Jason A Papin, Christophe H Schilling, and
Bernhard O Palsson. Genome-scale microbial in silico models: the
constraints-based approach. Trends in Biotechnology, 21[4]:162169, apr
2003. 7
[140] Fatemeh Rajabi-Alni, Alireza Bagheri, and Behrouz Minaei-
Bidgoli. An o (n 3) time algorithm for the maximum weight b-matching
problem on bipartite graphs. arXiv preprint arXiv:1410.3408, 2014. 152
220
REFERENCES
[141] Paul Ralph and Yair Wand. A Proposal for a Formal Definition of the
Design Concept. In Design requirements engineering: A ten-year perspective,
pages 103136. Springer Berlin Heidelberg, Berlin, Heidelberg, 2009. 2
[142] Sergi Regot, Javier Macia, Núria Conde, Kentaro Fu-
rukawa, Jimmy Kjellén, Tom Peeters, Stefan Hohmann, Eulàlia
de Nadal, Francesc Posas, and Ricard Solé. Distributed biological
computation with multicellular engineered networks. Nature, 469[7329]:207
211, December 2010. 13
[143] Elijah Roberts, Andrew Magis, Julio O. Ortiz, Wolfgang
Baumeister, and Zaida Luthey-Schulten. Noise Contributions in an
Inducible Genetic Switch: A Whole-Cell Simulation Study. PLoS Computa-
tional Biology, 7[3]:e1002010, mar 2011. 7
[144] BF Robertson and DF Radcliffe. Impact of cad tools on creative
problem solving in engineering design. Computer-Aided Design, 41[3]:136
146, 2009. 81
[145] M L Ryder. Medieval Sheep and Wool Types. The Agricultural History
Review, 1984. 11
[146] Laure Saias, Julien Autebert, Laurent Malaquin, and Jean-
Louis Viovy. Design, modeling and characterization of microfluidic ar-
chitectures for high flow rate, small footprint microfluidic systems. Lab on a
Chip, 11[5]:822832, 2011. 126
[147] Jayodita C Sanghvi, Sergi Regot, Silvia Carrasco, Jonathan R
Karr, Miriam V Gutschow, Benjamin Bolival, Markus W
Covert, and Markus W. Covert. Accelerated discovery via a whole-cell
model. Nature methods, 10[12]:11925, dec 2013. 7
[148] Claudia Schillings, Mikael Sunnåker, Jörg Stelling, Christoph
Schwab, and Costas D Maranas. Efficient Characterization of Para-




[149] Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise,
Verena Kaynig, Mark Longair, Tobias Pietzsch, Stephan
Preibisch, Curtis Rueden, Stephan Saalfeld, Benjamin Schmid,
et al. Fiji: an open-source platform for biological-image analysis. Nature
methods, 9[7]:676682, 2012. 126
[150] Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise,
Verena Kaynig, Mark Longair, Tobias Pietzsch, Stephan
Preibisch, Curtis Rueden, Stephan Saalfeld, Benjamin Schmid,
Jean-Yves Tinevez, Daniel James White, Volker Hartenstein,
Kevin Eliceiri, Pavel Tomancak, and Albert Cardona. Fiji:
an open-source platform for biological-image analysis. Nature methods,
9[7]:676682, June 2012. 143
[151] Caroline A Schneider, Wayne S Rasband, and Kevin W Eliceiri.
NIH Image to ImageJ: 25 years of image analysis. Nature methods, 9[7]:671
675, June 2012. 143
[152] Markus Schwehm. Parallel stochastic simulation of whole-cell models.
Proceedings of 2nd International Conference of Systems Biology, pages 333
341, 2001. 7
[153] G Sezonov, D Joseleau-Petit, and R D'Ari. Escherichia coli Phys-
iology in Luria-Bertani Broth. Journal of Bacteriology, 189[23]:87468749,
November 2007. 56, 106
[154] Herbert A Simon. The architecture of complexity. In Facets of systems
science, pages 457476. Springer, 1991. 83
[155] Herbert A. Simon. Decision Making: Rational, Nonrational, and Irra-
tional. Educational Administration Quarterly, 29[3]:392411, aug 1993. 53
[156] DJ Skelton, JS Hallinan, S Park, and Anil Wipat. Computational
intelligence for metabolic pathway design: Application to the pentose phos-
phate pathway. In 2016 IEEE Conference on Computational Intelligence




[157] Leyla Slamti and Mathieu Picardeau. Construction of a Library
of Random Mutants in the Spirochete Leptospira Biflexa Using a Mariner
Transposon. In Methods in molecular biology (Clifton, N.J.), 859, pages
169176. 2012. 55
[158] B Smith, A Grossman, and G Walker. Visualization of mismatch
repair in bacterial cells. Molecular cell, 2001. 63
[159] Hamilton O Smith, Clyde A Hutchison, Cynthia Pfannkoch, and
J Craig Venter. Generating a synthetic genome by whole genome as-
sembly: phiX174 bacteriophage from synthetic oligonucleotides. Proceed-
ings of the National Academy of Sciences of the United States of America,
100[26]:1544015445, December 2003. 16
[160] Elliott Sober. The principle of parsimony. The British Journal for the
Philosophy of Science, 32[2]:145156, 1981. 85
[161] Hyun-Seob Song and Chongxuan Liu. Dynamic Metabolic Modeling
of Denitrifying Bacterial Growth: The Cybernetic Approach. Industrial &
Engineering Chemistry Research, 54[42]:1022110227, oct 2015. 7
[162] Heidi M Sosik, Robert J Olson, Michael G Neubert, Alexi Sha-
lapyonok, and Andrew R Solow. Growth rates of coastal phytoplank-
ton from time-series measurements with a submersible flow cytometer. Lim-
nology and Oceanography, 48[5]:17561765, 2003. 126
[163] David G Spiller, Christopher D Wood, David A Rand, and
Michael RH White. Measurement of single-cell dynamics. Nature,
465[7299]:736745, 2010. 125
[164] K-P Stahmann, JL Revuelta, and H Seulberger. Three biotechnical
processes using ashbya gossypii, candida famata, or bacillus subtilis compete
with chemical riboflavin production. Applied Microbiology and Biotechnol-
ogy, 53[5]:509516, 2000. 59
[165] Brynne C Stanton, Alec A K Nielsen, Alvin Tamsir, Kevin
Clancy, Todd Peterson, and Christopher A Voigt. Genomic min-
223
REFERENCES
ing of prokaryotic repressors for orthogonal logic gates. Nature chemical
biology, 10[2]:99105, December 2013. 13
[166] C R Stewart. Mutagenesis by acridine yellow in Bacillus subtilis. Genetics,
59[1]:2331, may 1968. 55
[167] Jeffrey V. Straight and Doraiswami Ramkrishna. Cybernetic
Modeling and Regulation of Metabolic Pathways. Growth on Complemen-
tary Nutrients. Biotechnology Progress, 10[6]:574587, nov 1994. 7
[168] Ivan E Sutherland. Sketchpad a man-machine graphical communication
system. Transactions of the Society for Computer Simulation, 2[5]:R3, 1964.
85
[169] Yu-ichiro Tago, Masaru Imai, Makoto Ihara, Hironari Atofuji,
Yuki Nagata, and Kazuo Yamamoto. Escherichia coli mutator δpola is
defective in base mismatch correction: the nature of in vivo dna replication
errors. Journal of molecular biology, 351[2]:299308, 2005. 55
[170] Alvin Tamsir, Jeffrey J Tabor, and Christopher A Voigt. Robust
multicellular computing using genetically encoded NOR gates and chemical
'wires'. Nature, 469[7329]:212215, January 2011. 13
[171] Brandon K Tan, Mikhail Bogdanov, Jinshi Zhao, William
Dowhan, Christian R H Raetz, and Ziqiang Guan. Discovery of a
cardiolipin synthase utilizing phosphatidylethanolamine and phosphatidyl-
glycerol as substrates. Proceedings of the National Academy of Sciences of
the United States of America, 109[41]:165049, oct 2012. 23
[172] Kosei Tanaka, Christopher S Henry, Jenifer F Zinner, Edmond
Jolivet, Matthew P Cohoon, Fangfang Xia, Vladimir Bidnenko,
S Dusko Ehrlich, Rick L Stevens, and Philippe Noirot. Building
the repertoire of dispensable chromosome regions in Bacillus subtilis entails
major refinement of cognate large-scale metabolic model. Nucleic Acids Re-
search, 41[1]:687699, January 2013. 16
224
REFERENCES
[173] Karsten Temme, Dehua Zhao, and Christopher A Voigt. Refac-
toring the nitrogen fixation gene cluster from Klebsiella oxytoca. Proceedings
of the National Sciences, 2012. 16
[174] Kostas Terzidis. The Etymology of Design: Pre-Socratic Perspective.
Design Issues, 23[4]:6978, October 2007. 2
[175] M. Thomas and F. McGarry. Top-down vs. bottom-up process improve-
ment. IEEE Software, 11[4]:1213, jul 1994. 4
[176] M Tomita. Whole-cell simulation: a grand challenge of the 21st century.
Trends in biotechnology, 19[6]:20510, jun 2001. 7
[177] M Tomita, K Hashimoto, K Takahashi, T. Shimizu, Y Matsuzaki,
F Miyoshi, K Saito, S Tanida, K Yugi, J. Venter, and C. Hutchi-
son. E-CELL: software environment for whole-cell simulation. Bioinformat-
ics, 15[1]:7284, jan 1999. 7
[178] Ampere A Tseng, Kuan Chen, Chii D Chen, and Kung J Ma. Elec-
tron beam lithography in nanoscale fabrication: recent development. IEEE
Transactions on Electronics Packaging Manufacturing, 26[2]:141149, 2003.
127
[179] María-Carmen Turrientes, Fernando Baquero, Bruce R Levin,
José-Luis Martínez, Aida Ripoll, José-María González-Alba,
Raquel Tobes, Marina Manrique, Maria-Rosario Baquero,
Mario-José Rodríguez-Domínguez, Rafael Cantón, and Juan-
Carlos Galán. Normal Mutation Rate Variants Arise in a Mutator (Mut
S) Escherichia coli Population. PloS one, 8[9]:e72963, September 2013. 55,
56
[180] V Vagner, E Dervyn, and S Ehrlich. A vector for systematic gene
inactivation in Bacillus subtilis. Microbiology, 1998. 24, 25, 65
[181] Marc H V Van Regenmortel. The rational design of biological com-
plexity: A deceptive metaphor. Proteomics, 7[6]:965975, 2007. 53
225
REFERENCES
[182] Marc HV Van Regenmortel. Reductionism and complexity in molecular
biology. EMBO reports, 5[11]:10161020, 2004. 8, 82
[183] John Carl Villanueva. How many atoms are there in the universe.
Universe Today, 30, 2009. 110
[184] Alexey G Vitreschak, Dmitry A Rodionov, Andrey A Mironov,
and Mikhail S Gelfand. Regulation of riboflavin biosynthesis and trans-
port genes in bacteria by transcriptional and translational attenuation. Nu-
cleic Acids Research, 2002. 87, 88
[185] Adam C. Wilson and Hendrik Szurmant. Transposon-Mediated Ran-
dom Mutagenesis of Bacillus subtilis. In Methods in molecular biology
(Clifton, N.J.), 765, pages 359371. 2011. 55
[186] W Winkler, R Breaker, and D Crothers. The speed of RNA tran-
scription and metabolite binding kinetics operate an FMN riboswitch. Molec-
ular cell, 2005. 61
[187] Sydnor T. Withers and Jay D. Keasling. Biosynthesis and engineer-
ing of isoprenoid small molecules. Applied Microbiology and Biotechnology,
73[5]:980990, dec 2006. 15
[188] Tuck Seng Wong, Danilo Roccatano, Martin Zacharias, and Ul-
rich Schwaneberg. A statistical analysis of random mutagenesis methods
used for directed protein evolution. Journal of molecular biology, 355[4]:858
871, 2006. 55
[189] Niel Woodford and Matthew J Ellington. The emergence of antibi-
otic resistance by mutation. Clinical Microbiology and Infection, 13[1]:518,
2007. 56
[190] A Wysoker, K Tibbetts, and T Fennell. Picard tools version 1.90,
2013. 67
[191] Younan Xia and George M Whitesides. Soft lithography. Annual
review of materials science, 28[1]:153184, 1998. 126
226
REFERENCES
[192] Tim Wing Yam and Joseph Arditti. History of orchid propagation: a
mirror of the history of biotechnology. Plant Biotechnology Reports, 3[1]:1
56, January 2009. 11
[193] G Yang, J Rich, M Gilbert, and W Wakarchuk. Fluorescence ac-
tivated cell sorting as a general ultra-high-throughput screening method for
directed evolution of glycosyltransferases. Journal of the American Chemical
Society, 2010. 57, 58
[194] Daniel R Zeigler, Zoltán Prágai, Sabrina Rodriguez, Bastien
Chevreux, Andrea Muffler, Thomas Albert, Renyuan Bai,
Markus Wyss, and John B Perkins. The origins of 168, W23, and
other Bacillus subtilis legacy strains. Journal of bacteriology, 190[21]:6983
95, nov 2008. 23
227
